{"c84af203275e3d64b400d55a36650584daba6274": [["Myocarditis refers to inflammatory injuries caused by various pathogens that can finally result in dysfunction of the heart, such as decreased systolic or diastolic function and arrhythmias (Caforio et al., 2013; Caforio et al., 2017; Fung et al., 2016; Lazaros et al., 2017; Luyt et al., 2016; Pollack et al., 2015) .", [["heart", "ANATOMY", 118, 123], ["Myocarditis", "DISEASE", 0, 11], ["injuries", "DISEASE", 35, 43], ["dysfunction of the heart", "DISEASE", 99, 123], ["decreased systolic or diastolic function", "DISEASE", 133, 173], ["arrhythmias", "DISEASE", 178, 189], ["heart", "ORGAN", 118, 123], ["Myocarditis", "PROBLEM", 0, 11], ["inflammatory injuries", "PROBLEM", 22, 43], ["various pathogens", "PROBLEM", 54, 71], ["dysfunction of the heart", "PROBLEM", 99, 123], ["decreased systolic or diastolic function", "PROBLEM", 133, 173], ["arrhythmias", "PROBLEM", 178, 189], ["inflammatory", "OBSERVATION_MODIFIER", 22, 34], ["various", "OBSERVATION_MODIFIER", 54, 61], ["pathogens", "OBSERVATION", 62, 71], ["heart", "ANATOMY", 118, 123], ["decreased", "OBSERVATION_MODIFIER", 133, 142], ["systolic", "OBSERVATION_MODIFIER", 143, 151], ["diastolic function", "OBSERVATION", 155, 173]]], ["The common causes can be classified into three classes: infection; autoimmune disease (giant cell myocarditis, sarcoidosis, systemic lupus erythematosus, Churg-Strauss syndrome, and mucocutaneous lymph node syndrome) and drug hypersensitivity; and poisons or toxic drug effects.", [["giant cell", "ANATOMY", 87, 97], ["lymph node", "ANATOMY", 196, 206], ["infection", "DISEASE", 56, 65], ["autoimmune disease", "DISEASE", 67, 85], ["giant cell myocarditis", "DISEASE", 87, 109], ["sarcoidosis", "DISEASE", 111, 122], ["systemic lupus erythematosus", "DISEASE", 124, 152], ["Churg-Strauss syndrome", "DISEASE", 154, 176], ["mucocutaneous lymph node syndrome", "DISEASE", 182, 215], ["drug hypersensitivity", "DISEASE", 221, 242], ["giant cell", "CELL", 87, 97], ["lymph node", "MULTI-TISSUE_STRUCTURE", 196, 206], ["infection", "PROBLEM", 56, 65], ["autoimmune disease", "PROBLEM", 67, 85], ["giant cell myocarditis", "PROBLEM", 87, 109], ["sarcoidosis", "PROBLEM", 111, 122], ["systemic lupus erythematosus", "PROBLEM", 124, 152], ["Churg", "PROBLEM", 154, 159], ["Strauss syndrome", "PROBLEM", 160, 176], ["mucocutaneous lymph node syndrome", "PROBLEM", 182, 215], ["drug hypersensitivity", "PROBLEM", 221, 242], ["toxic drug effects", "PROBLEM", 259, 277], ["infection", "OBSERVATION", 56, 65], ["autoimmune disease", "OBSERVATION", 67, 85], ["giant cell myocarditis", "OBSERVATION", 87, 109], ["sarcoidosis", "OBSERVATION", 111, 122], ["systemic", "OBSERVATION_MODIFIER", 124, 132], ["lupus erythematosus", "OBSERVATION", 133, 152], ["Strauss syndrome", "OBSERVATION", 160, 176], ["mucocutaneous", "OBSERVATION_MODIFIER", 182, 195], ["lymph node syndrome", "OBSERVATION", 196, 215], ["toxic", "OBSERVATION_MODIFIER", 259, 264]]], ["Infections cause the majority of cases of myocarditis with the most common pathogens being viruses, including enteroviruses (especially Coxsackie B virus), adenovirus, cytomegalovirus, Epstein-Barr virus (EBV), and influenza virus.", [["Infections", "DISEASE", 0, 10], ["myocarditis", "DISEASE", 42, 53], ["enteroviruses", "DISEASE", 110, 123], ["Coxsackie B virus", "DISEASE", 136, 153], ["Epstein-Barr virus (EBV)", "DISEASE", 185, 209], ["influenza virus", "DISEASE", 215, 230], ["Coxsackie B virus", "ORGANISM", 136, 153], ["adenovirus", "ORGANISM", 156, 166], ["cytomegalovirus", "ORGANISM", 168, 183], ["Epstein-Barr virus", "ORGANISM", 185, 203], ["EBV", "ORGANISM", 205, 208], ["influenza virus", "ORGANISM", 215, 230], ["Coxsackie B virus", "SPECIES", 136, 153], ["Barr virus", "SPECIES", 193, 203], ["influenza virus", "SPECIES", 215, 230], ["Coxsackie B virus", "SPECIES", 136, 153], ["adenovirus", "SPECIES", 156, 166], ["Epstein-Barr virus", "SPECIES", 185, 203], ["EBV", "SPECIES", 205, 208], ["influenza virus", "SPECIES", 215, 230], ["Infections", "PROBLEM", 0, 10], ["myocarditis", "PROBLEM", 42, 53], ["viruses", "PROBLEM", 91, 98], ["enteroviruses", "PROBLEM", 110, 123], ["Coxsackie B virus", "PROBLEM", 136, 153], ["adenovirus", "PROBLEM", 156, 166], ["cytomegalovirus", "PROBLEM", 168, 183], ["Epstein-Barr virus (EBV)", "PROBLEM", 185, 209], ["influenza virus", "PROBLEM", 215, 230], ["myocarditis", "OBSERVATION", 42, 53], ["most common", "OBSERVATION_MODIFIER", 63, 74], ["viruses", "OBSERVATION", 91, 98], ["Barr virus", "OBSERVATION", 193, 203], ["influenza virus", "OBSERVATION", 215, 230]]], ["There are usually three clinical stages of myocarditis: the acute phase, subacute phase, and chronic phase.", [["myocarditis", "DISEASE", 43, 54], ["myocarditis", "PROBLEM", 43, 54], ["the acute phase", "TEST", 56, 71], ["subacute phase, and chronic phase", "PROBLEM", 73, 106], ["myocarditis", "OBSERVATION", 43, 54], ["acute phase", "OBSERVATION_MODIFIER", 60, 71], ["subacute phase", "OBSERVATION_MODIFIER", 73, 87], ["chronic phase", "OBSERVATION_MODIFIER", 93, 106]]], ["The acute phase lasts for 3-5 days, during which active viral replication and invasion severely damage the myocardium.", [["myocardium", "ANATOMY", 107, 117], ["myocardium", "ORGAN", 107, 117], ["active viral replication", "TREATMENT", 49, 73], ["invasion severely damage the myocardium", "PROBLEM", 78, 117], ["acute", "OBSERVATION_MODIFIER", 4, 9], ["phase", "OBSERVATION_MODIFIER", 10, 15], ["active", "OBSERVATION_MODIFIER", 49, 55], ["viral replication", "OBSERVATION", 56, 73], ["myocardium", "ANATOMY", 107, 117]]], ["Immunological reaction plays a major role in the subacute phase, and only a few patients eventually enter the chronic phase.", [["patients", "ORGANISM", 80, 88], ["patients", "SPECIES", 80, 88], ["Immunological reaction", "PROBLEM", 0, 22], ["chronic phase", "OBSERVATION_MODIFIER", 110, 123]]], ["In this phase, patients may suffer from chronic, persistent, but sudden aggravated inflammatory reactions as well as decreased contractility, myocardial fibrosis, and cardiomegaly (Caforio et al., 2013; Fung et al., 2016; Pollack et al., 2015) .", [["myocardial", "ANATOMY", 142, 152], ["myocardial fibrosis", "DISEASE", 142, 161], ["cardiomegaly", "DISEASE", 167, 179], ["patients", "ORGANISM", 15, 23], ["myocardial", "MULTI-TISSUE_STRUCTURE", 142, 152], ["patients", "SPECIES", 15, 23], ["sudden aggravated inflammatory reactions", "PROBLEM", 65, 105], ["decreased contractility", "PROBLEM", 117, 140], ["myocardial fibrosis", "PROBLEM", 142, 161], ["cardiomegaly", "PROBLEM", 167, 179], ["chronic", "OBSERVATION_MODIFIER", 40, 47], ["persistent", "OBSERVATION_MODIFIER", 49, 59], ["sudden", "OBSERVATION_MODIFIER", 65, 71], ["aggravated", "OBSERVATION_MODIFIER", 72, 82], ["inflammatory", "OBSERVATION", 83, 95], ["decreased contractility", "OBSERVATION", 117, 140], ["myocardial", "ANATOMY", 142, 152], ["fibrosis", "OBSERVATION", 153, 161], ["cardiomegaly", "OBSERVATION", 167, 179]]], ["Myocarditis has a wide range of clinical manifestations, ranging from slight squeezing chest depression after activity, to acute left heart failure, cardiogenic shock, and even sudden death.", [["chest", "ANATOMY", 87, 92], ["heart", "ANATOMY", 134, 139], ["Myocarditis", "DISEASE", 0, 11], ["chest depression", "DISEASE", 87, 103], ["left heart failure", "DISEASE", 129, 147], ["cardiogenic shock", "DISEASE", 149, 166], ["sudden death", "DISEASE", 177, 189], ["chest", "ORGANISM_SUBDIVISION", 87, 92], ["heart", "ORGAN", 134, 139], ["Myocarditis", "PROBLEM", 0, 11], ["clinical manifestations", "PROBLEM", 32, 55], ["slight squeezing chest depression", "PROBLEM", 70, 103], ["acute left heart failure", "PROBLEM", 123, 147], ["cardiogenic shock", "PROBLEM", 149, 166], ["even sudden death", "PROBLEM", 172, 189], ["wide range", "OBSERVATION_MODIFIER", 18, 28], ["slight", "OBSERVATION_MODIFIER", 70, 76], ["squeezing", "OBSERVATION_MODIFIER", 77, 86], ["chest", "ANATOMY", 87, 92], ["depression", "OBSERVATION", 93, 103], ["acute", "OBSERVATION_MODIFIER", 123, 128], ["left", "ANATOMY_MODIFIER", 129, 133], ["heart", "ANATOMY", 134, 139], ["failure", "OBSERVATION", 140, 147], ["cardiogenic shock", "OBSERVATION", 149, 166], ["sudden", "OBSERVATION_MODIFIER", 177, 183], ["death", "OBSERVATION", 184, 189]]], ["Therefore, treatment must be personalized according to the severity of the condition.", [["treatment", "TREATMENT", 11, 20]]]], "49297a6217ddc3ac15d1d11209f889cce130c8f4": [["Introduction:COVID-19 and influenza are both highly infectious viral diseases characterized by pneumonia and acute respiratory failure in severe cases.", [["respiratory", "ANATOMY", 115, 126], ["COVID-19", "CHEMICAL", 13, 21], ["influenza", "DISEASE", 26, 35], ["viral diseases", "DISEASE", 63, 77], ["pneumonia", "DISEASE", 95, 104], ["acute respiratory failure", "DISEASE", 109, 134], ["COVID-19", "ORGANISM", 13, 21], ["influenza", "ORGANISM", 26, 35], ["COVID-19", "SPECIES", 13, 21], ["COVID", "TEST", 13, 18], ["influenza", "PROBLEM", 26, 35], ["highly infectious viral diseases", "PROBLEM", 45, 77], ["pneumonia", "PROBLEM", 95, 104], ["acute respiratory failure in severe cases", "PROBLEM", 109, 150], ["infectious", "OBSERVATION", 52, 62], ["pneumonia", "OBSERVATION", 95, 104], ["acute", "OBSERVATION_MODIFIER", 109, 114], ["respiratory failure", "OBSERVATION", 115, 134], ["severe", "OBSERVATION_MODIFIER", 138, 144]]], ["Both place a burden on the health care system, but objective granular assessments of their comparative impact on individuals and the healthcare system are lacking in the literature.Introduction:The epidemiology, symptomology and annual public health burden presented by influenza is generally well characterized; however, this is largely through estimates as opposed to comprehensive reporting.", [["influenza", "DISEASE", 270, 279], ["objective granular assessments", "TEST", 51, 81], ["symptomology", "PROBLEM", 212, 224], ["annual public health burden", "PROBLEM", 229, 256], ["influenza", "PROBLEM", 270, 279], ["burden", "OBSERVATION", 13, 19]]], ["1 The Centers for Disease Control and Prevention (CDC) estimates that over the past 10 years, between 9 and 45 million people have contracted influenza annually in the United States, with annual hospitalizations ranging from 140,000 -810,000 and annual mortality ranging from 12,000 to 61,000 (between 0.10% and 0.17% of all cases), depending on the severity of the season.", [["influenza", "DISEASE", 142, 151], ["people", "ORGANISM", 119, 125], ["people", "SPECIES", 119, 125], ["Disease Control", "TREATMENT", 18, 33], ["influenza", "PROBLEM", 142, 151], ["annual mortality", "TEST", 246, 262], ["Disease", "OBSERVATION", 18, 25], ["influenza", "OBSERVATION", 142, 151]]], ["2 Influenza generally achieves community spread nationwide and can strike all age groups, but mortality is consistently higher in patients who are elderly, immunocompromised, and/or have pre-existing comorbidities such as chronic obstructive pulmonary disease, chronic kidney injury, cirrhosis, or cardiac disease.", [["pulmonary", "ANATOMY", 242, 251], ["kidney", "ANATOMY", 269, 275], ["cardiac", "ANATOMY", 298, 305], ["Influenza", "DISEASE", 2, 11], ["chronic obstructive pulmonary disease", "DISEASE", 222, 259], ["chronic kidney injury", "DISEASE", 261, 282], ["cirrhosis", "DISEASE", 284, 293], ["cardiac disease", "DISEASE", 298, 313], ["patients", "ORGANISM", 130, 138], ["pulmonary", "ORGAN", 242, 251], ["kidney", "ORGAN", 269, 275], ["cardiac", "ORGAN", 298, 305], ["patients", "SPECIES", 130, 138], ["Influenza", "PROBLEM", 2, 11], ["immunocompromised", "PROBLEM", 156, 173], ["pre-existing comorbidities", "PROBLEM", 187, 213], ["chronic obstructive pulmonary disease", "PROBLEM", 222, 259], ["chronic kidney injury", "PROBLEM", 261, 282], ["cirrhosis", "PROBLEM", 284, 293], ["cardiac disease", "PROBLEM", 298, 313], ["chronic", "OBSERVATION_MODIFIER", 222, 229], ["obstructive", "OBSERVATION_MODIFIER", 230, 241], ["pulmonary", "ANATOMY", 242, 251], ["disease", "OBSERVATION", 252, 259], ["chronic", "OBSERVATION_MODIFIER", 261, 268], ["kidney", "ANATOMY", 269, 275], ["injury", "OBSERVATION", 276, 282], ["cirrhosis", "OBSERVATION", 284, 293], ["cardiac", "ANATOMY", 298, 305], ["disease", "OBSERVATION", 306, 313]]], ["[3] [4] [5] [6] [7] [8] [9] Decades of experience with influenza have led to vaccination programs which can mitigate the impact of influenza in years when the predominant circulating strain is accurately predicted.", [["influenza", "DISEASE", 55, 64], ["influenza", "DISEASE", 131, 140], ["[3] [4] [5] [6] [7] [8] [9", "SIMPLE_CHEMICAL", 0, 26], ["influenza", "PROBLEM", 55, 64], ["vaccination programs", "TREATMENT", 77, 97], ["influenza", "PROBLEM", 131, 140], ["the predominant circulating strain", "PROBLEM", 155, 189], ["circulating strain", "OBSERVATION", 171, 189]]], ["10 Official CDC counts indicate that over one million people in the United States have contracted COVID-19 between the virus's first detected cases through April 30, 2020, with over outcomes of those patients without comorbid disease, frequency of non-pulmonary organ injury, and mortality are lacking, yet essential for understanding these two disease processes.Introduction:In this study, we compared the epidemiology and clinical characteristics of COVID-19 patients admitted to a large tertiary care teaching hospital in March and April of 2020 with those of influenza patients admitted to the same hospital over the prior five years.Methods:Design: This was a single center, retrospective study at an urban tertiary care center.Methods:We compared patients admitted to the hospital with influenza during five influenza seasons (September-April 2014-2019) to patients admitted to the hospital with COVID-19 in March and April 2020.", [["organ", "ANATOMY", 262, 267], ["non-pulmonary organ injury", "DISEASE", 248, 274], ["influenza", "DISEASE", 563, 572], ["influenza", "DISEASE", 792, 801], ["people", "ORGANISM", 54, 60], ["patients", "ORGANISM", 200, 208], ["organ", "ORGAN", 262, 267], ["patients", "ORGANISM", 461, 469], ["patients", "ORGANISM", 573, 581], ["patients", "ORGANISM", 753, 761], ["patients", "ORGANISM", 863, 871], ["people", "SPECIES", 54, 60], ["patients", "SPECIES", 200, 208], ["patients", "SPECIES", 461, 469], ["patients", "SPECIES", 573, 581], ["patients", "SPECIES", 753, 761], ["patients", "SPECIES", 863, 871], ["Official CDC counts", "TEST", 3, 22], ["comorbid disease", "PROBLEM", 217, 233], ["non-pulmonary organ injury", "PROBLEM", 248, 274], ["these two disease processes", "PROBLEM", 335, 362], ["this study", "TEST", 379, 389], ["influenza", "PROBLEM", 563, 572], ["retrospective study", "TEST", 680, 699], ["influenza", "PROBLEM", 792, 801], ["COVID", "TREATMENT", 902, 907], ["non-pulmonary organ", "ANATOMY", 248, 267], ["injury", "OBSERVATION", 268, 274]]], ["This study was reviewed by the Institutional Review Board at Beth Israel Deaconess Medical Center, which determined the study met exempt status.", [["This study", "TEST", 0, 10], ["the study", "TEST", 116, 125]]], ["Written informed consent was therefore not required.Methods:Patient Population: Adult (aged >17 years) patients were included if they were admitted to the hospital for confirmed influenza or COVID-19 during the time frames of interest.", [["influenza", "DISEASE", 178, 187], ["patients", "ORGANISM", 103, 111], ["Patient", "SPECIES", 60, 67], ["patients", "SPECIES", 103, 111], ["influenza", "PROBLEM", 178, 187], ["COVID", "TREATMENT", 191, 196]]], ["Patients with influenza or COVID-19 were identified by ICD-10 codes (see appendix) and/or laboratorybased testing.", [["influenza", "DISEASE", 14, 23], ["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["influenza", "PROBLEM", 14, 23], ["COVID", "TEST", 27, 32], ["laboratorybased testing", "TEST", 90, 113], ["appendix", "ANATOMY", 73, 81]]], ["Laboratory diagnosis of influenza and COVID-19 were carried out through specific real-time reverse transcriptase-polymerase chain reaction (RT-PCR) assays of nasal swab specimens.", [["nasal swab specimens", "ANATOMY", 158, 178], ["influenza", "DISEASE", 24, 33], ["nasal swab specimens", "CANCER", 158, 178], ["reverse transcriptase", "PROTEIN", 91, 112], ["influenza", "PROBLEM", 24, 33], ["COVID", "TEST", 38, 43], ["polymerase chain reaction", "PROBLEM", 113, 138], ["RT-PCR", "TEST", 140, 146], ["nasal swab specimens", "TEST", 158, 178], ["nasal", "ANATOMY", 158, 163]]], ["COVID-19 or influenza diagnosis for all subjects identified by ICD-10 codes were manually reviewed for confirmation.", [["influenza", "DISEASE", 12, 21], ["COVID", "TEST", 0, 5], ["influenza diagnosis", "TEST", 12, 31]]], ["The ICD-10 codes are displayed in supplement Table S1 .Methods:Study Data Abstraction: Study data was abstracted from patient electronic medical records based on the mechanism for identification of subjects described above.", [["patient", "ORGANISM", 118, 125], ["ICD-10 codes", "DNA", 4, 16], ["patient", "SPECIES", 118, 125], ["The ICD", "TREATMENT", 0, 7], ["Study data", "TEST", 87, 97], ["ICD", "OBSERVATION", 4, 7], ["S1", "ANATOMY", 51, 53]]], ["No reuse allowed without permission.Methods:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Methods:The copyright holder for this preprint this version posted August 22, 2020. . demographics, personal medical histories (e.g. chronic comorbid conditions), laboratory findings on admission, intensive care unit admission status, intensive care unit length of stay, mechanical ventilation, hospital length of stay, and mortality.", [["chronic comorbid conditions", "PROBLEM", 312, 339], ["mechanical ventilation", "TREATMENT", 450, 472], ["med", "ANATOMY", 123, 126], ["mechanical ventilation", "OBSERVATION", 450, 472]]], ["Key variables including presence and duration of mechanical ventilation and mortality were manually reviewed to verify the data.Methods:To compute volume of admissions between the two diseases, weekly counts of hospital admissions and mechanically ventilated patients were assessed during the peak two months of influenza seasons from 2014-2019 and from March-April 2020 for COVID-19.", [["patients", "ORGANISM", 259, 267], ["patients", "SPECIES", 259, 267], ["mechanical ventilation", "TREATMENT", 49, 71], ["the data", "TEST", 119, 127], ["the two diseases", "PROBLEM", 176, 192], ["mechanically ventilated", "TREATMENT", 235, 258], ["influenza seasons", "PROBLEM", 312, 329], ["COVID", "TEST", 375, 380]]], ["Reasons for intubation were manually categorized and all past medical history was manually extracted.", [["intubation", "TREATMENT", 12, 22]]], ["All cases for which laboratory testing occurred greater than five days after admission were reviewed to determine if disease was believed to be nosocomial.", [["nosocomial", "DISEASE", 144, 154], ["laboratory testing", "TEST", 20, 38], ["disease", "PROBLEM", 117, 124], ["nosocomial", "PROBLEM", 144, 154], ["nosocomial", "OBSERVATION", 144, 154]]], ["For other variables (e.g., laboratory values), a sample of randomly chosen data was verified using manual chart review.Methods:Definitions for elements of the data abstraction are displayed in supplement Table S2 .Methods:Data Analysis: Continuous data are presented as medians with interquartile ranges and categorical data are presented as counts and percentages.", [["laboratory values", "TEST", 27, 44], ["manual chart review", "TEST", 99, 118], ["the data abstraction", "TEST", 155, 175], ["categorical data", "TEST", 308, 324]]], ["For continuous outcomes (duration of mechanical ventilation, duration of index hospital stay, number of weekly admissions, number of weekly incident mechanical ventilations), medians were compared using a Wilcoxon ranksum test.", [["mechanical ventilation", "TREATMENT", 37, 59], ["mechanical ventilations", "TREATMENT", 149, 172], ["a Wilcoxon ranksum test", "TEST", 203, 226]]], ["For categorical outcomes (incidence of mechanical ventilation, incidence of shock, incidence of renal replacement therapy, hospital readmissions, ICU admissions, in-hospital mortality, reason for mechanical ventilation, and proportion of patients on mechanical ventilation with no major comorbidities), proportions were compared using chi-squared or Fisher's exact tests, as appropriate.", [["renal", "ANATOMY", 96, 101], ["shock", "DISEASE", 76, 81], ["renal", "ORGAN", 96, 101], ["patients", "ORGANISM", 238, 246], ["patients", "SPECIES", 238, 246], ["mechanical ventilation", "TREATMENT", 39, 61], ["shock", "PROBLEM", 76, 81], ["renal replacement therapy", "TREATMENT", 96, 121], ["mechanical ventilation", "TREATMENT", 196, 218], ["mechanical ventilation", "TREATMENT", 250, 272], ["major comorbidities", "PROBLEM", 281, 300], ["Fisher's exact tests", "TEST", 350, 370], ["mechanical ventilation", "OBSERVATION", 39, 61], ["shock", "OBSERVATION", 76, 81], ["renal", "ANATOMY", 96, 101], ["replacement", "OBSERVATION", 102, 113]]], ["All analyses were done using Stata 14.2 (College Station, TX) and a pvalue <0.05 was considered statistically significant.", [["All analyses", "TEST", 0, 12], ["Stata", "TEST", 29, 34], ["TX", "TEST", 58, 60]]], ["No reuse allowed without permission.Methods:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Methods:The copyright holder for this preprint this version posted August 22, 2020. .Overview of COVID-19 and Influenza Admissions with Key OutcomesIn total, 1855 patients were identified and 1635 were included in the study ( Figure 1 ).", [["Influenza", "DISEASE", 289, 298], ["patients", "ORGANISM", 342, 350], ["patients", "SPECIES", 342, 350], ["the study", "TEST", 393, 402], ["med", "ANATOMY", 123, 126]]], ["Of these, 583 patients had laboratory-confirmed COVID-19 and 1052 patients had laboratoryconfirmed influenza.", [["influenza", "DISEASE", 99, 108], ["patients", "ORGANISM", 14, 22], ["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 14, 22], ["patients", "SPECIES", 66, 74], ["COVID", "TEST", 48, 53], ["laboratoryconfirmed influenza", "PROBLEM", 79, 108], ["influenza", "OBSERVATION", 99, 108]]], ["An overview of admissions, intensive care unit admissions, receipt of mechanical ventilation, and mortality is illustrated per influenza season compared to COVID-19 (Table 1 ).", [["mechanical ventilation", "TREATMENT", 70, 92], ["COVID", "TEST", 156, 161], ["mechanical ventilation", "OBSERVATION", 70, 92]]], ["The total admissions for influenza per eight-month influenza season averaged 210 compared to a total of 583 COVID-19 admissions over the two month COVID-19 study period.", [["influenza", "DISEASE", 25, 34], ["influenza", "PROBLEM", 25, 34]]], ["No reuse allowed without permission.Overview of COVID-19 and Influenza Admissions with Key Outcomes(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Overview of COVID-19 and Influenza Admissions with Key OutcomesThe copyright holder for this preprint this version posted August 22, 2020. .Demographics and Clinical CharacteristicsPatient demographics and medical history are summarized in Table 2 Table 3 .", [["Influenza", "DISEASE", 61, 70], ["Influenza", "DISEASE", 259, 268], ["COVID", "TEST", 246, 251], ["med", "ANATOMY", 178, 181]]], ["Overall, the reasons for intubation in COVID-19 patients were different than those intubated for influenza (p<0.001).", [["influenza", "DISEASE", 97, 106], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["intubation", "TREATMENT", 25, 35], ["COVID", "TEST", 39, 44], ["influenza", "PROBLEM", 97, 106]]], ["Pneumonia and/or acute respiratory distress syndrome (ARDS) was the reason for 94% of intubations in COVID-19 patients, while this accounted for only 56% of intubations in influenza patients.Demographics and Clinical CharacteristicsAdditionally, no COVID-19 patients received mechanical ventilation due to exacerbation of preexisting conditions compared to 14% of influenza cases who received mechanical ventilation for this indication.", [["respiratory", "ANATOMY", 23, 34], ["Pneumonia", "DISEASE", 0, 9], ["acute respiratory distress syndrome", "DISEASE", 17, 52], ["ARDS", "DISEASE", 54, 58], ["influenza", "DISEASE", 172, 181], ["influenza", "DISEASE", 364, 373], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 182, 190], ["patients", "ORGANISM", 258, 266], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 182, 190], ["patients", "SPECIES", 258, 266], ["Pneumonia", "PROBLEM", 0, 9], ["acute respiratory distress syndrome", "PROBLEM", 17, 52], ["ARDS", "PROBLEM", 54, 58], ["intubations", "TREATMENT", 86, 97], ["intubations", "TREATMENT", 157, 168], ["influenza", "PROBLEM", 172, 181], ["COVID", "TEST", 249, 254], ["mechanical ventilation", "TREATMENT", 276, 298], ["exacerbation", "PROBLEM", 306, 318], ["preexisting conditions", "PROBLEM", 322, 344], ["influenza cases", "PROBLEM", 364, 379], ["mechanical ventilation", "TREATMENT", 393, 415], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory distress", "OBSERVATION", 23, 43]]], ["No reuse allowed without permission.Demographics and Clinical Characteristics(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Demographics and Clinical CharacteristicsThe copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20163857 doi: medRxiv preprint Table 4Discussion:COVID-19 has been compared to influenza by both health care professionals and the lay public 12-16 but limited detailed objective data are available for comparing and contrasting the impact of these two disease processes on patients and hospitals.", [["influenza", "DISEASE", 445, 454], ["patients", "ORGANISM", 639, 647], ["patients", "SPECIES", 639, 647], ["influenza", "PROBLEM", 445, 454], ["med", "ANATOMY", 156, 159]]], ["We found that admissions for COVID-19 over a two month period at our medical center were more than double the total All rights reserved.", [["COVID", "TEST", 29, 34], ["double the total All rights", "TREATMENT", 99, 126]]], ["No reuse allowed without permission.Discussion:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Discussion:The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20163857 doi: medRxiv preprint number of admissions for influenza during any 8-month influenza season in the past five years.Discussion:In addition to the larger volume of cases within a much shorter time period, severity of illness and lethality for COVID-19 were also markedly higher than for influenza.", [["influenza", "DISEASE", 362, 371], ["illness", "DISEASE", 531, 538], ["influenza", "DISEASE", 601, 610], ["influenza", "PROBLEM", 362, 371], ["illness", "PROBLEM", 531, 538], ["lethality", "PROBLEM", 543, 552], ["COVID", "TEST", 557, 562], ["influenza", "PROBLEM", 601, 610], ["med", "ANATOMY", 126, 129]]], ["We observed more mechanically ventilated COVID-19 patients (i.e., those with severe, life-threatening illness) in a two month period than occurred in five entire seasons of influenza combined, and a similar observation was made with patient deaths.", [["illness", "DISEASE", 102, 109], ["influenza", "DISEASE", 173, 182], ["deaths", "DISEASE", 241, 247], ["patients", "ORGANISM", 50, 58], ["patient", "ORGANISM", 233, 240], ["patients", "SPECIES", 50, 58], ["patient", "SPECIES", 233, 240], ["influenza", "PROBLEM", 173, 182], ["influenza", "OBSERVATION", 173, 182]]], ["Taken together, these findings indicate that COVID-19 causes more severe disease and is more lethal than influenza.", [["COVID-19", "CHEMICAL", 45, 53], ["influenza", "DISEASE", 105, 114], ["COVID-19", "ORGANISM", 45, 53], ["COVID", "TEST", 45, 50], ["more severe disease", "PROBLEM", 61, 80], ["influenza", "PROBLEM", 105, 114], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["disease", "OBSERVATION", 73, 80]]], ["Other studies aimed at total incidence (hospitalized plus non-hospitalized) suggest a higher rate of spread (Ro) of COVID-19 than influenza [17] [18] [19] In this specific subgroup, five patients with COVID-19 died in the two-month period compared to one with influenza over five years.", [["influenza", "DISEASE", 130, 139], ["influenza", "DISEASE", 260, 269], ["COVID-19", "CHEMICAL", 116, 124], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["Other studies", "TEST", 0, 13], ["COVID", "TEST", 116, 121], ["influenza", "PROBLEM", 130, 139], ["COVID", "TEST", 201, 206], ["influenza", "PROBLEM", 260, 269]]], ["Pneumonia and acute respiratory distress syndrome were the predominant causes of mechanical ventilation for COVID-19 (94%), whereas this was not the case for influenza (55%).", [["respiratory", "ANATOMY", 20, 31], ["Pneumonia", "DISEASE", 0, 9], ["acute respiratory distress syndrome", "DISEASE", 14, 49], ["COVID-19", "CHEMICAL", 108, 116], ["influenza", "DISEASE", 158, 167], ["Pneumonia", "PROBLEM", 0, 9], ["acute respiratory distress syndrome", "PROBLEM", 14, 49], ["mechanical ventilation", "TREATMENT", 81, 103], ["COVID", "TEST", 108, 113], ["influenza", "PROBLEM", 158, 167], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["respiratory distress", "OBSERVATION", 20, 40], ["mechanical ventilation", "OBSERVATION", 81, 103]]], ["With influenza, the need for mechanical ventilation often developed as a result of exacerbation of a pre-existing health condition such as asthma or chronic obstructive pulmonary disease (COPD), which did not occur in COVID-19.", [["pulmonary", "ANATOMY", 169, 178], ["influenza", "DISEASE", 5, 14], ["asthma", "DISEASE", 139, 145], ["chronic obstructive pulmonary disease", "DISEASE", 149, 186], ["COPD", "DISEASE", 188, 192], ["pulmonary", "ORGAN", 169, 178], ["influenza", "PROBLEM", 5, 14], ["mechanical ventilation", "TREATMENT", 29, 51], ["exacerbation", "PROBLEM", 83, 95], ["a pre-existing health condition", "PROBLEM", 99, 130], ["asthma", "PROBLEM", 139, 145], ["chronic obstructive pulmonary disease", "PROBLEM", 149, 186], ["COPD", "PROBLEM", 188, 192], ["COVID", "TEST", 218, 223], ["influenza", "OBSERVATION", 5, 14], ["chronic", "OBSERVATION_MODIFIER", 149, 156], ["obstructive", "OBSERVATION_MODIFIER", 157, 168], ["pulmonary", "ANATOMY", 169, 178], ["disease", "OBSERVATION", 179, 186], ["COPD", "OBSERVATION", 188, 192]]], ["The apparently higher rate of pneumonia and ARDS in our COVID-19 cohort may at least partly All rights reserved.", [["pneumonia", "DISEASE", 30, 39], ["ARDS", "DISEASE", 44, 48], ["pneumonia", "PROBLEM", 30, 39], ["ARDS", "PROBLEM", 44, 48], ["our COVID", "TEST", 52, 61], ["higher", "OBSERVATION_MODIFIER", 15, 21], ["rate", "OBSERVATION_MODIFIER", 22, 26], ["pneumonia", "OBSERVATION", 30, 39], ["ARDS", "OBSERVATION", 44, 48]]], ["No reuse allowed without permission.Discussion:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Discussion:The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20163857 doi: medRxiv preprint explain the more frequent occurrence of respiratory failure and death even in the absence of serious comorbidities.Discussion:In addition to acute respiratory failure, rates of vasopressor and renal replacement therapy were significantly increased in COVID-19 compared to influenza.", [["respiratory", "ANATOMY", 377, 388], ["respiratory", "ANATOMY", 484, 495], ["renal", "ANATOMY", 530, 535], ["respiratory failure", "DISEASE", 377, 396], ["death", "DISEASE", 401, 406], ["respiratory failure", "DISEASE", 484, 503], ["COVID-19", "CHEMICAL", 588, 596], ["influenza", "DISEASE", 609, 618], ["renal", "ORGAN", 530, 535], ["COVID-19", "SPECIES", 588, 596], ["medRxiv", "TREATMENT", 320, 327], ["respiratory failure", "PROBLEM", 377, 396], ["death", "PROBLEM", 401, 406], ["serious comorbidities", "PROBLEM", 430, 451], ["acute respiratory failure", "PROBLEM", 478, 503], ["vasopressor", "TREATMENT", 514, 525], ["renal replacement therapy", "TREATMENT", 530, 555], ["COVID", "TEST", 588, 593], ["influenza", "PROBLEM", 609, 618], ["med", "ANATOMY", 126, 129], ["respiratory", "ANATOMY", 377, 388], ["failure", "OBSERVATION", 389, 396], ["acute", "OBSERVATION_MODIFIER", 478, 483], ["respiratory failure", "OBSERVATION", 484, 503], ["renal", "ANATOMY", 530, 535], ["replacement", "OBSERVATION", 536, 547]]], ["The increased disease severity reflected in the rates of acute respiratory failure and other-organ injury paralleled the overall higher lethality of COVID-19 which resulted in 119 deaths in 2 months compared to 34 deaths from influenza over five seasons.", [["respiratory", "ANATOMY", 63, 74], ["organ", "ANATOMY", 93, 98], ["respiratory failure", "DISEASE", 63, 82], ["COVID-19", "CHEMICAL", 149, 157], ["deaths", "DISEASE", 180, 186], ["deaths", "DISEASE", 214, 220], ["influenza", "DISEASE", 226, 235], ["COVID-19", "CHEMICAL", 149, 157], ["organ", "ORGAN", 93, 98], ["The increased disease severity", "PROBLEM", 0, 30], ["acute respiratory failure", "PROBLEM", 57, 82], ["organ injury", "PROBLEM", 93, 105], ["COVID", "TEST", 149, 154], ["influenza", "PROBLEM", 226, 235], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["disease", "OBSERVATION", 14, 21], ["severity", "OBSERVATION_MODIFIER", 22, 30], ["acute", "OBSERVATION_MODIFIER", 57, 62], ["respiratory failure", "OBSERVATION", 63, 82], ["organ", "ANATOMY", 93, 98], ["injury", "OBSERVATION", 99, 105]]], ["The disparity in deaths was driven by both increased volume of cases and increased lethality within that volume in COVID-19 patients.", [["deaths", "DISEASE", 17, 23], ["patients", "ORGANISM", 124, 132], ["patients", "SPECIES", 124, 132], ["increased lethality", "PROBLEM", 73, 92], ["disparity", "OBSERVATION_MODIFIER", 4, 13], ["deaths", "OBSERVATION", 17, 23], ["increased", "OBSERVATION_MODIFIER", 43, 52], ["volume", "OBSERVATION_MODIFIER", 53, 59], ["increased", "OBSERVATION_MODIFIER", 73, 82], ["lethality", "OBSERVATION", 83, 92]]], ["This study did not evaluate organ-injury such as liver failure, neurological injury, and coagulation disorders, all of which have been reported with COVID-19.", [["organ", "ANATOMY", 28, 33], ["liver", "ANATOMY", 49, 54], ["neurological", "ANATOMY", 64, 76], ["organ-injury", "DISEASE", 28, 40], ["liver failure", "DISEASE", 49, 62], ["neurological injury", "DISEASE", 64, 83], ["coagulation disorders", "DISEASE", 89, 110], ["COVID-19", "CHEMICAL", 149, 157], ["organ", "ORGAN", 28, 33], ["liver", "ORGAN", 49, 54], ["This study", "TEST", 0, 10], ["injury", "PROBLEM", 34, 40], ["liver failure", "PROBLEM", 49, 62], ["neurological injury", "PROBLEM", 64, 83], ["coagulation disorders", "PROBLEM", 89, 110], ["COVID", "TEST", 149, 154], ["injury", "OBSERVATION", 34, 40], ["liver", "ANATOMY", 49, 54], ["failure", "OBSERVATION", 55, 62], ["neurological", "OBSERVATION_MODIFIER", 64, 76], ["injury", "OBSERVATION", 77, 83]]], ["[20] [21] [22] [23] [24] [25] [26] The increase in volume of COVID-19 cases compared to influenza is noted in Figure 2 .", [["influenza", "DISEASE", 88, 97], ["[20] [21] [22] [23] [24] [25] [26]", "CHEMICAL", 0, 34], ["[20] [21] [22] [23] [24] [25] [26]", "SIMPLE_CHEMICAL", 0, 34], ["COVID", "TEST", 61, 66], ["influenza", "PROBLEM", 88, 97]]], ["This increase in patient volume occurred despite the implementation of increasingly stringent social distancing in Boston starting on March 15, 2020 27 and a statewide stay-at-home advisory starting on March 24, 2020.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["This increase in patient volume", "PROBLEM", 0, 31], ["increase", "OBSERVATION_MODIFIER", 5, 13]]], ["28 New cases began to decrease approximately 6 weeks after these measures were taken.", [["these measures", "TEST", 59, 73], ["decrease", "OBSERVATION_MODIFIER", 22, 30]]], ["Thus, the overall volume of cases of COVID-19 in this report was likely modified by these measures, whereas these mitigation measures were not taken during any influenza season.", [["COVID", "TEST", 37, 42]]], ["Influenza, however, can be modified by the implementation of widespread vaccination programs which are currently not available for COVID-19.Discussion:While not a focus of this study, the critical care resources required to manage the marked increase and severity of disease in COVID19 included the emergent conversion of surgical and cardiac intensive care units to medical intensive care units, and the conversion of postanesthesia care units and multiple medical wards to intensive care units.", [["cardiac", "ANATOMY", 335, 342], ["Influenza", "DISEASE", 0, 9], ["Influenza", "PROBLEM", 0, 9], ["widespread vaccination programs", "TREATMENT", 61, 92], ["COVID", "TEST", 131, 136], ["this study", "TEST", 172, 182], ["the marked increase and severity of disease", "PROBLEM", 231, 274], ["postanesthesia care units", "TREATMENT", 419, 444], ["intensive care units", "TREATMENT", 475, 495], ["marked", "OBSERVATION_MODIFIER", 235, 241], ["increase", "OBSERVATION_MODIFIER", 242, 250]]], ["The conversion of any such space to an intensive care unit has not been done for any influenza season.", [["any influenza season", "PROBLEM", 81, 101]]], ["In addition to space conversion, human resources (i.e., staffing models for new intensive care units), personal protective equipment, and increased use of dialysis were all part of the hospital-wide response (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Discussion:The copyright holder for this preprint this version posted August 22, 2020. .", [["human", "ORGANISM", 33, 38], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["personal protective equipment", "TREATMENT", 103, 132], ["dialysis", "TREATMENT", 155, 163], ["med", "ANATOMY", 287, 290]]], ["No reuse allowed without permission.Discussion:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Discussion:The copyright holder for this preprint this version posted August 22, 2020. .", [["med", "ANATOMY", 126, 129]]], ["No reuse allowed without permission.Discussion:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Discussion:The copyright holder for this preprint this version posted August 22, 2020. .", [["med", "ANATOMY", 126, 129]]], ["Alcohol Use Disorder: n (%) 33 (6) 147 (14) 16 (9) 7 (8) Tobacco: n (%) 107 (18) 211 (20) 29 (17) 22 (26) *BMIs were missing from 77 patients with COVID-19 and 22 patients with influenza All rights reserved.", [["Alcohol", "CHEMICAL", 0, 7], ["Disorder", "DISEASE", 12, 20], ["influenza", "DISEASE", 177, 186], ["patients", "ORGANISM", 133, 141], ["patients", "ORGANISM", 163, 171], ["patients", "SPECIES", 133, 141], ["patients", "SPECIES", 163, 171], ["COVID", "TEST", 147, 152], ["influenza", "PROBLEM", 177, 186]]], ["No reuse allowed without permission.Discussion:(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Discussion:The copyright holder for this preprint this version posted August 22, 2020. .", [["med", "ANATOMY", 126, 129]]], ["(6) 1 (1) 2 (1) 2 (1) 1 (1) 0 (0) 0 (0)Discussion:1 (1) 3 (2) 17 (30) 4 (5) 8 (10) 1 (1) 2 (2) 1 (1) 1 (1) 0 (0)(10)All rights reserved.", [["1 (1) 2 (1) 2 (1) 1 (1) 0 (0", "SIMPLE_CHEMICAL", 4, 32], ["1 (1) 3 (2) 17 (30) 4 (5) 8 (10) 1 (1) 2 (2) 1 (1", "SIMPLE_CHEMICAL", 50, 99]]], ["No reuse allowed without permission.(10)(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(10)The copyright holder for this preprint this version posted August 22, 2020. . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(10)The copyright holder for this preprint this version posted August 22, 2020. . https://doi.org/10.1101/2020.08.19.20163857 doi: medRxiv preprint", [["The copyright holder", "TREATMENT", 179, 199], ["The copyright holder", "TREATMENT", 396, 416], ["medRxiv", "TREATMENT", 523, 530], ["med", "ANATOMY", 119, 122], ["med", "ANATOMY", 336, 339]]]], "PMC6473618": [], "8a31d9fe4b0c6c2d774712b2d225a16572b54360": [["IntroductionAutophagy is a eukaryotic degradation process that is activated during nutrient deprivation, metabolic stress, developmental processes, and in response to some microbial infections (Wirawan et al., 2012) .", [["infections", "DISEASE", 182, 192], ["IntroductionAutophagy", "TREATMENT", 0, 21], ["a eukaryotic degradation process", "PROBLEM", 25, 57], ["nutrient deprivation", "TREATMENT", 83, 103], ["metabolic stress", "PROBLEM", 105, 121], ["developmental processes", "PROBLEM", 123, 146], ["some microbial infections", "PROBLEM", 167, 192], ["eukaryotic degradation", "OBSERVATION", 27, 49], ["microbial", "OBSERVATION_MODIFIER", 172, 181], ["infections", "OBSERVATION", 182, 192]]], ["Early in autophagy a fold of membrane, known as the isolation membrane, curves around cytoplasmic cargo destined for degradation.", [["fold", "ANATOMY", 21, 25], ["membrane", "ANATOMY", 29, 37], ["membrane", "ANATOMY", 62, 70], ["cytoplasmic", "ANATOMY", 86, 97], ["membrane", "CELLULAR_COMPONENT", 29, 37], ["membrane", "CELLULAR_COMPONENT", 62, 70], ["cytoplasmic", "ORGANISM_SUBSTANCE", 86, 97], ["cytoplasmic cargo", "PROTEIN", 86, 103], ["the isolation membrane", "TREATMENT", 48, 70]]], ["The ends of the isolation membrane join together to form a double membranous vesicle.", [["membrane", "ANATOMY", 26, 34], ["membranous vesicle", "ANATOMY", 66, 84], ["membrane", "CELLULAR_COMPONENT", 26, 34], ["membranous vesicle", "CELLULAR_COMPONENT", 66, 84], ["the isolation membrane join", "TREATMENT", 12, 39], ["a double membranous vesicle", "PROBLEM", 57, 84], ["isolation membrane", "OBSERVATION", 16, 34], ["double", "OBSERVATION_MODIFIER", 59, 65], ["membranous vesicle", "OBSERVATION", 66, 84]]], ["This new structure, known as an autophagosome, fuses with the lysosome forming the autolysosome, which is rich in hydrolases that act to enzymatically catabolize the vesicular contents (Juhasz and Neufeld, 2006) .", [["autophagosome", "ANATOMY", 32, 45], ["lysosome", "ANATOMY", 62, 70], ["autolysosome", "ANATOMY", 83, 95], ["vesicular", "ANATOMY", 166, 175], ["autophagosome", "CELLULAR_COMPONENT", 32, 45], ["lysosome", "CELLULAR_COMPONENT", 62, 70], ["vesicular", "MULTI-TISSUE_STRUCTURE", 166, 175], ["autolysosome", "PROTEIN", 83, 95], ["hydrolases", "PROTEIN", 114, 124], ["autophagosome", "OBSERVATION", 32, 45], ["vesicular contents", "OBSERVATION", 166, 184]]], ["By isolating and then directing organelles and large biomolecules toward the lysosome, autophagy enables the cell to break down and redistribute molecules to pathways that are more critical for cell survival.IntroductionFor some intracellular pathogens autophagy acts as antimicrobial defense by helping to deliver invading microorganisms to the lysosome for degradation, antigen presentation, or toll-like receptor engagement (Lee et al., 2007; Gutierrez et al., 2004; Talloczy et al., 2006; Liang et al., 1998; Virgin and Levine, 2009; Dengjel et al., 2005) .IntroductionAutophagy degrades some intracellular pathogens, such as Mycoplasma tuberculosis and herpes simplex virus-1 (HSV-1) (Gutierrez et al., 2004; Jiang et al., 2011; Talloczy et al., 2006) .", [["organelles", "ANATOMY", 32, 42], ["lysosome", "ANATOMY", 77, 85], ["cell", "ANATOMY", 109, 113], ["cell", "ANATOMY", 194, 198], ["intracellular", "ANATOMY", 229, 242], ["lysosome", "ANATOMY", 346, 354], ["intracellular", "ANATOMY", 597, 610], ["Mycoplasma tuberculosis", "DISEASE", 630, 653], ["herpes simplex virus", "DISEASE", 658, 678], ["organelles", "CELLULAR_COMPONENT", 32, 42], ["lysosome", "CELLULAR_COMPONENT", 77, 85], ["cell", "CELL", 109, 113], ["cell", "CELL", 194, 198], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 229, 242], ["lysosome", "CELLULAR_COMPONENT", 346, 354], ["toll-like receptor", "GENE_OR_GENE_PRODUCT", 397, 415], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 597, 610], ["Mycoplasma tuberculosis", "ORGANISM", 630, 653], ["herpes simplex virus-1", "ORGANISM", 658, 680], ["HSV-1", "ORGANISM", 682, 687], ["Mycoplasma tuberculosis", "SPECIES", 630, 653], ["herpes simplex virus-1", "SPECIES", 658, 680], ["HSV-1", "SPECIES", 682, 687], ["Mycoplasma tuberculosis", "SPECIES", 630, 653], ["herpes simplex virus-1", "SPECIES", 658, 680], ["HSV-1", "SPECIES", 682, 687], ["large biomolecules", "PROBLEM", 47, 65], ["the cell", "PROBLEM", 105, 113], ["cell survival", "TREATMENT", 194, 207], ["some intracellular pathogens autophagy", "PROBLEM", 224, 262], ["invading microorganisms", "PROBLEM", 315, 338], ["IntroductionAutophagy", "TREATMENT", 561, 582], ["some intracellular pathogens", "PROBLEM", 592, 620], ["Mycoplasma tuberculosis", "PROBLEM", 630, 653], ["herpes simplex virus", "PROBLEM", 658, 678], ["HSV", "TEST", 682, 685], ["large", "OBSERVATION_MODIFIER", 47, 52], ["biomolecules", "OBSERVATION", 53, 65], ["intracellular pathogens", "OBSERVATION", 597, 620], ["Mycoplasma tuberculosis", "OBSERVATION", 630, 653]]], ["Interestingly, some viruses utilize the autophagosome to promote viral replication, translation, and regulate cell lysis (Hussein et al., 2012; Dreux et al., 2009; Sir et al., 2012; Zhou and Munger, 2009; O'Donnell et al., 2011) .", [["autophagosome", "ANATOMY", 40, 53], ["cell", "ANATOMY", 110, 114], ["autophagosome", "CELLULAR_COMPONENT", 40, 53], ["cell", "CELL", 110, 114], ["some viruses", "PROBLEM", 15, 27], ["viruses", "OBSERVATION", 20, 27], ["viral replication", "OBSERVATION", 65, 82], ["cell lysis", "OBSERVATION", 110, 120]]], ["Many RNA virus including poliovirus, coxsackievirus, coronavirus, and hepatitis C virus induce autophagy levels in the infected host cell to benefit the viral life cycle (Dreux et al., 2009; Wong et al., 2008; Taylor and Kirkegaard, 2008; Maier and Britton, 2012) .", [["cell", "ANATOMY", 133, 137], ["hepatitis C", "DISEASE", 70, 81], ["poliovirus", "ORGANISM", 25, 35], ["coxsackievirus, coronavirus", "ORGANISM", 37, 64], ["hepatitis C virus", "ORGANISM", 70, 87], ["host cell", "CELL", 128, 137], ["infected host cell", "CELL_TYPE", 119, 137], ["coxsackievirus, coronavirus", "SPECIES", 37, 64], ["hepatitis C virus", "SPECIES", 70, 87], ["hepatitis C virus", "SPECIES", 70, 87], ["Many RNA virus", "PROBLEM", 0, 14], ["poliovirus", "PROBLEM", 25, 35], ["coxsackievirus", "PROBLEM", 37, 51], ["coronavirus", "PROBLEM", 53, 64], ["hepatitis C virus", "PROBLEM", 70, 87], ["autophagy levels", "PROBLEM", 95, 111], ["RNA virus", "OBSERVATION", 5, 14], ["poliovirus", "OBSERVATION", 25, 35], ["infected host cell", "OBSERVATION", 119, 137]]], ["RNA viruses are thought to utilize the double membranous autophagosome structure as a platform for promoting viral transcription or replication (Maier and Britton, 2012) .IntroductionThe human BK polyomavirus, (BKPyV), is a small doublestranded DNA virus known to cause tumors in rodents.", [["autophagosome", "ANATOMY", 57, 70], ["tumors", "ANATOMY", 270, 276], ["tumors", "DISEASE", 270, 276], ["human", "ORGANISM", 187, 192], ["BK polyomavirus", "ORGANISM", 193, 208], ["BKPyV", "GENE_OR_GENE_PRODUCT", 211, 216], ["DNA", "CELLULAR_COMPONENT", 245, 248], ["tumors", "CANCER", 270, 276], ["human", "SPECIES", 187, 192], ["human BK polyomavirus", "SPECIES", 187, 208], ["BKPyV", "SPECIES", 211, 216], ["RNA viruses", "PROBLEM", 0, 11], ["the double membranous autophagosome structure", "PROBLEM", 35, 80], ["promoting viral transcription", "TREATMENT", 99, 128], ["The human BK polyomavirus", "TEST", 183, 208], ["a small doublestranded DNA virus", "PROBLEM", 222, 254], ["tumors in rodents", "PROBLEM", 270, 287], ["viruses", "OBSERVATION", 4, 11], ["double membranous", "OBSERVATION_MODIFIER", 39, 56], ["autophagosome structure", "OBSERVATION", 57, 80], ["human BK", "ANATOMY", 187, 195], ["polyomavirus", "OBSERVATION", 196, 208], ["small", "OBSERVATION_MODIFIER", 224, 229], ["tumors", "OBSERVATION", 270, 276]]], ["In humans BKPyV is the causative agent of polyomavirus associated nephropathy, a viral complication that affects approximately 5-10% of kidney transplant recipients (Drachenberg et al., 2007; Schaub et al., 2010) .", [["kidney", "ANATOMY", 136, 142], ["nephropathy", "DISEASE", 66, 77], ["humans", "ORGANISM", 3, 9], ["BKPyV", "GENE_OR_GENE_PRODUCT", 10, 15], ["polyomavirus", "ORGANISM", 42, 54], ["kidney", "ORGAN", 136, 142], ["recipients", "ORGANISM", 154, 164], ["humans", "SPECIES", 3, 9], ["humans", "SPECIES", 3, 9], ["polyomavirus associated nephropathy", "PROBLEM", 42, 77], ["a viral complication", "PROBLEM", 79, 99], ["kidney transplant recipients", "TREATMENT", 136, 164], ["BKPyV", "OBSERVATION", 10, 15], ["polyomavirus", "OBSERVATION", 42, 54], ["nephropathy", "OBSERVATION", 66, 77], ["viral complication", "OBSERVATION", 81, 99], ["kidney", "ANATOMY", 136, 142], ["transplant", "OBSERVATION", 143, 153]]], ["As BKPyV is an intracellular pathogen, its life cycle is intimately connected with its host cell.", [["intracellular", "ANATOMY", 15, 28], ["cell", "ANATOMY", 92, 96], ["BKPyV", "CHEMICAL", 3, 8], ["BKPyV", "GENE_OR_GENE_PRODUCT", 3, 8], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 15, 28], ["host cell", "CELL", 87, 96], ["BKPyV", "SPECIES", 3, 8], ["an intracellular pathogen", "PROBLEM", 12, 37], ["intracellular", "OBSERVATION_MODIFIER", 15, 28], ["pathogen", "OBSERVATION", 29, 37], ["host cell", "OBSERVATION", 87, 96]]], ["Previous studies have shown the BKPyV requires vesicular acidification during the infectious process, but the virus does not seem to use the canonical endosome-lysosome pathway (Eash and Atwood, 2005; Eash et al., 2004; Jiang et al., 2009) .", [["vesicular", "ANATOMY", 47, 56], ["BKPyV", "GENE_OR_GENE_PRODUCT", 32, 37], ["vesicular", "MULTI-TISSUE_STRUCTURE", 47, 56], ["endosome", "CELLULAR_COMPONENT", 151, 159], ["lysosome", "CELLULAR_COMPONENT", 160, 168], ["BKPyV", "PROTEIN", 32, 37], ["Previous studies", "TEST", 0, 16], ["the BKPyV", "PROBLEM", 28, 37], ["vesicular acidification", "PROBLEM", 47, 70], ["the infectious process", "PROBLEM", 78, 100], ["the virus", "PROBLEM", 106, 115], ["BKPyV", "OBSERVATION", 32, 37], ["vesicular", "OBSERVATION_MODIFIER", 47, 56], ["acidification", "OBSERVATION", 57, 70], ["infectious", "OBSERVATION", 82, 92]]], ["In this study, we explored the importance of autophagy in BKPyV infection.Excess amino acids reduce BKPyV infectionTo test the affect of nutrient availability on BKPyV infection levels, Vero cells, a green monkey renal epithelial cell line, were incubated with media containing differing concentrations of essential amino acids before and after being challenged with BKPyV (Fig. 1A) .", [["Vero cells", "ANATOMY", 186, 196], ["renal epithelial cell line", "ANATOMY", 213, 239], ["infection", "DISEASE", 64, 73], ["amino acids", "CHEMICAL", 81, 92], ["BKPyV", "CHEMICAL", 100, 105], ["infection", "DISEASE", 106, 115], ["infection", "DISEASE", 168, 177], ["amino acids", "CHEMICAL", 316, 327], ["amino acids", "CHEMICAL", 81, 92], ["amino acids", "CHEMICAL", 316, 327], ["BKPyV", "CANCER", 58, 63], ["amino acids", "AMINO_ACID", 81, 92], ["BKPyV", "SIMPLE_CHEMICAL", 100, 105], ["BKPyV", "SIMPLE_CHEMICAL", 162, 167], ["Vero cells", "CELL", 186, 196], ["monkey", "ORGANISM", 206, 212], ["renal epithelial cell line", "CELL", 213, 239], ["amino acids", "AMINO_ACID", 316, 327], ["Vero cells", "CELL_LINE", 186, 196], ["green monkey renal epithelial cell line", "CELL_LINE", 200, 239], ["BKPyV", "SPECIES", 58, 63], ["green monkey", "SPECIES", 200, 212], ["this study", "TEST", 3, 13], ["autophagy", "PROBLEM", 45, 54], ["BKPyV infection", "PROBLEM", 58, 73], ["Excess amino acids", "TREATMENT", 74, 92], ["BKPyV infection", "PROBLEM", 100, 115], ["BKPyV infection levels", "PROBLEM", 162, 184], ["Vero cells", "PROBLEM", 186, 196], ["a green monkey renal epithelial cell line", "TREATMENT", 198, 239], ["media", "TREATMENT", 261, 266], ["essential amino acids", "TREATMENT", 306, 327], ["BKPyV (Fig", "TREATMENT", 367, 377], ["BKPyV", "OBSERVATION_MODIFIER", 58, 63], ["infection", "OBSERVATION", 64, 73], ["amino acids", "OBSERVATION", 81, 92], ["infection", "OBSERVATION", 106, 115], ["renal", "ANATOMY", 213, 218], ["epithelial cell line", "OBSERVATION", 219, 239], ["amino acids", "OBSERVATION", 316, 327]]], ["Sodium hydroxide was added to amino acidsupplemented media so that media had identical pH levels.", [["Sodium hydroxide", "CHEMICAL", 0, 16], ["amino acidsupplemented", "CHEMICAL", 30, 52], ["Sodium hydroxide", "CHEMICAL", 0, 16], ["amino", "CHEMICAL", 30, 35], ["Sodium hydroxide", "SIMPLE_CHEMICAL", 0, 16], ["Sodium hydroxide", "TREATMENT", 0, 16], ["amino acidsupplemented media", "TREATMENT", 30, 58], ["identical pH levels", "TEST", 77, 96]]], ["Increasing the concentration of amino acids led to a decrease in BKPyV infection in host cells indicating that higher levels of amino acids hinder BKPyV infectivity.", [["cells", "ANATOMY", 89, 94], ["amino acids", "CHEMICAL", 32, 43], ["BKPyV", "CHEMICAL", 65, 70], ["infection", "DISEASE", 71, 80], ["amino acids", "CHEMICAL", 128, 139], ["amino acids", "CHEMICAL", 32, 43], ["amino acids", "CHEMICAL", 128, 139], ["amino acids", "AMINO_ACID", 32, 43], ["BKPyV", "SIMPLE_CHEMICAL", 65, 70], ["host cells", "CELL", 84, 94], ["amino acids", "AMINO_ACID", 128, 139], ["BKPyV", "GENE_OR_GENE_PRODUCT", 147, 152], ["host cells", "CELL_TYPE", 84, 94], ["amino acids", "TREATMENT", 32, 43], ["a decrease in BKPyV infection in host cells", "PROBLEM", 51, 94], ["amino acids", "TREATMENT", 128, 139], ["BKPyV infectivity", "PROBLEM", 147, 164], ["decrease", "OBSERVATION_MODIFIER", 53, 61], ["BKPyV", "OBSERVATION_MODIFIER", 65, 70], ["infection", "OBSERVATION", 71, 80], ["host cells", "OBSERVATION", 84, 94]]], ["Addition of amino acids did not lead to a change in Vero cell death or proliferation (Fig. 1B) .", [["Vero cell", "ANATOMY", 52, 61], ["amino acids", "CHEMICAL", 12, 23], ["death", "DISEASE", 62, 67], ["amino acids", "CHEMICAL", 12, 23], ["amino acids", "AMINO_ACID", 12, 23], ["Vero cell", "CELL", 52, 61], ["amino acids", "TREATMENT", 12, 23], ["a change in Vero cell death", "PROBLEM", 40, 67], ["Vero cell death", "OBSERVATION", 52, 67]]], ["One hypothesis is that cells treated with amino acids have lower autophagy levels, as nutrient deprivation is a major activator of cellular autophagy.", [["cells", "ANATOMY", 23, 28], ["cellular", "ANATOMY", 131, 139], ["amino acids", "CHEMICAL", 42, 53], ["amino acids", "CHEMICAL", 42, 53], ["cells", "CELL", 23, 28], ["amino acids", "AMINO_ACID", 42, 53], ["cellular", "CELL", 131, 139], ["amino acids", "TREATMENT", 42, 53], ["lower autophagy levels", "PROBLEM", 59, 81], ["nutrient deprivation", "TREATMENT", 86, 106], ["cellular autophagy", "OBSERVATION", 131, 149]]], ["To evaluate the level of autophagy in amino acid supplemented cells, a plasmid encoding microtubuleassociated protein light chain 3 fused to green fluorescent protein (LC3-GFP) was transfected into cells.", [["cells", "ANATOMY", 62, 67], ["plasmid", "ANATOMY", 71, 78], ["cells", "ANATOMY", 198, 203], ["amino acid", "CHEMICAL", 38, 48], ["amino acid", "CHEMICAL", 38, 48], ["amino acid", "AMINO_ACID", 38, 48], ["cells", "CELL", 62, 67], ["microtubuleassociated protein light chain 3", "GENE_OR_GENE_PRODUCT", 88, 131], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 141, 166], ["LC3-GFP", "GENE_OR_GENE_PRODUCT", 168, 175], ["cells", "CELL", 198, 203], ["amino acid supplemented cells", "CELL_LINE", 38, 67], ["microtubuleassociated protein light chain 3", "PROTEIN", 88, 131], ["green fluorescent protein", "PROTEIN", 141, 166], ["LC3", "PROTEIN", 168, 171], ["GFP", "PROTEIN", 172, 175], ["amino acid supplemented cells", "TREATMENT", 38, 67], ["a plasmid encoding microtubuleassociated protein light chain", "TEST", 69, 129], ["green fluorescent protein", "TEST", 141, 166], ["LC3-GFP", "TEST", 168, 175]]], ["LC3 is distributed in a diffuse pattern throughout the cytoplasm in the presence of low levels of autophagy (LC3-I), and acquires a distinct punctate distribution during autophagy (LC3-II) (Mizushima, 2004; Kabeya et al., 2000) .", [["cytoplasm", "ANATOMY", 55, 64], ["LC3", "GENE_OR_GENE_PRODUCT", 0, 3], ["cytoplasm", "ORGANISM_SUBSTANCE", 55, 64], ["LC3-I", "GENE_OR_GENE_PRODUCT", 109, 114], ["LC3-II", "GENE_OR_GENE_PRODUCT", 181, 187], ["LC3", "PROTEIN", 0, 3], ["LC3", "PROTEIN", 109, 112], ["LC3", "PROTEIN", 181, 184], ["LC3", "PROBLEM", 0, 3], ["a diffuse pattern throughout the cytoplasm", "PROBLEM", 22, 64], ["low levels of autophagy", "PROBLEM", 84, 107], ["a distinct punctate distribution during autophagy", "PROBLEM", 130, 179], ["distributed", "OBSERVATION_MODIFIER", 7, 18], ["diffuse", "OBSERVATION_MODIFIER", 24, 31], ["pattern", "OBSERVATION_MODIFIER", 32, 39], ["cytoplasm", "OBSERVATION_MODIFIER", 55, 64], ["low levels", "OBSERVATION_MODIFIER", 84, 94], ["autophagy", "OBSERVATION", 98, 107], ["distinct", "OBSERVATION_MODIFIER", 132, 140], ["punctate", "OBSERVATION_MODIFIER", 141, 149], ["distribution", "OBSERVATION_MODIFIER", 150, 162]]], ["LC3-GFP transfected cells were treated with 100 nM rapamycin, a drug known to activate autophagy, in media with different concentrations of amino acids.", [["cells", "ANATOMY", 20, 25], ["rapamycin", "CHEMICAL", 51, 60], ["amino acids", "CHEMICAL", 140, 151], ["rapamycin", "CHEMICAL", 51, 60], ["amino acids", "CHEMICAL", 140, 151], ["LC3", "GENE_OR_GENE_PRODUCT", 0, 3], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["cells", "CELL", 20, 25], ["rapamycin", "SIMPLE_CHEMICAL", 51, 60], ["amino acids", "AMINO_ACID", 140, 151], ["LC3", "PROTEIN", 0, 3], ["GFP transfected cells", "CELL_LINE", 4, 25], ["LC3", "TEST", 0, 3], ["100 nM rapamycin", "TREATMENT", 44, 60], ["a drug", "TREATMENT", 62, 68], ["amino acids", "TREATMENT", 140, 151], ["GFP transfected cells", "OBSERVATION", 4, 25]]], ["24 h later the number of LC3-GFP \u00fe punctae per cell was scored for 80 cells.", [["punctae", "ANATOMY", 35, 42], ["cell", "ANATOMY", 47, 51], ["cells", "ANATOMY", 70, 75], ["LC3", "GENE_OR_GENE_PRODUCT", 25, 28], ["GFP", "GENE_OR_GENE_PRODUCT", 29, 32], ["cell", "CELL", 47, 51], ["cells", "CELL", 70, 75], ["LC3", "PROTEIN", 25, 28], ["GFP", "PROTEIN", 29, 32], ["LC3", "TEST", 25, 28]]], ["Addition of amino acids led to a decrease in the number of LC3-GFP \u00fepunctae per cell suggesting that amino acid supplementation suppressed autophagy (Fig. 1C) .Modulating autophagy levels affects BKPyV infectionTo determine whether autophagy is important in BKPyV infection, host cells were treated with pharmacological agents that affect autophagy levels, infected with BKPyV, and stained for VP1 72 h post infection.", [["cell", "ANATOMY", 80, 84], ["BKPyV", "ANATOMY", 258, 263], ["cells", "ANATOMY", 280, 285], ["amino acids", "CHEMICAL", 12, 23], ["amino acid", "CHEMICAL", 101, 111], ["infection", "DISEASE", 264, 273], ["infection", "DISEASE", 408, 417], ["amino acids", "CHEMICAL", 12, 23], ["amino acid", "CHEMICAL", 101, 111], ["amino acids", "AMINO_ACID", 12, 23], ["LC3", "GENE_OR_GENE_PRODUCT", 59, 62], ["GFP", "GENE_OR_GENE_PRODUCT", 63, 66], ["cell", "CELL", 80, 84], ["amino acid", "AMINO_ACID", 101, 111], ["BKPyV", "GENE_OR_GENE_PRODUCT", 196, 201], ["BKPyV", "GENE_OR_GENE_PRODUCT", 258, 263], ["host cells", "CELL", 275, 285], ["LC3", "PROTEIN", 59, 62], ["GFP", "PROTEIN", 63, 66], ["host cells", "CELL_TYPE", 275, 285], ["BKPyV", "PROTEIN", 371, 376], ["BKPyV", "SPECIES", 196, 201], ["BKPyV", "SPECIES", 258, 263], ["BKPyV", "SPECIES", 371, 376], ["amino acids", "TREATMENT", 12, 23], ["a decrease", "PROBLEM", 31, 41], ["amino acid supplementation", "TREATMENT", 101, 127], ["Modulating autophagy levels", "PROBLEM", 160, 187], ["BKPyV infectionTo", "PROBLEM", 196, 213], ["autophagy", "PROBLEM", 232, 241], ["BKPyV infection", "PROBLEM", 258, 273], ["host cells", "PROBLEM", 275, 285], ["pharmacological agents", "TREATMENT", 304, 326], ["autophagy levels", "PROBLEM", 339, 355], ["BKPyV", "PROBLEM", 371, 376], ["VP1", "PROBLEM", 394, 397], ["infection", "PROBLEM", 408, 417], ["decrease", "OBSERVATION_MODIFIER", 33, 41], ["infection", "OBSERVATION", 408, 417]]], ["Rapamycin is a drug that inactivates the protein mammalian target of rapamycin (mTOR), a kinase that promotes cell growth and protein synthesis.", [["cell", "ANATOMY", 110, 114], ["Rapamycin", "CHEMICAL", 0, 9], ["rapamycin", "CHEMICAL", 69, 78], ["Rapamycin", "CHEMICAL", 0, 9], ["rapamycin", "CHEMICAL", 69, 78], ["Rapamycin", "SIMPLE_CHEMICAL", 0, 9], ["mammalian target of rapamycin", "GENE_OR_GENE_PRODUCT", 49, 78], ["mTOR", "GENE_OR_GENE_PRODUCT", 80, 84], ["cell", "CELL", 110, 114], ["protein mammalian target of rapamycin", "PROTEIN", 41, 78], ["mTOR", "PROTEIN", 80, 84], ["Rapamycin", "TREATMENT", 0, 9], ["a drug", "TREATMENT", 13, 19], ["rapamycin (mTOR", "TREATMENT", 69, 84], ["protein synthesis", "PROBLEM", 126, 143], ["protein synthesis", "OBSERVATION", 126, 143]]], ["Rapamycin also elevates autophagy levels Noda and Ohsumi, 1998) .", [["Rapamycin", "CHEMICAL", 0, 9], ["Rapamycin", "CHEMICAL", 0, 9], ["Rapamycin", "SIMPLE_CHEMICAL", 0, 9], ["Rapamycin", "TREATMENT", 0, 9]]], ["Vero cells treated with 100 nM rapamycin showed elevated BKPyV infection levels compared to DMSO-treated cells indicating that inhibition of mTOR elevates infection ( Fig. 2A and F ).", [["Vero cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 105, 110], ["rapamycin", "CHEMICAL", 31, 40], ["infection", "DISEASE", 63, 72], ["DMSO", "CHEMICAL", 92, 96], ["infection", "DISEASE", 155, 164], ["rapamycin", "CHEMICAL", 31, 40], ["DMSO", "CHEMICAL", 92, 96], ["Vero cells", "CELL", 0, 10], ["rapamycin", "SIMPLE_CHEMICAL", 31, 40], ["BKPyV", "SIMPLE_CHEMICAL", 57, 62], ["DMSO", "SIMPLE_CHEMICAL", 92, 96], ["cells", "CELL", 105, 110], ["mTOR", "GENE_OR_GENE_PRODUCT", 141, 145], ["Vero cells", "CELL_LINE", 0, 10], ["BKPyV", "PROTEIN", 57, 62], ["DMSO-treated cells", "CELL_LINE", 92, 110], ["mTOR", "PROTEIN", 141, 145], ["Vero cells", "PROBLEM", 0, 10], ["100 nM rapamycin", "TREATMENT", 24, 40], ["elevated BKPyV infection levels", "PROBLEM", 48, 79], ["DMSO-treated cells", "TREATMENT", 92, 110], ["mTOR elevates infection", "PROBLEM", 141, 164], ["elevated", "OBSERVATION_MODIFIER", 48, 56], ["BKPyV infection", "OBSERVATION", 57, 72], ["infection", "OBSERVATION", 155, 164]]], ["3-MA is an inhibitor of autophagy that blocks phosphatidylinositol 3-kinase (PI3K) activation, an event that is necessary for membrane trafficking during autophagy (Blommaart et al., 1997; Petiot et al., 2000) .", [["membrane", "ANATOMY", 126, 134], ["3-MA", "CHEMICAL", 0, 4], ["3-MA", "CHEMICAL", 0, 4], ["phosphatidylinositol", "CHEMICAL", 46, 66], ["3-MA", "SIMPLE_CHEMICAL", 0, 4], ["phosphatidylinositol 3-kinase", "GENE_OR_GENE_PRODUCT", 46, 75], ["PI3K", "GENE_OR_GENE_PRODUCT", 77, 81], ["membrane", "CELLULAR_COMPONENT", 126, 134], ["phosphatidylinositol 3-kinase", "PROTEIN", 46, 75], ["PI3K", "PROTEIN", 77, 81], ["phosphatidylinositol", "TEST", 46, 66], ["membrane trafficking", "PROBLEM", 126, 146]]], ["Cells treated with 3-MA showed a dose-dependent decrease in infection ( Fig. 2B and F) suggesting that autophagy promotes BKPyV infection.", [["Cells", "ANATOMY", 0, 5], ["3-MA", "CHEMICAL", 19, 23], ["infection", "DISEASE", 60, 69], ["infection", "DISEASE", 128, 137], ["3-MA", "CHEMICAL", 19, 23], ["Cells", "CELL", 0, 5], ["3-MA", "SIMPLE_CHEMICAL", 19, 23], ["BKPyV", "GENE_OR_GENE_PRODUCT", 122, 127], ["BKPyV", "SPECIES", 122, 127], ["dependent decrease in infection", "PROBLEM", 38, 69], ["autophagy", "PROBLEM", 103, 112], ["BKPyV infection", "PROBLEM", 122, 137], ["dependent", "OBSERVATION_MODIFIER", 38, 47], ["decrease", "OBSERVATION_MODIFIER", 48, 56], ["infection", "OBSERVATION", 60, 69], ["BKPyV infection", "OBSERVATION", 122, 137]]], ["Rapamycin was able to restore infection to 3-MA-treated Vero cells (Fig. 2C ).", [["Vero cells", "ANATOMY", 56, 66], ["Rapamycin", "CHEMICAL", 0, 9], ["infection", "DISEASE", 30, 39], ["3-MA", "CHEMICAL", 43, 47], ["Rapamycin", "CHEMICAL", 0, 9], ["3-MA", "CHEMICAL", 43, 47], ["Rapamycin", "SIMPLE_CHEMICAL", 0, 9], ["3-MA", "SIMPLE_CHEMICAL", 43, 47], ["Vero cells", "CELL", 56, 66], ["Fig. 2C", "CELL", 68, 75], ["3-MA-treated Vero cells", "CELL_LINE", 43, 66], ["Rapamycin", "TREATMENT", 0, 9], ["restore infection", "PROBLEM", 22, 39], ["infection", "OBSERVATION", 30, 39]]], ["Another autophagy inhibitor, spautin-1, degrades class III PI3K by inhibiting the activity of the ubiquitin specific peptidases, USP10 and USP13 (Mateo et al., 2013; Liu et al., 2011) .", [["spautin-1", "GENE_OR_GENE_PRODUCT", 29, 38], ["class III PI3K", "GENE_OR_GENE_PRODUCT", 49, 63], ["USP10", "GENE_OR_GENE_PRODUCT", 129, 134], ["USP13", "GENE_OR_GENE_PRODUCT", 139, 144], ["class III PI3K", "PROTEIN", 49, 63], ["ubiquitin specific peptidases", "PROTEIN", 98, 127], ["USP10", "PROTEIN", 129, 134], ["USP13", "PROTEIN", 139, 144], ["Another autophagy inhibitor", "TEST", 0, 27], ["spautin", "TEST", 29, 36]]], ["Spautin-1 also reduced BKPyV infection in a dose-dependent manner ( Fig. 2D and F).", [["Spautin-1", "CHEMICAL", 0, 9], ["infection", "DISEASE", 29, 38], ["Spautin-1", "CHEMICAL", 0, 9], ["Spautin-1", "GENE_OR_GENE_PRODUCT", 0, 9], ["BKPyV", "GENE_OR_GENE_PRODUCT", 23, 28], ["BKPyV", "SPECIES", 23, 28], ["reduced BKPyV infection", "PROBLEM", 15, 38], ["reduced", "OBSERVATION_MODIFIER", 15, 22], ["BKPyV", "OBSERVATION_MODIFIER", 23, 28], ["infection", "OBSERVATION", 29, 38]]], ["Vero cells treated with bafilomycin A1, a vacuolar H \u00fe ATPase inhibitor that blocks lysosomal acidification that is necessary for both autophagic degradation and endosome maturation, were also less susceptible to BKPyV infection suggesting that vesicular acidification is important for BKPyV infection ( Fig. 2E and F) (Tanigaki et al., 2003) .", [["Vero cells", "ANATOMY", 0, 10], ["lysosomal", "ANATOMY", 84, 93], ["autophagic", "ANATOMY", 135, 145], ["endosome", "ANATOMY", 162, 170], ["vesicular", "ANATOMY", 245, 254], ["bafilomycin A1", "CHEMICAL", 24, 38], ["BKPyV", "CHEMICAL", 213, 218], ["infection", "DISEASE", 219, 228], ["infection", "DISEASE", 292, 301], ["bafilomycin A1", "CHEMICAL", 24, 38], ["H", "CHEMICAL", 51, 52], ["Vero cells", "CELL", 0, 10], ["bafilomycin A1", "SIMPLE_CHEMICAL", 24, 38], ["vacuolar H \u00fe ATPase", "GENE_OR_GENE_PRODUCT", 42, 61], ["lysosomal", "CELLULAR_COMPONENT", 84, 93], ["endosome", "CELLULAR_COMPONENT", 162, 170], ["BKPyV", "GENE_OR_GENE_PRODUCT", 213, 218], ["vesicular", "MULTI-TISSUE_STRUCTURE", 245, 254], ["BKPyV", "GENE_OR_GENE_PRODUCT", 286, 291], ["Vero cells", "CELL_LINE", 0, 10], ["vacuolar H \u00fe ATPase", "PROTEIN", 42, 61], ["BKPyV", "SPECIES", 213, 218], ["BKPyV", "SPECIES", 286, 291], ["Vero cells", "PROBLEM", 0, 10], ["bafilomycin A1", "TREATMENT", 24, 38], ["a vacuolar H \u00fe ATPase inhibitor", "TREATMENT", 40, 71], ["blocks lysosomal acidification", "PROBLEM", 77, 107], ["both autophagic degradation", "PROBLEM", 130, 157], ["BKPyV infection", "PROBLEM", 213, 228], ["vesicular acidification", "PROBLEM", 245, 268], ["BKPyV infection", "PROBLEM", 286, 301], ["lysosomal acidification", "OBSERVATION", 84, 107], ["autophagic degradation", "OBSERVATION", 135, 157], ["endosome maturation", "OBSERVATION", 162, 181], ["infection", "OBSERVATION", 219, 228], ["vesicular acidification", "OBSERVATION", 245, 268]]], ["Taken together these data suggest that autophagy may be important in BKPyV infection.", [["infection", "DISEASE", 75, 84], ["BKPyV", "CANCER", 69, 74], ["BKPyV", "SPECIES", 69, 74], ["these data", "TEST", 15, 25], ["autophagy", "PROBLEM", 39, 48], ["BKPyV infection", "PROBLEM", 69, 84], ["may be important", "UNCERTAINTY", 49, 65], ["BKPyV", "OBSERVATION_MODIFIER", 69, 74], ["infection", "OBSERVATION", 75, 84]]], ["A trypan blue exclusion assay verified that the pharmacological agents used in this study no statistically significant difference in cytotoxicity compared to no drug control (Supplemental Fig. 1 ).", [["trypan blue", "CHEMICAL", 2, 13], ["trypan blue", "CHEMICAL", 2, 13], ["trypan blue", "SIMPLE_CHEMICAL", 2, 13], ["A trypan blue exclusion assay", "TEST", 0, 29], ["the pharmacological agents", "TREATMENT", 44, 70], ["this study", "TEST", 79, 89], ["statistically significant difference in cytotoxicity", "PROBLEM", 93, 145], ["drug control", "TREATMENT", 161, 173]]], ["BKPyV-infected HeLa cells, which are permissive to BKPyV and have similar infection kinetics to Vero cells, showed nearly identical infection levels after drug treatments (Supplemental Fig. 2 ).", [["HeLa cells", "ANATOMY", 15, 25], ["Vero cells", "ANATOMY", 96, 106], ["infection", "DISEASE", 74, 83], ["infection", "DISEASE", 132, 141], ["BKPyV", "GENE_OR_GENE_PRODUCT", 0, 5], ["HeLa cells", "CELL", 15, 25], ["BKPyV", "GENE_OR_GENE_PRODUCT", 51, 56], ["Vero cells", "CELL", 96, 106], ["BKPyV-infected HeLa cells", "CELL_LINE", 0, 25], ["BKPyV", "PROTEIN", 51, 56], ["Vero cells", "CELL_LINE", 96, 106], ["BKPyV", "PROBLEM", 0, 5], ["infected HeLa cells", "PROBLEM", 6, 25], ["BKPyV", "PROBLEM", 51, 56], ["similar infection kinetics", "PROBLEM", 66, 92], ["Vero cells", "PROBLEM", 96, 106], ["nearly identical infection levels", "PROBLEM", 115, 148], ["drug treatments", "TREATMENT", 155, 170], ["infected", "OBSERVATION_MODIFIER", 6, 14], ["HeLa cells", "OBSERVATION", 15, 25], ["similar", "OBSERVATION_MODIFIER", 66, 73], ["infection", "OBSERVATION", 74, 83], ["Vero cells", "OBSERVATION", 96, 106], ["identical", "OBSERVATION_MODIFIER", 122, 131], ["infection", "OBSERVATION", 132, 141]]], ["When VP1 staining was compared in untreated cells infected with BKPyV for 3 h versus 72 h, VP1 nuclear staining was only observed in the 72 h condition with BKPyV in EMEM media with 5% fetal bovine serum with and without additional essential amino acids.", [["cells", "ANATOMY", 44, 49], ["nuclear", "ANATOMY", 95, 102], ["fetal bovine serum", "ANATOMY", 185, 203], ["BKPyV", "CHEMICAL", 157, 162], ["amino acids", "CHEMICAL", 242, 253], ["amino acids", "CHEMICAL", 242, 253], ["VP1", "GENE_OR_GENE_PRODUCT", 5, 8], ["cells", "CELL", 44, 49], ["VP1", "ORGANISM", 91, 94], ["nuclear", "CELLULAR_COMPONENT", 95, 102], ["BKPyV", "SIMPLE_CHEMICAL", 157, 162], ["bovine", "ORGANISM", 191, 197], ["serum", "ORGANISM_SUBSTANCE", 198, 203], ["amino acids", "AMINO_ACID", 242, 253], ["VP1", "PROTEIN", 5, 8], ["untreated cells", "CELL_TYPE", 34, 49], ["BKPyV", "PROTEIN", 64, 69], ["VP1", "PROTEIN", 91, 94], ["bovine", "SPECIES", 191, 197], ["BKPyV", "SPECIES", 64, 69], ["BKPyV", "SPECIES", 157, 162], ["bovine", "SPECIES", 191, 197], ["VP1 staining", "TEST", 5, 17], ["untreated cells", "PROBLEM", 34, 49], ["BKPyV", "PROBLEM", 64, 69], ["VP1 nuclear staining", "TEST", 91, 111], ["BKPyV in EMEM media", "TREATMENT", 157, 176], ["5% fetal bovine serum", "TEST", 182, 203], ["additional essential amino acids", "TREATMENT", 221, 253], ["BKPyV", "OBSERVATION", 157, 162], ["amino acids", "OBSERVATION", 242, 253]]], ["EMEM without additional supplementation is labeled 0 \u00c2 .", [["EMEM", "CHEMICAL", 0, 4]]], ["After infection, the cells were replaced with EMEM media with 5% fetal bovine serum with or without the addition of amino acids and left for duration of infection.", [["cells", "ANATOMY", 21, 26], ["fetal bovine serum", "ANATOMY", 65, 83], ["infection", "DISEASE", 6, 15], ["amino acids", "CHEMICAL", 116, 127], ["infection", "DISEASE", 153, 162], ["amino acids", "CHEMICAL", 116, 127], ["cells", "CELL", 21, 26], ["bovine", "ORGANISM", 71, 77], ["serum", "ORGANISM_SUBSTANCE", 78, 83], ["amino acids", "AMINO_ACID", 116, 127], ["bovine", "SPECIES", 71, 77], ["bovine", "SPECIES", 71, 77], ["infection", "PROBLEM", 6, 15], ["the cells", "PROBLEM", 17, 26], ["EMEM media", "TREATMENT", 46, 56], ["5% fetal bovine serum", "TREATMENT", 62, 83], ["amino acids", "TREATMENT", 116, 127], ["infection", "PROBLEM", 153, 162], ["infection", "OBSERVATION", 6, 15], ["infection", "OBSERVATION", 153, 162]]], ["Cells were fixed at 72 h post infection using paraformaldehyde and permeabilized with Triton X-100.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 30, 39], ["paraformaldehyde", "CHEMICAL", 46, 62], ["Triton X-100", "CHEMICAL", 86, 98], ["paraformaldehyde", "CHEMICAL", 46, 62], ["Triton X-100", "CHEMICAL", 86, 98], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 46, 62], ["Triton X-100", "SIMPLE_CHEMICAL", 86, 98], ["Cells", "TEST", 0, 5], ["infection", "PROBLEM", 30, 39], ["paraformaldehyde", "TREATMENT", 46, 62], ["Triton", "TREATMENT", 86, 92], ["infection", "OBSERVATION", 30, 39]]], ["Infection was determined by using an antibody (PAB597) specific to the viral protein VP1 and then scoring the number of VP1\u00fe cells using indirect immunofluorescence.", [["VP1\u00fe cells", "ANATOMY", 120, 130], ["PAB597", "GENE_OR_GENE_PRODUCT", 47, 53], ["VP1", "GENE_OR_GENE_PRODUCT", 85, 88], ["VP1\u00fe cells", "CELL", 120, 130], ["PAB597", "PROTEIN", 47, 53], ["viral protein VP1", "PROTEIN", 71, 88], ["VP1\u00fe cells", "CELL_LINE", 120, 130], ["Infection", "PROBLEM", 0, 9], ["an antibody", "TEST", 34, 45], ["the viral protein VP1", "TEST", 67, 88], ["indirect immunofluorescence", "TEST", 137, 164], ["VP1\u00fe cells", "OBSERVATION", 120, 130]]], ["(B) Cell death was evaluated 24 h following amino acid supplementation by scoring the number of cells excluding trypan blue and graphing the percentage of cells that excluded the trypan blue dye.", [["Cell", "ANATOMY", 4, 8], ["cells", "ANATOMY", 96, 101], ["cells", "ANATOMY", 155, 160], ["death", "DISEASE", 9, 14], ["amino acid", "CHEMICAL", 44, 54], ["trypan blue", "CHEMICAL", 112, 123], ["trypan blue", "CHEMICAL", 179, 190], ["amino acid", "CHEMICAL", 44, 54], ["trypan blue", "CHEMICAL", 112, 123], ["trypan blue", "CHEMICAL", 179, 190], ["Cell", "CELL", 4, 8], ["amino acid", "AMINO_ACID", 44, 54], ["cells", "CELL", 96, 101], ["trypan blue", "SIMPLE_CHEMICAL", 112, 123], ["cells", "CELL", 155, 160], ["trypan blue dye", "SIMPLE_CHEMICAL", 179, 194], ["Cell death", "PROBLEM", 4, 14], ["amino acid supplementation", "TREATMENT", 44, 70], ["trypan blue", "TEST", 112, 123], ["the trypan blue dye", "PROBLEM", 175, 194], ["trypan blue dye", "OBSERVATION", 179, 194]]], ["To measure cell proliferation a MTS assay was used.", [["cell", "ANATOMY", 11, 15], ["cell", "CELL", 11, 15], ["a MTS assay", "TEST", 30, 41], ["cell proliferation", "OBSERVATION", 11, 29]]], ["Vero cells in 96 well plate were incubated with amino acids for 24 h after which 20 \u03bcl of CellTiter 96 AQueous One Solution Reagent -MTS (Promega) reagent was added directly to cells and media for 2 h, and absorbance was measure at 450 nm.", [["Vero cells", "ANATOMY", 0, 10], ["cells", "ANATOMY", 177, 182], ["amino acids", "CHEMICAL", 48, 59], ["amino acids", "CHEMICAL", 48, 59], ["MTS", "CHEMICAL", 133, 136], ["Vero cells", "CELL", 0, 10], ["amino acids", "AMINO_ACID", 48, 59], ["Promega", "ORGANISM", 138, 145], ["cells", "CELL", 177, 182], ["Vero cells", "CELL_LINE", 0, 10], ["Vero cells", "TEST", 0, 10], ["amino acids", "TREATMENT", 48, 59], ["CellTiter", "TEST", 90, 99], ["AQueous One Solution Reagent -MTS (Promega) reagent", "TREATMENT", 103, 154]]], ["The absorbance of 0 \u00c2 was used as a control for cell viability.", [["cell", "ANATOMY", 48, 52], ["cell", "CELL", 48, 52], ["cell viability", "PROBLEM", 48, 62]]], ["(C) Vero cells were transfected with a plasmid expressing LC3-GFP and incubated for 24 h.", [["Vero cells", "ANATOMY", 4, 14], ["plasmid", "ANATOMY", 39, 46], ["Vero cells", "CELL", 4, 14], ["LC3", "GENE_OR_GENE_PRODUCT", 58, 61], ["GFP", "GENE_OR_GENE_PRODUCT", 62, 65], ["(C) Vero cells", "CELL_LINE", 0, 14], ["LC3", "PROTEIN", 58, 61], ["GFP", "PROTEIN", 62, 65], ["Vero cells", "PROBLEM", 4, 14]]], ["Cells were treated with different concentrations of amino acid for 24 h in the presence of 100 nM rapamycin.", [["Cells", "ANATOMY", 0, 5], ["amino acid", "CHEMICAL", 52, 62], ["rapamycin", "CHEMICAL", 98, 107], ["amino acid", "CHEMICAL", 52, 62], ["rapamycin", "CHEMICAL", 98, 107], ["Cells", "CELL", 0, 5], ["amino acid", "AMINO_ACID", 52, 62], ["rapamycin", "SIMPLE_CHEMICAL", 98, 107], ["amino acid", "TREATMENT", 52, 62], ["100 nM rapamycin", "TREATMENT", 91, 107]]], ["LC3-GFP distribution was observed using immunofluorescence.", [["LC3", "GENE_OR_GENE_PRODUCT", 0, 3], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["LC3", "PROTEIN", 0, 3], ["immunofluorescence", "TEST", 40, 58], ["GFP distribution", "OBSERVATION", 4, 20]]], ["The average number of LC3-GFP \u00fe punctae per cell for 80 cells was scored.", [["punctae", "ANATOMY", 32, 39], ["cell", "ANATOMY", 44, 48], ["cells", "ANATOMY", 56, 61], ["LC3", "GENE_OR_GENE_PRODUCT", 22, 25], ["GFP", "GENE_OR_GENE_PRODUCT", 26, 29], ["cell", "CELL", 44, 48], ["cells", "CELL", 56, 61], ["LC3", "PROTEIN", 22, 25], ["GFP", "PROTEIN", 26, 29], ["LC3", "TEST", 22, 25], ["average", "OBSERVATION_MODIFIER", 4, 11], ["number", "OBSERVATION_MODIFIER", 12, 18], ["LC3", "OBSERVATION_MODIFIER", 22, 25]]], ["Error bars on bar graphs represent the SEM. nn p-value o 0.02. with a plasmid expressing LC3-GFP and incubated for 24 h.", [["plasmid", "ANATOMY", 70, 77], ["LC3", "GENE_OR_GENE_PRODUCT", 89, 92], ["GFP", "GENE_OR_GENE_PRODUCT", 93, 96], ["plasmid", "DNA", 70, 77], ["LC3", "PROTEIN", 89, 92], ["GFP", "PROTEIN", 93, 96], ["SEM", "OBSERVATION", 39, 42]]], ["Cells were treated with media alone (no drug), serum free media for 3 h, 100 nM rapamycin for 24 h, 5 uM spautin-1 for 24 h, 5 mM 3-MA for 3 h, DMSO for 24 h and fixed then with paraformaldehyde.", [["Cells", "ANATOMY", 0, 5], ["serum", "ANATOMY", 47, 52], ["rapamycin", "CHEMICAL", 80, 89], ["3-MA", "CHEMICAL", 130, 134], ["DMSO", "CHEMICAL", 144, 148], ["paraformaldehyde", "CHEMICAL", 178, 194], ["rapamycin", "CHEMICAL", 80, 89], ["spautin-1", "CHEMICAL", 105, 114], ["3-MA", "CHEMICAL", 130, 134], ["DMSO", "CHEMICAL", 144, 148], ["paraformaldehyde", "CHEMICAL", 178, 194], ["Cells", "CELL", 0, 5], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["rapamycin", "SIMPLE_CHEMICAL", 80, 89], ["3-MA", "SIMPLE_CHEMICAL", 130, 134], ["DMSO", "SIMPLE_CHEMICAL", 144, 148], ["paraformaldehyde", "SIMPLE_CHEMICAL", 178, 194], ["media alone", "TREATMENT", 24, 35], ["serum free media", "TREATMENT", 47, 63], ["rapamycin", "TREATMENT", 80, 89], ["DMSO", "TREATMENT", 144, 148], ["paraformaldehyde", "TREATMENT", 178, 194]]], ["LC3-GFP distribution was observed using immunofluorescence.", [["LC3", "GENE_OR_GENE_PRODUCT", 0, 3], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["LC3", "PROTEIN", 0, 3], ["immunofluorescence", "TEST", 40, 58], ["GFP distribution", "OBSERVATION", 4, 20]]], ["A representative image of an LC3-GFP \u00fe expressing cell after treatment shows the change in LC3 localization (magnification 1000 \u00c2).", [["cell", "ANATOMY", 50, 54], ["LC3", "GENE_OR_GENE_PRODUCT", 29, 32], ["GFP", "GENE_OR_GENE_PRODUCT", 33, 36], ["cell", "CELL", 50, 54], ["LC3", "GENE_OR_GENE_PRODUCT", 91, 94], ["LC3", "PROTEIN", 29, 32], ["GFP \u00fe expressing cell", "CELL_LINE", 33, 54], ["LC3", "PROTEIN", 91, 94], ["A representative image", "TEST", 0, 22], ["an LC3", "TEST", 26, 32], ["treatment", "TREATMENT", 61, 70], ["the change in LC3 localization", "PROBLEM", 77, 107], ["change", "OBSERVATION_MODIFIER", 81, 87], ["LC3 localization", "OBSERVATION", 91, 107]]], ["The number in the top right corner is the average number of punctae scored for 80 cells.", [["right corner", "ANATOMY", 22, 34], ["punctae", "ANATOMY", 60, 67], ["cells", "ANATOMY", 82, 87], ["punctae", "CELLULAR_COMPONENT", 60, 67], ["cells", "CELL", 82, 87], ["number", "OBSERVATION_MODIFIER", 4, 10], ["top", "OBSERVATION_MODIFIER", 18, 21], ["right", "ANATOMY_MODIFIER", 22, 27], ["corner", "ANATOMY_MODIFIER", 28, 34], ["average", "OBSERVATION_MODIFIER", 42, 49], ["number", "OBSERVATION_MODIFIER", 50, 56]]], ["(H) The average number of LC3-GFP \u00fe punctae per cell for 80 cells was scored.", [["punctae", "ANATOMY", 36, 43], ["cell", "ANATOMY", 48, 52], ["cells", "ANATOMY", 60, 65], ["LC3", "GENE_OR_GENE_PRODUCT", 26, 29], ["GFP", "GENE_OR_GENE_PRODUCT", 30, 33], ["cell", "CELL", 48, 52], ["cells", "CELL", 60, 65], ["LC3", "PROTEIN", 26, 29], ["GFP", "PROTEIN", 30, 33], ["LC3", "TEST", 26, 29]]], ["The treatments were as follows: 100 nM rapamycin, DMSO, and 5 uM spautin-1 for 24 h, and serum free media and 5 mM 3-MA for 3 h.", [["serum", "ANATOMY", 89, 94], ["rapamycin", "CHEMICAL", 39, 48], ["DMSO", "CHEMICAL", 50, 54], ["3-MA", "CHEMICAL", 115, 119], ["rapamycin", "CHEMICAL", 39, 48], ["DMSO", "CHEMICAL", 50, 54], ["spautin-1", "CHEMICAL", 65, 74], ["3-MA", "CHEMICAL", 115, 119], ["rapamycin", "SIMPLE_CHEMICAL", 39, 48], ["DMSO", "SIMPLE_CHEMICAL", 50, 54], ["serum", "ORGANISM_SUBSTANCE", 89, 94], ["3-MA", "SIMPLE_CHEMICAL", 115, 119], ["The treatments", "TREATMENT", 0, 14], ["nM rapamycin", "TREATMENT", 36, 48], ["DMSO", "TREATMENT", 50, 54], ["5 uM spautin", "TREATMENT", 60, 72], ["serum free media", "TEST", 89, 105]]], ["Error bars on bar graphs represent the SEM. n p-value \u00bc0.02-0.05 and nn p-valueo 0.02, or p-value was included. indicating that input virus canot cause the strong nuclear signal dize in Fig. 2F (data not shown).Pharmacological agents influence LC3 distributionTo test the effect of these drugs on autophagy levels in Vero cells, cells were transfected with a plasmid encoding LC3-GFP.", [["nuclear", "ANATOMY", 163, 170], ["Vero cells", "ANATOMY", 317, 327], ["cells", "ANATOMY", 329, 334], ["plasmid", "ANATOMY", 359, 366], ["LC3", "GENE_OR_GENE_PRODUCT", 244, 247], ["Vero cells", "CELL", 317, 327], ["cells", "CELL", 329, 334], ["LC3", "GENE_OR_GENE_PRODUCT", 376, 379], ["GFP", "GENE_OR_GENE_PRODUCT", 380, 383], ["LC3", "PROTEIN", 244, 247], ["Vero cells", "CELL_LINE", 317, 327], ["plasmid", "DNA", 359, 366], ["LC3", "PROTEIN", 376, 379], ["GFP", "PROTEIN", 380, 383], ["p-value \u00bc", "TEST", 46, 55], ["nn p-valueo", "TEST", 69, 80], ["p-value", "TEST", 90, 97], ["input virus ca", "PROBLEM", 128, 142], ["the strong nuclear signal dize in Fig", "PROBLEM", 152, 189], ["Pharmacological agents", "TREATMENT", 211, 233], ["these drugs", "TREATMENT", 282, 293], ["autophagy levels", "TEST", 297, 313], ["Vero cells", "PROBLEM", 317, 327], ["SEM", "OBSERVATION", 39, 42], ["signal dize", "OBSERVATION", 171, 182], ["LC3 distribution", "OBSERVATION", 244, 260]]], ["In LC3-GFP-expressing Vero cells, we found rapamycin and serum starvation increased autophagy levels as determined by a change in cellular LC3 localization and an increase in LC3-GFP \u00fe punctae, while 3-MA and spautin-1 inhibited serum starvation and rapamycin-induced autophagy, respectively ( Fig. 2G and H).", [["Vero cells", "ANATOMY", 22, 32], ["serum", "ANATOMY", 57, 62], ["cellular", "ANATOMY", 130, 138], ["punctae", "ANATOMY", 185, 192], ["serum", "ANATOMY", 229, 234], ["rapamycin", "CHEMICAL", 43, 52], ["3-MA", "CHEMICAL", 200, 204], ["spautin-1", "CHEMICAL", 209, 218], ["rapamycin", "CHEMICAL", 250, 259], ["rapamycin", "CHEMICAL", 43, 52], ["3-MA", "CHEMICAL", 200, 204], ["spautin-1", "CHEMICAL", 209, 218], ["rapamycin", "CHEMICAL", 250, 259], ["LC3", "GENE_OR_GENE_PRODUCT", 3, 6], ["GFP", "GENE_OR_GENE_PRODUCT", 7, 10], ["Vero cells", "CELL", 22, 32], ["rapamycin", "SIMPLE_CHEMICAL", 43, 52], ["serum", "ORGANISM_SUBSTANCE", 57, 62], ["cellular", "CELL", 130, 138], ["LC3", "GENE_OR_GENE_PRODUCT", 139, 142], ["LC3-GFP", "GENE_OR_GENE_PRODUCT", 175, 182], ["punctae", "ORGANISM_SUBSTANCE", 185, 192], ["3-MA", "SIMPLE_CHEMICAL", 200, 204], ["spautin-1", "GENE_OR_GENE_PRODUCT", 209, 218], ["serum", "ORGANISM_SUBSTANCE", 229, 234], ["rapamycin", "SIMPLE_CHEMICAL", 250, 259], ["LC3-GFP-expressing Vero cells", "CELL_LINE", 3, 32], ["LC3", "PROTEIN", 139, 142], ["LC3", "PROTEIN", 175, 178], ["LC3", "TEST", 3, 6], ["GFP", "TEST", 7, 10], ["Vero cells", "PROBLEM", 22, 32], ["rapamycin", "TREATMENT", 43, 52], ["serum starvation increased autophagy levels", "PROBLEM", 57, 100], ["a change in cellular LC3 localization", "PROBLEM", 118, 155], ["LC3", "TEST", 175, 178], ["spautin", "TEST", 209, 216], ["serum starvation", "TEST", 229, 245], ["rapamycin", "TREATMENT", 250, 259], ["Vero cells", "OBSERVATION", 22, 32], ["cellular", "OBSERVATION", 130, 138], ["LC3 localization", "OBSERVATION", 139, 155], ["increase", "OBSERVATION_MODIFIER", 163, 171], ["LC3", "OBSERVATION_MODIFIER", 175, 178]]], ["Our results were consistent with previous findings showing these drugs influence autophagy levels (Hussein et al., 2012; Noda and Ohsumi, 1998; Blommaart et al., 1997; Mateo et al., 2013; Tanigaki et al., 2003; Seglen and Gordon, 1982; Blazquez et al., 2013) .Autophagy inhibitors reduce BKPyV infection early in the viral life cycleTo elucidate the kinetics of autophagy-specific regulation of BKPyV infection, Vero cells were treated with autophagy inhibitors for various intervals before and following viral challenge.", [["Vero cells", "ANATOMY", 412, 422], ["infection", "DISEASE", 294, 303], ["infection", "DISEASE", 401, 410], ["BKPyV", "GENE_OR_GENE_PRODUCT", 288, 293], ["BKPyV", "GENE_OR_GENE_PRODUCT", 395, 400], ["Vero cells", "CELL", 412, 422], ["Vero cells", "CELL_LINE", 412, 422], ["BKPyV", "SPECIES", 288, 293], ["BKPyV", "SPECIES", 395, 400], ["Autophagy inhibitors", "TREATMENT", 260, 280], ["BKPyV infection", "PROBLEM", 288, 303], ["autophagy", "PROBLEM", 362, 371], ["BKPyV infection", "PROBLEM", 395, 410], ["Vero cells", "PROBLEM", 412, 422], ["autophagy inhibitors", "TREATMENT", 441, 461], ["viral challenge", "TREATMENT", 505, 520], ["consistent with", "UNCERTAINTY", 17, 32], ["BKPyV", "OBSERVATION_MODIFIER", 288, 293], ["infection", "OBSERVATION", 294, 303], ["BKPyV infection", "OBSERVATION", 395, 410]]], ["A significant decrease in infection was observed when cells were treated within the first 24 h following infection or for the 72 h duration of infection (Fig. 3) .", [["cells", "ANATOMY", 54, 59], ["infection", "DISEASE", 26, 35], ["infection", "DISEASE", 105, 114], ["infection", "DISEASE", 143, 152], ["cells", "CELL", 54, 59], ["A significant decrease in infection", "PROBLEM", 0, 35], ["infection", "PROBLEM", 105, 114], ["infection", "PROBLEM", 143, 152], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["decrease", "OBSERVATION_MODIFIER", 14, 22], ["infection", "OBSERVATION", 26, 35], ["infection", "OBSERVATION", 105, 114], ["infection", "OBSERVATION", 143, 152]]], ["BKPyV was significantly inhibited by the addition of 3-MA, spautin-1 and bafilomycin A1 during the first 8 h of infection suggesting that autophagy is important early in the BKPyV infectious process (Fig. 3) .", [["3-MA", "CHEMICAL", 53, 57], ["spautin-1 and bafilomycin A1", "CHEMICAL", 59, 87], ["infection", "DISEASE", 112, 121], ["3-MA", "CHEMICAL", 53, 57], ["spautin-1", "CHEMICAL", 59, 68], ["bafilomycin A1", "CHEMICAL", 73, 87], ["BKPyV", "GENE_OR_GENE_PRODUCT", 0, 5], ["3-MA", "SIMPLE_CHEMICAL", 53, 57], ["spautin-1", "SIMPLE_CHEMICAL", 59, 68], ["bafilomycin A1", "SIMPLE_CHEMICAL", 73, 87], ["BKPyV", "SPECIES", 174, 179], ["BKPyV", "PROBLEM", 0, 5], ["spautin", "TEST", 59, 66], ["bafilomycin A1", "TREATMENT", 73, 87], ["infection", "PROBLEM", 112, 121], ["autophagy", "PROBLEM", 138, 147], ["the BKPyV infectious process", "PROBLEM", 170, 198], ["infection", "OBSERVATION", 112, 121], ["autophagy", "OBSERVATION", 138, 147], ["BKPyV", "OBSERVATION_MODIFIER", 174, 179], ["infectious", "OBSERVATION", 180, 190]]], ["Autophagy may play an antiviral role at later stages in infection as addition of autophagy inhibitors at time intervals later in the viral life cycle increases infection.Knockdown of autophagy genes decrease BKPyV infectionTo further test the effect of restricting autophagy on BKPyV infection, siRNA molecular silencing was used to reduce levels of LC3, Beclin-1, and ATG7, genes that regulate autophagy.", [["infection", "DISEASE", 56, 65], ["infection", "DISEASE", 160, 169], ["infection", "DISEASE", 284, 293], ["BKPyV", "GENE_OR_GENE_PRODUCT", 208, 213], ["BKPyV", "GENE_OR_GENE_PRODUCT", 278, 283], ["LC3", "GENE_OR_GENE_PRODUCT", 350, 353], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 355, 363], ["ATG7", "GENE_OR_GENE_PRODUCT", 369, 373], ["autophagy genes", "DNA", 183, 198], ["BKPyV", "PROTEIN", 208, 213], ["LC3", "PROTEIN", 350, 353], ["Beclin-1", "PROTEIN", 355, 363], ["ATG7", "PROTEIN", 369, 373], ["BKPyV", "SPECIES", 208, 213], ["BKPyV", "SPECIES", 278, 283], ["Autophagy", "TREATMENT", 0, 9], ["infection", "PROBLEM", 56, 65], ["autophagy inhibitors", "TREATMENT", 81, 101], ["infection", "PROBLEM", 160, 169], ["autophagy genes", "PROBLEM", 183, 198], ["BKPyV infectionTo", "PROBLEM", 208, 225], ["restricting autophagy", "PROBLEM", 253, 274], ["BKPyV infection", "PROBLEM", 278, 293], ["siRNA molecular silencing", "TREATMENT", 295, 320], ["LC3", "TEST", 350, 353], ["Beclin", "TEST", 355, 361], ["ATG7", "PROBLEM", 369, 373], ["antiviral", "OBSERVATION", 22, 31], ["infection", "OBSERVATION", 56, 65], ["infection", "OBSERVATION", 160, 169], ["autophagy genes", "OBSERVATION", 183, 198], ["decrease", "OBSERVATION_MODIFIER", 199, 207], ["BKPyV", "OBSERVATION", 208, 213], ["BKPyV", "OBSERVATION_MODIFIER", 278, 283], ["infection", "OBSERVATION", 284, 293]]], ["In HeLa cells, a mixture of 3-5 siRNA molecules directed against Beclin-1 or ATG7 reduced BKPyV infection.", [["HeLa cells", "ANATOMY", 3, 13], ["infection", "DISEASE", 96, 105], ["HeLa cells", "CELL", 3, 13], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 65, 73], ["ATG7", "GENE_OR_GENE_PRODUCT", 77, 81], ["BKPyV", "GENE_OR_GENE_PRODUCT", 90, 95], ["HeLa cells", "CELL_LINE", 3, 13], ["Beclin-1", "PROTEIN", 65, 73], ["ATG7", "PROTEIN", 77, 81], ["BKPyV", "SPECIES", 90, 95], ["3-5 siRNA molecules", "TREATMENT", 28, 47], ["Beclin", "TEST", 65, 71], ["ATG7 reduced BKPyV infection", "PROBLEM", 77, 105], ["HeLa cells", "OBSERVATION", 3, 13], ["reduced", "OBSERVATION_MODIFIER", 82, 89], ["BKPyV", "OBSERVATION_MODIFIER", 90, 95], ["infection", "OBSERVATION", 96, 105]]], ["Interestingly, LC3 siRNA treatment did not decrease BKPyV infection (Fig. 4B) , suggesting that greater knockdown of the autophagic LC3-II form is required to effectively inhibit BKPyV (Fig. 4A ).", [["autophagic", "ANATOMY", 121, 131], ["infection", "DISEASE", 58, 67], ["LC3", "GENE_OR_GENE_PRODUCT", 15, 18], ["BKPyV", "GENE_OR_GENE_PRODUCT", 52, 57], ["LC3-II", "GENE_OR_GENE_PRODUCT", 132, 138], ["LC3", "PROTEIN", 15, 18], ["autophagic LC3-II form", "PROTEIN", 121, 143], ["BKPyV", "PROTEIN", 179, 184], ["Fig. 4A", "PROTEIN", 186, 193], ["BKPyV", "SPECIES", 52, 57], ["LC3 siRNA treatment", "TREATMENT", 15, 34], ["BKPyV infection", "PROBLEM", 52, 67], ["LC3 siRNA", "OBSERVATION", 15, 24], ["decrease", "OBSERVATION_MODIFIER", 43, 51], ["BKPyV", "OBSERVATION_MODIFIER", 52, 57], ["infection", "OBSERVATION", 58, 67], ["greater", "OBSERVATION_MODIFIER", 96, 103], ["knockdown", "OBSERVATION_MODIFIER", 104, 113], ["autophagic LC3", "OBSERVATION", 121, 135]]], ["Taken together, these data suggest autophagy-specific proteins promote BKPyV infection in HeLa cells.BKPyV associates with autophagosomeWe next asked whether BKPyV physically interacts with the autophagosome.", [["HeLa cells", "ANATOMY", 90, 100], ["autophagosome", "ANATOMY", 194, 207], ["infection", "DISEASE", 77, 86], ["BKPyV", "GENE_OR_GENE_PRODUCT", 71, 76], ["HeLa cells", "CELL", 90, 100], ["BKPyV", "GENE_OR_GENE_PRODUCT", 101, 106], ["BKPyV", "GENE_OR_GENE_PRODUCT", 158, 163], ["autophagosome", "CELLULAR_COMPONENT", 194, 207], ["HeLa cells", "CELL_LINE", 90, 100], ["BKPyV", "PROTEIN", 101, 106], ["BKPyV", "PROTEIN", 158, 163], ["these data", "TEST", 16, 26], ["autophagy", "PROBLEM", 35, 44], ["specific proteins", "PROBLEM", 45, 62], ["BKPyV infection in HeLa cells", "PROBLEM", 71, 100], ["BKPyV", "PROBLEM", 101, 106], ["BKPyV", "OBSERVATION_MODIFIER", 71, 76], ["infection", "OBSERVATION", 77, 86], ["HeLa cells", "OBSERVATION", 90, 100]]], ["To address this the localization of BKPyV and LC3-GPF vesicles was analyzed using confocal microscopy.", [["LC3-GPF vesicles", "ANATOMY", 46, 62], ["BKPyV", "GENE_OR_GENE_PRODUCT", 36, 41], ["LC3", "GENE_OR_GENE_PRODUCT", 46, 49], ["GPF vesicles", "CELLULAR_COMPONENT", 50, 62], ["BKPyV", "PROTEIN", 36, 41], ["LC3", "PROTEIN", 46, 49], ["BKPyV", "TEST", 36, 41], ["LC3-GPF vesicles", "TREATMENT", 46, 62], ["confocal microscopy", "TEST", 82, 101], ["BKPyV", "OBSERVATION", 36, 41], ["GPF vesicles", "ANATOMY", 50, 62]]], ["LC3-GFP-expressing Vero cells were infected with infectious AlexFluor-633-labeled BKPyV (BKPyV-633).", [["Vero cells", "ANATOMY", 19, 29], ["AlexFluor-633", "CHEMICAL", 60, 73], ["BKPyV-633", "CHEMICAL", 89, 98], ["AlexFluor-633", "CHEMICAL", 60, 73], ["BKPyV-633", "CHEMICAL", 89, 98], ["LC3", "GENE_OR_GENE_PRODUCT", 0, 3], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["Vero cells", "CELL", 19, 29], ["AlexFluor-633", "SIMPLE_CHEMICAL", 60, 73], ["BKPyV", "CELL", 82, 87], ["BKPyV-633", "ORGANISM", 89, 98], ["LC3-GFP-expressing Vero cells", "CELL_LINE", 0, 29], ["LC3-GFP", "TEST", 0, 7], ["Vero cells", "PROBLEM", 19, 29], ["infectious AlexFluor", "TEST", 49, 69], ["BKPyV", "TEST", 89, 94], ["Vero cells", "OBSERVATION", 19, 29], ["infectious", "OBSERVATION_MODIFIER", 49, 59]]], ["Of the 60 cells that were analyzed, 27% (n \u00bc16) of cells showed viral particles had penetrated the cell membrane and entered the host cell.", [["cells", "ANATOMY", 10, 15], ["cells", "ANATOMY", 51, 56], ["cell membrane", "ANATOMY", 99, 112], ["cell", "ANATOMY", 134, 138], ["cells", "CELL", 10, 15], ["cells", "CELL", 51, 56], ["cell membrane", "CELLULAR_COMPONENT", 99, 112], ["host cell", "CELL", 129, 138], ["host cell", "CELL_TYPE", 129, 138], ["cells", "TEST", 51, 56], ["viral particles", "PROBLEM", 64, 79], ["60 cells", "OBSERVATION_MODIFIER", 7, 15], ["viral particles", "OBSERVATION", 64, 79], ["cell membrane", "OBSERVATION", 99, 112], ["host cell", "OBSERVATION", 129, 138]]], ["Analysis of the infected cells revealed that 38% of these cells (6/16 cells) showed strong colocalization of BKPyV and LC3-GFP \u00fe in small or large autophagosomes.", [["cells", "ANATOMY", 25, 30], ["cells", "ANATOMY", 58, 63], ["6/16 cells", "ANATOMY", 65, 75], ["autophagosomes", "ANATOMY", 147, 161], ["cells", "CELL", 25, 30], ["cells", "CELL", 58, 63], ["6/16 cells", "CELL", 65, 75], ["BKPyV", "GENE_OR_GENE_PRODUCT", 109, 114], ["LC3", "GENE_OR_GENE_PRODUCT", 119, 122], ["GFP", "GENE_OR_GENE_PRODUCT", 123, 126], ["autophagosomes", "CELLULAR_COMPONENT", 147, 161], ["infected cells", "CELL_TYPE", 16, 30], ["6/16 cells", "CELL_LINE", 65, 75], ["BKPyV", "PROTEIN", 109, 114], ["LC3", "PROTEIN", 119, 122], ["GFP", "PROTEIN", 123, 126], ["the infected cells", "TEST", 12, 30], ["these cells", "TEST", 52, 63], ["cells", "TEST", 70, 75], ["BKPyV", "TEST", 109, 114], ["LC3", "TEST", 119, 122], ["small or large autophagosomes", "PROBLEM", 132, 161], ["infected cells", "OBSERVATION", 16, 30], ["BKPyV", "OBSERVATION", 109, 114], ["small", "OBSERVATION_MODIFIER", 132, 137], ["large", "OBSERVATION_MODIFIER", 141, 146], ["autophagosomes", "OBSERVATION", 147, 161]]], ["This differed from the 0% of cells (0/16 cells) that showed BKPyV colocalized with the diffusely expressed, nonautophagic LC3-GFP \u00fe.", [["cells", "ANATOMY", 29, 34], ["0/16 cells", "ANATOMY", 36, 46], ["cells", "CELL", 29, 34], ["0/16 cells", "CELL", 36, 46], ["BKPyV", "GENE_OR_GENE_PRODUCT", 60, 65], ["LC3", "GENE_OR_GENE_PRODUCT", 122, 125], ["GFP", "GENE_OR_GENE_PRODUCT", 126, 129], ["0/16 cells", "CELL_LINE", 36, 46], ["BKPyV", "PROTEIN", 60, 65], ["LC3", "PROTEIN", 122, 125], ["GFP", "PROTEIN", 126, 129], ["BKPyV colocalized", "PROBLEM", 60, 77], ["BKPyV", "OBSERVATION", 60, 65], ["diffusely", "OBSERVATION_MODIFIER", 87, 96]]], ["Our data suggest that BKPyV is more likely to colocalize with LC3-GFP \u00fe when it is found in an autophagosome.", [["autophagosome", "ANATOMY", 95, 108], ["BKPyV", "GENE_OR_GENE_PRODUCT", 22, 27], ["LC3", "GENE_OR_GENE_PRODUCT", 62, 65], ["GFP", "GENE_OR_GENE_PRODUCT", 66, 69], ["autophagosome", "CELLULAR_COMPONENT", 95, 108], ["BKPyV", "PROTEIN", 22, 27], ["LC3", "PROTEIN", 62, 65], ["GFP", "PROTEIN", 66, 69], ["Our data", "TEST", 0, 8], ["BKPyV", "PROBLEM", 22, 27], ["LC3", "TEST", 62, 65], ["BKPyV", "OBSERVATION", 22, 27], ["more likely", "UNCERTAINTY", 31, 42], ["autophagosome", "OBSERVATION", 95, 108]]], ["This colocalization of BKPyV with the LC3-GFP \u00fe autophagosomes was observed at 3 h post infection, indicating that the virus associates with an autophagic vesicle at a time point consistent with endocytic trafficking (Fig. 5A-D) .BKPyV associates with autophagosomeIn LC3-GFP \u00fe transfected Vero cells, localization of LC3 was found in one of three patterns: diffuse (Fig. 2G) , small and filled-in autophagosomes (Fig. 5D ), or in larger donut-shaped autophagosomes (Fig. 5C ).", [["autophagic vesicle", "ANATOMY", 144, 162], ["Vero cells", "ANATOMY", 290, 300], ["autophagosomes", "ANATOMY", 398, 412], ["autophagosomes", "ANATOMY", 451, 465], ["infection", "DISEASE", 88, 97], ["BKPyV", "GENE_OR_GENE_PRODUCT", 23, 28], ["LC3", "GENE_OR_GENE_PRODUCT", 38, 41], ["GFP", "GENE_OR_GENE_PRODUCT", 42, 45], ["autophagic vesicle", "CELLULAR_COMPONENT", 144, 162], ["BKPyV", "GENE_OR_GENE_PRODUCT", 230, 235], ["LC3", "GENE_OR_GENE_PRODUCT", 268, 271], ["GFP", "GENE_OR_GENE_PRODUCT", 272, 275], ["Vero cells", "CELL", 290, 300], ["LC3", "GENE_OR_GENE_PRODUCT", 318, 321], ["autophagosomes", "CELLULAR_COMPONENT", 398, 412], ["autophagosomes", "CELLULAR_COMPONENT", 451, 465], ["BKPyV", "PROTEIN", 23, 28], ["LC3", "PROTEIN", 38, 41], ["GFP", "PROTEIN", 42, 45], ["BKPyV", "PROTEIN", 230, 235], ["autophagosomeIn LC3-GFP \u00fe transfected Vero cells", "CELL_LINE", 252, 300], ["LC3", "PROTEIN", 318, 321], ["donut-shaped autophagosomes", "CELL_TYPE", 438, 465], ["BKPyV", "PROBLEM", 23, 28], ["the LC3", "TEST", 34, 41], ["autophagosomes", "PROBLEM", 48, 62], ["infection", "PROBLEM", 88, 97], ["the virus", "PROBLEM", 115, 124], ["an autophagic vesicle", "PROBLEM", 141, 162], ["BKPyV", "PROBLEM", 230, 235], ["autophagosomeIn LC3", "TEST", 252, 271], ["transfected Vero cells", "PROBLEM", 278, 300], ["localization of LC3", "TEST", 302, 321], ["diffuse (Fig. 2G)", "PROBLEM", 358, 375], ["small and filled-in autophagosomes", "PROBLEM", 378, 412], ["BKPyV", "OBSERVATION", 23, 28], ["infection", "OBSERVATION", 88, 97], ["virus", "OBSERVATION", 119, 124], ["autophagic vesicle", "OBSERVATION", 144, 162], ["consistent with", "UNCERTAINTY", 179, 194], ["endocytic trafficking", "OBSERVATION", 195, 216], ["Vero cells", "OBSERVATION", 290, 300], ["diffuse", "OBSERVATION_MODIFIER", 358, 365], ["small", "OBSERVATION_MODIFIER", 378, 383], ["shaped", "OBSERVATION_MODIFIER", 444, 450], ["autophagosomes", "OBSERVATION", 451, 465]]], ["After establishing that BKPyV localized to LC3-GFP autophagosome ( Fig. 5A and B) , we next examined if the cellular location of BKPyV correlated with autophagosome formation.", [["cellular", "ANATOMY", 108, 116], ["autophagosome", "ANATOMY", 151, 164], ["BKPyV", "GENE_OR_GENE_PRODUCT", 24, 29], ["LC3", "GENE_OR_GENE_PRODUCT", 43, 46], ["GFP", "GENE_OR_GENE_PRODUCT", 47, 50], ["autophagosome", "CELLULAR_COMPONENT", 51, 64], ["B", "GENE_OR_GENE_PRODUCT", 79, 80], ["cellular", "CELL", 108, 116], ["BKPyV", "GENE_OR_GENE_PRODUCT", 129, 134], ["autophagosome", "CELLULAR_COMPONENT", 151, 164], ["BKPyV", "PROTEIN", 24, 29], ["LC3", "PROTEIN", 43, 46], ["GFP autophagosome", "PROTEIN", 47, 64], ["Fig. 5A and B", "PROTEIN", 67, 80], ["BKPyV", "PROTEIN", 129, 134], ["LC3", "TEST", 43, 46], ["GFP autophagosome", "TEST", 47, 64], ["BKPyV", "PROBLEM", 129, 134], ["GFP autophagosome", "OBSERVATION", 47, 64], ["BKPyV", "OBSERVATION", 129, 134], ["autophagosome formation", "OBSERVATION", 151, 174]]], ["LC3-GFP expressing Vero cells were challenged with BKPyV-633 and then location of BKPyV-633 and type of LC3-GFP pattern recorded.", [["Vero cells", "ANATOMY", 19, 29], ["BKPyV-633", "CHEMICAL", 51, 60], ["BKPyV-633", "CHEMICAL", 51, 60], ["LC3", "GENE_OR_GENE_PRODUCT", 0, 3], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["Vero cells", "CELL", 19, 29], ["BKPyV-633", "GENE_OR_GENE_PRODUCT", 51, 60], ["BKPyV-633", "GENE_OR_GENE_PRODUCT", 82, 91], ["LC3", "GENE_OR_GENE_PRODUCT", 104, 107], ["GFP", "GENE_OR_GENE_PRODUCT", 108, 111], ["LC3", "PROTEIN", 0, 3], ["GFP expressing Vero cells", "CELL_LINE", 4, 29], ["BKPyV", "PROTEIN", 51, 56], ["BKPyV", "PROTEIN", 82, 87], ["LC3", "PROTEIN", 104, 107], ["LC3", "TEST", 0, 3], ["Vero cells", "PROBLEM", 19, 29], ["BKPyV", "TEST", 51, 56], ["BKPyV", "TEST", 82, 87], ["LC3", "TEST", 104, 107], ["GFP pattern", "TEST", 108, 119], ["Vero cells", "OBSERVATION", 19, 29], ["BKPyV", "OBSERVATION", 82, 87], ["LC3", "OBSERVATION", 104, 107], ["GFP pattern", "OBSERVATION", 108, 119]]], ["In Vero cells that showed no internalized BKPyV-633, LC3-GFP was found to be primarily diffuse or in small punctae (Fig. 5E, left) .", [["Vero cells", "ANATOMY", 3, 13], ["punctae", "ANATOMY", 107, 114], ["BKPyV-633", "CHEMICAL", 42, 51], ["Vero cells", "CELL", 3, 13], ["BKPyV-633", "GENE_OR_GENE_PRODUCT", 42, 51], ["LC3", "GENE_OR_GENE_PRODUCT", 53, 56], ["GFP", "GENE_OR_GENE_PRODUCT", 57, 60], ["punctae", "CELLULAR_COMPONENT", 107, 114], ["Vero cells", "CELL_LINE", 3, 13], ["BKPyV", "PROTEIN", 42, 47], ["LC3", "PROTEIN", 53, 56], ["GFP", "PROTEIN", 57, 60], ["Vero cells", "TEST", 3, 13], ["internalized BKPyV", "TEST", 29, 47], ["LC3-GFP", "TEST", 53, 60], ["no", "UNCERTAINTY", 26, 28], ["diffuse", "OBSERVATION_MODIFIER", 87, 94], ["small", "OBSERVATION_MODIFIER", 101, 106], ["punctae", "OBSERVATION", 107, 114], ["left", "ANATOMY_MODIFIER", 125, 129]]], ["In cells infected with BKPyV, as determined by the presence of intracellular BKPyV-633, LC3-GFP localization changed and it localized to small punctae and larger autophagosomes (Fig. 5E , middle and right).", [["cells", "ANATOMY", 3, 8], ["intracellular", "ANATOMY", 63, 76], ["punctae", "ANATOMY", 143, 150], ["autophagosomes", "ANATOMY", 162, 176], ["BKPyV-633", "CHEMICAL", 77, 86], ["BKPyV-633", "CHEMICAL", 77, 86], ["cells", "CELL", 3, 8], ["BKPyV", "GENE_OR_GENE_PRODUCT", 23, 28], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["BKPyV-633", "GENE_OR_GENE_PRODUCT", 77, 86], ["LC3", "GENE_OR_GENE_PRODUCT", 88, 91], ["GFP", "GENE_OR_GENE_PRODUCT", 92, 95], ["punctae", "CELLULAR_COMPONENT", 143, 150], ["autophagosomes", "CELLULAR_COMPONENT", 162, 176], ["BKPyV", "PROTEIN", 23, 28], ["BKPyV", "PROTEIN", 77, 82], ["LC3", "PROTEIN", 88, 91], ["GFP", "PROTEIN", 92, 95], ["BKPyV", "SPECIES", 23, 28], ["BKPyV", "PROBLEM", 23, 28], ["intracellular BKPyV", "TEST", 63, 82], ["LC3", "TEST", 88, 91], ["GFP localization", "TEST", 92, 108], ["infected", "OBSERVATION_MODIFIER", 9, 17], ["BKPyV", "OBSERVATION", 23, 28], ["BKPyV", "OBSERVATION", 77, 82], ["small", "OBSERVATION_MODIFIER", 137, 142], ["punctae", "OBSERVATION", 143, 150], ["larger", "OBSERVATION_MODIFIER", 155, 161], ["autophagosomes", "OBSERVATION", 162, 176], ["middle", "ANATOMY_MODIFIER", 188, 194], ["right", "ANATOMY_MODIFIER", 199, 204]]], ["Cells that showed colocalization of BKV-AF633 and LC3-GFP were scored for the pattern of LC3-GFP distribution.", [["Cells", "ANATOMY", 0, 5], ["Cells", "CELL", 0, 5], ["BKV", "ORGANISM", 36, 39], ["AF633", "GENE_OR_GENE_PRODUCT", 40, 45], ["LC3-GFP", "GENE_OR_GENE_PRODUCT", 50, 57], ["LC3", "GENE_OR_GENE_PRODUCT", 89, 92], ["GFP", "GENE_OR_GENE_PRODUCT", 93, 96], ["AF633", "PROTEIN", 40, 45], ["LC3", "PROTEIN", 50, 53], ["GFP", "PROTEIN", 54, 57], ["LC3", "PROTEIN", 89, 92], ["Cells", "TEST", 0, 5], ["BKV", "TEST", 36, 39], ["LC3", "TEST", 50, 53], ["GFP", "TEST", 54, 57], ["BKV", "OBSERVATION", 36, 39], ["LC3", "OBSERVATION", 89, 92], ["GFP distribution", "OBSERVATION", 93, 109]]], ["When BKV-AF633 and LC3-GFP showed overlapping localization, LC3-GFP was distributed to small or larger autophagosomes (Fig. 5E, right) .", [["autophagosomes", "ANATOMY", 103, 117], ["BKV", "ORGANISM", 5, 8], ["AF633", "GENE_OR_GENE_PRODUCT", 9, 14], ["LC3", "GENE_OR_GENE_PRODUCT", 19, 22], ["GFP", "GENE_OR_GENE_PRODUCT", 23, 26], ["LC3", "GENE_OR_GENE_PRODUCT", 60, 63], ["GFP", "GENE_OR_GENE_PRODUCT", 64, 67], ["autophagosomes", "CELLULAR_COMPONENT", 103, 117], ["AF633", "PROTEIN", 9, 14], ["LC3", "PROTEIN", 19, 22], ["GFP", "PROTEIN", 23, 26], ["LC3", "PROTEIN", 60, 63], ["GFP", "PROTEIN", 64, 67], ["BKV-AF633", "SPECIES", 5, 14], ["BKV", "TEST", 5, 8], ["LC3", "TEST", 19, 22], ["GFP", "TEST", 23, 26], ["LC3", "TEST", 60, 63], ["GFP", "TEST", 64, 67], ["small", "OBSERVATION_MODIFIER", 87, 92], ["larger", "OBSERVATION_MODIFIER", 96, 102], ["autophagosomes", "OBSERVATION", 103, 117], ["right", "ANATOMY_MODIFIER", 128, 133]]], ["These data suggest that BKPyV infection may not only rely on autophagy for viral infection, but may also play an active role in promoting cellular autophagy.DiscussionAutophagy functions as an antimicrobial defense against some viruses and promotes the replication and infection of other viruses (Gutierrez et al., 2004; Liang et al., 1998; Talloczy et al., 2006; Hussein et al., 2012; O'Donnell et al., 2011; Sir and Ou, 2010) .", [["cellular", "ANATOMY", 138, 146], ["BKPyV", "CHEMICAL", 24, 29], ["infection", "DISEASE", 30, 39], ["viral infection", "DISEASE", 75, 90], ["infection", "DISEASE", 269, 278], ["BKPyV", "GENE_OR_GENE_PRODUCT", 24, 29], ["cellular", "CELL", 138, 146], ["BKPyV", "SPECIES", 24, 29], ["These data", "TEST", 0, 10], ["BKPyV infection", "PROBLEM", 24, 39], ["viral infection", "PROBLEM", 75, 90], ["some viruses", "PROBLEM", 223, 235], ["BKPyV", "OBSERVATION_MODIFIER", 24, 29], ["infection", "OBSERVATION", 30, 39], ["infection", "OBSERVATION", 81, 90], ["cellular autophagy", "OBSERVATION", 138, 156]]], ["Autophagy may have evolved as an antimicrobial defense process because its degradative function within the cell eliminates some invading microbes.", [["cell", "ANATOMY", 107, 111], ["cell", "CELL", 107, 111], ["Autophagy", "PROBLEM", 0, 9], ["an antimicrobial defense process", "PROBLEM", 30, 62], ["antimicrobial defense", "OBSERVATION", 33, 54], ["invading", "OBSERVATION_MODIFIER", 128, 136]]], ["For example, autophagy is believed to control and degrade both Sindbis virus and herpes simplex virus-1 (HSV-1) (Liang et al., 1998; Talloczy et al., 2006) .", [["herpes simplex virus", "DISEASE", 81, 101], ["Sindbis virus", "ORGANISM", 63, 76], ["herpes simplex virus-1", "ORGANISM", 81, 103], ["HSV-1", "ORGANISM", 105, 110], ["Sindbis virus", "SPECIES", 63, 76], ["herpes simplex virus-1", "SPECIES", 81, 103], ["HSV-1", "SPECIES", 105, 110], ["Sindbis virus", "SPECIES", 63, 76], ["herpes simplex virus-1", "SPECIES", 81, 103], ["HSV-1", "SPECIES", 105, 110], ["autophagy", "PROBLEM", 13, 22], ["both Sindbis virus", "PROBLEM", 58, 76], ["herpes simplex virus", "TEST", 81, 101], ["HSV", "TEST", 105, 108], ["Sindbis virus", "OBSERVATION", 63, 76]]], ["HSV-1 is equipped with a viral protein called ICP34.5, which inactivates autophagy.", [["HSV-1", "ORGANISM", 0, 5], ["ICP34.5", "GENE_OR_GENE_PRODUCT", 46, 53], ["viral protein", "PROTEIN", 25, 38], ["ICP34.5", "PROTEIN", 46, 53], ["HSV-1", "SPECIES", 0, 5], ["HSV-1", "SPECIES", 0, 5], ["HSV", "TEST", 0, 3], ["a viral protein", "TEST", 23, 38]]], ["HSV-1 mutants missing ICP34.5 show greater autophagic degradation and an attenuated neurovirulence phenotype in mice (Talloczy et al., 2006; Orvedahl et al., 2007) .", [["HSV-1", "ORGANISM", 0, 5], ["ICP34.5", "GENE_OR_GENE_PRODUCT", 22, 29], ["mice", "ORGANISM", 112, 116], ["ICP34.5", "PROTEIN", 22, 29], ["HSV-1", "SPECIES", 0, 5], ["mice", "SPECIES", 112, 116], ["HSV-1", "SPECIES", 0, 5], ["mice", "SPECIES", 112, 116], ["HSV", "TEST", 0, 3], ["greater autophagic degradation", "PROBLEM", 35, 65], ["an attenuated neurovirulence phenotype", "PROBLEM", 70, 108], ["greater", "OBSERVATION_MODIFIER", 35, 42], ["autophagic degradation", "OBSERVATION", 43, 65]]], ["Autophagy has also been shown to stimulate the innate immune system and link it to the adaptive immune system.", [["immune system", "ANATOMY", 54, 67], ["immune system", "ANATOMY", 96, 109]]], ["Autophagy can promote antigen processing and presentation on major histocompatibility (MHC) molecules (Dengjel et al., 2005) .", [["major histocompatibility (MHC) molecules", "PROTEIN", 61, 101]]], ["Autophagosomes have been reported to help transport microbial cargo towards the lysosome where toll like receptor (TLR) engagement leads to Type I interferon production and other innate immune responses (Lee et al., 2007) .", [["lysosome", "ANATOMY", 80, 88], ["Autophagosomes", "GENE_OR_GENE_PRODUCT", 0, 14], ["lysosome", "CELLULAR_COMPONENT", 80, 88], ["toll like receptor", "GENE_OR_GENE_PRODUCT", 95, 113], ["TLR", "GENE_OR_GENE_PRODUCT", 115, 118], ["Type I interferon", "GENE_OR_GENE_PRODUCT", 140, 157], ["Autophagosomes", "PROTEIN", 0, 14], ["toll like receptor", "PROTEIN", 95, 113], ["TLR", "PROTEIN", 115, 118], ["Type I interferon", "PROTEIN", 140, 157], ["receptor (TLR) engagement", "TREATMENT", 105, 130], ["Type I interferon production", "PROBLEM", 140, 168]]], ["Moreover, surface TLR engagement and signaling can activate autophagy (Xu et al., 2007) .", [["surface", "ANATOMY", 10, 17], ["surface", "CELLULAR_COMPONENT", 10, 17], ["TLR", "GENE_OR_GENE_PRODUCT", 18, 21], ["TLR", "PROTEIN", 18, 21], ["surface TLR engagement", "TREATMENT", 10, 32]]], ["Mutations and deletions in autophagy genes are also associated with intestinal inflammation, disrupted Paneth cell secretion, and altered gut microflora (Virgin and Levine, 2009) .DiscussionParadoxically, autophagy promotes the replication and infection of a number of viruses (Hussein et al., 2012; O'Donnell et al., 2011; Sir and Ou, 2010) .", [["intestinal", "ANATOMY", 68, 78], ["Paneth cell", "ANATOMY", 103, 114], ["gut microflora", "ANATOMY", 138, 152], ["intestinal inflammation", "DISEASE", 68, 91], ["infection", "DISEASE", 244, 253], ["intestinal", "ORGAN", 68, 78], ["Paneth cell", "CELL", 103, 114], ["gut microflora", "MULTI-TISSUE_STRUCTURE", 138, 152], ["autophagy genes", "DNA", 27, 42], ["Mutations and deletions in autophagy genes", "PROBLEM", 0, 42], ["intestinal inflammation", "PROBLEM", 68, 91], ["disrupted Paneth cell secretion", "PROBLEM", 93, 124], ["altered gut microflora", "PROBLEM", 130, 152], ["infection", "PROBLEM", 244, 253], ["autophagy genes", "OBSERVATION", 27, 42], ["intestinal", "ANATOMY", 68, 78], ["inflammation", "OBSERVATION", 79, 91], ["Paneth cell secretion", "OBSERVATION", 103, 124]]], ["There are multiple ways that autophagy promotes viral infection.", [["viral infection", "DISEASE", 48, 63], ["viral infection", "PROBLEM", 48, 63], ["multiple", "OBSERVATION_MODIFIER", 10, 18], ["viral", "OBSERVATION_MODIFIER", 48, 53], ["infection", "OBSERVATION", 54, 63]]], ["RNA viruses require intracellular membranes to serve as scaffolds for viral replication within the cytoplasm (Salonen et al., 2005) .", [["intracellular membranes", "ANATOMY", 20, 43], ["cytoplasm", "ANATOMY", 99, 108], ["intracellular membranes", "CELLULAR_COMPONENT", 20, 43], ["cytoplasm", "ORGANISM_SUBSTANCE", 99, 108], ["RNA viruses", "PROBLEM", 0, 11], ["intracellular membranes", "TREATMENT", 20, 43], ["viral replication", "PROBLEM", 70, 87], ["viruses", "OBSERVATION", 4, 11], ["intracellular membranes", "OBSERVATION", 20, 43]]], ["Autophagy orchestrates the trafficking of vesicles to new locations within the cell thereby providing new membranous structures for viral replication to occur.", [["vesicles", "ANATOMY", 42, 50], ["cell", "ANATOMY", 79, 83], ["membranous structures", "ANATOMY", 106, 127], ["vesicles", "CELLULAR_COMPONENT", 42, 50], ["cell", "CELL", 79, 83], ["Autophagy", "TREATMENT", 0, 9], ["viral replication", "TREATMENT", 132, 149], ["new", "OBSERVATION_MODIFIER", 54, 57], ["cell", "OBSERVATION", 79, 83], ["new", "OBSERVATION_MODIFIER", 102, 105], ["membranous", "OBSERVATION", 106, 116], ["viral replication", "OBSERVATION", 132, 149]]], ["Autophagy proteins have also been shown to aid in the translation of Hepatitis C virus proteins as well as viral replication (Sir et al., 2012; Dreux et al., 2009) .", [["Hepatitis C virus", "ORGANISM", 69, 86], ["Autophagy proteins", "PROTEIN", 0, 18], ["Hepatitis C virus proteins", "PROTEIN", 69, 95], ["Hepatitis C virus", "SPECIES", 69, 86], ["Hepatitis C virus", "SPECIES", 69, 86], ["Autophagy proteins", "PROBLEM", 0, 18], ["Hepatitis C virus proteins", "TREATMENT", 69, 95], ["Hepatitis", "OBSERVATION", 69, 78]]], ["Some DNA viruses also utilize autophagy.", [["DNA", "CELLULAR_COMPONENT", 5, 8], ["Some DNA viruses", "PROBLEM", 0, 16], ["DNA viruses", "OBSERVATION", 5, 16]]], ["For example, adenovirus and the E7 protein of human papillomavirus 16 (HPV16) induce autophagy, which researchers hypothesize stimulates host cell death resulting in greater release of viral progeny (Zhou and Munger, 2009; Rodriguez-Rocha et al., 2011) .DiscussionRecently, autophagy has been demonstrated to occur in human JC polyomavirus infected cells.", [["cell", "ANATOMY", 142, 146], ["cells", "ANATOMY", 349, 354], ["death", "DISEASE", 147, 152], ["JC polyomavirus infected", "DISEASE", 324, 348], ["adenovirus", "ORGANISM", 13, 23], ["E7", "GENE_OR_GENE_PRODUCT", 32, 34], ["human papillomavirus 16", "ORGANISM", 46, 69], ["HPV16", "ORGANISM", 71, 76], ["host cell", "CELL", 137, 146], ["human", "ORGANISM", 318, 323], ["JC polyomavirus", "ORGANISM", 324, 339], ["cells", "CELL", 349, 354], ["E7 protein", "PROTEIN", 32, 42], ["human JC polyomavirus infected cells", "CELL_TYPE", 318, 354], ["human", "SPECIES", 46, 51], ["papillomavirus", "SPECIES", 52, 66], ["human", "SPECIES", 318, 323], ["adenovirus", "SPECIES", 13, 23], ["human papillomavirus 16", "SPECIES", 46, 69], ["HPV16", "SPECIES", 71, 76], ["human JC polyomavirus", "SPECIES", 318, 339], ["adenovirus", "PROBLEM", 13, 23], ["the E7 protein", "TEST", 28, 42], ["human papillomavirus", "TEST", 46, 66], ["autophagy", "PROBLEM", 85, 94], ["host cell death", "PROBLEM", 137, 152], ["human JC polyomavirus infected cells", "PROBLEM", 318, 354], ["host cell death", "OBSERVATION", 137, 152], ["greater", "OBSERVATION_MODIFIER", 166, 173], ["viral progeny", "OBSERVATION", 185, 198], ["JC polyomavirus", "OBSERVATION", 324, 339], ["infected cells", "OBSERVATION", 340, 354]]], ["JC polyomavirus T-antigen (T-Ag) was found to suppress expression of a host autophagy gene called Bag3.", [["T-Ag", "CHEMICAL", 27, 31], ["Ag", "CHEMICAL", 29, 31], ["JC polyomavirus", "ORGANISM", 0, 15], ["T-antigen", "GENE_OR_GENE_PRODUCT", 16, 25], ["T-Ag", "GENE_OR_GENE_PRODUCT", 27, 31], ["Bag3", "GENE_OR_GENE_PRODUCT", 98, 102], ["JC polyomavirus T-antigen", "PROTEIN", 0, 25], ["T", "PROTEIN", 27, 28], ["Ag", "PROTEIN", 29, 31], ["autophagy gene", "DNA", 76, 90], ["Bag3", "DNA", 98, 102], ["JC polyomavirus T", "TEST", 0, 17]]], ["Overexpression of Bag3 in host cells, results in elevated autophagy levels and decreases JC infection.", [["cells", "ANATOMY", 31, 36], ["JC infection", "DISEASE", 89, 101], ["Bag3", "GENE_OR_GENE_PRODUCT", 18, 22], ["host cells", "CELL", 26, 36], ["Bag3", "PROTEIN", 18, 22], ["host cells", "CELL_TYPE", 26, 36], ["Bag3 in host cells", "TREATMENT", 18, 36], ["elevated autophagy levels", "PROBLEM", 49, 74], ["JC infection", "PROBLEM", 89, 101], ["Bag3", "OBSERVATION", 18, 22], ["host cells", "OBSERVATION", 26, 36], ["elevated", "OBSERVATION_MODIFIER", 49, 57], ["autophagy levels", "OBSERVATION", 58, 74], ["decreases", "OBSERVATION_MODIFIER", 79, 88], ["JC", "OBSERVATION_MODIFIER", 89, 91], ["infection", "OBSERVATION", 92, 101]]], ["These data suggest that autophagy acts as an anti-viral process in JC polyomavirus infection (Sariyer et al., 2012) .", [["JC polyomavirus infection", "DISEASE", 67, 92], ["JC polyomavirus", "ORGANISM", 67, 82], ["JC polyomavirus", "SPECIES", 67, 82], ["These data", "TEST", 0, 10], ["autophagy acts", "PROBLEM", 24, 38], ["an anti-viral process", "PROBLEM", 42, 63], ["JC polyomavirus infection", "PROBLEM", 67, 92], ["JC polyomavirus infection", "OBSERVATION", 67, 92]]], ["In contrast, elevation of host autophagy occurs when cells were made to express small t-antigen of simian virus 40 (SV40), a polyomavirus family member related to BKPyV (Kumar and Rangarajan, 2009 ).", [["cells", "ANATOMY", 53, 58], ["cells", "CELL", 53, 58], ["simian virus 40", "ORGANISM", 99, 114], ["SV40", "ORGANISM", 116, 120], ["polyomavirus", "ORGANISM", 125, 137], ["BKPyV", "GENE_OR_GENE_PRODUCT", 163, 168], ["t-antigen", "PROTEIN", 86, 95], ["simian virus", "SPECIES", 99, 111], ["simian virus 40", "SPECIES", 99, 114], ["elevation of host autophagy", "PROBLEM", 13, 40], ["small t-antigen of simian virus", "PROBLEM", 80, 111], ["elevation", "OBSERVATION_MODIFIER", 13, 22], ["host autophagy", "OBSERVATION", 26, 40]]], ["The small t antigen seems to help the cells to survive and respond to low nutrient conditions by stimulating host AMP-activated protein kinase (AMPK).", [["cells", "ANATOMY", 38, 43], ["AMP", "CHEMICAL", 114, 117], ["AMP", "CHEMICAL", 114, 117], ["small t antigen", "GENE_OR_GENE_PRODUCT", 4, 19], ["cells", "CELL", 38, 43], ["AMP-activated protein kinase", "GENE_OR_GENE_PRODUCT", 114, 142], ["AMPK", "GENE_OR_GENE_PRODUCT", 144, 148], ["small t antigen", "PROTEIN", 4, 19], ["AMP-activated protein kinase", "PROTEIN", 114, 142], ["AMPK", "PROTEIN", 144, 148], ["The small t antigen", "PROBLEM", 0, 19], ["low nutrient conditions", "PROBLEM", 70, 93], ["activated protein kinase", "TREATMENT", 118, 142], ["small", "OBSERVATION_MODIFIER", 4, 9]]], ["When AMPK is activated it inactivates mTOR and thus increases the amount of autophagy occurring within the cell.", [["cell", "ANATOMY", 107, 111], ["AMPK", "GENE_OR_GENE_PRODUCT", 5, 9], ["mTOR", "GENE_OR_GENE_PRODUCT", 38, 42], ["cell", "CELL", 107, 111], ["AMPK", "PROTEIN", 5, 9], ["mTOR", "PROTEIN", 38, 42], ["autophagy", "PROBLEM", 76, 85], ["amount", "OBSERVATION_MODIFIER", 66, 72], ["autophagy", "OBSERVATION", 76, 85]]], ["These steps are thought to block premature host cell death during the viral life cycle, a state that would maximize viral production (Kumar and Rangarajan, 2009 ).", [["cell", "ANATOMY", 48, 52], ["cell", "CELL", 48, 52], ["premature host cell death", "PROBLEM", 33, 58], ["host cell death", "OBSERVATION", 43, 58]]], ["Whether polyomavirus large and small t-antigen have opposing roles in controlling autophagy or if autophagy influences individual polyomaviruses members differently has yet to be determined.DiscussionIn this report, we show that induction of host autophagy early in the viral life cycle promotes BKPyV infection.", [["infection", "DISEASE", 302, 311], ["polyomavirus", "ORGANISM", 8, 20], ["t-antigen", "GENE_OR_GENE_PRODUCT", 37, 46], ["polyomaviruses", "ORGANISM", 130, 144], ["BKPyV", "GENE_OR_GENE_PRODUCT", 296, 301], ["polyomavirus large and small t-antigen", "PROTEIN", 8, 46], ["BKPyV", "SPECIES", 296, 301], ["polyomavirus large and small t-antigen", "PROBLEM", 8, 46], ["autophagy", "PROBLEM", 98, 107], ["host autophagy", "PROBLEM", 242, 256], ["the viral life cycle", "TREATMENT", 266, 286], ["BKPyV infection", "PROBLEM", 296, 311], ["polyomavirus", "OBSERVATION", 8, 20], ["large", "OBSERVATION_MODIFIER", 21, 26], ["small", "OBSERVATION_MODIFIER", 31, 36], ["t-antigen", "OBSERVATION", 37, 46], ["BKPyV infection", "OBSERVATION", 296, 311]]], ["Pharmacological Cells were then infected with BKPyV-AF633 at 37 1C for 3 h, fixed and mounted onto slides using DAPI mounting media.", [["Cells", "ANATOMY", 16, 21], ["BKPyV-AF633", "CHEMICAL", 46, 57], ["DAPI", "CHEMICAL", 112, 116], ["Cells", "CELL", 16, 21], ["BKPyV-AF633", "CELL", 46, 57], ["DAPI", "SIMPLE_CHEMICAL", 112, 116], ["Pharmacological Cells", "PROBLEM", 0, 21], ["BKPyV", "TEST", 46, 51], ["DAPI mounting media", "TREATMENT", 112, 131]]], ["Cells were analyzed for appearance of LC3-positive autophagosomes (green) and infection of labeled BKPyV (red) use a Zeiss 710 confocal microscope and Zen imaging software.", [["Cells", "ANATOMY", 0, 5], ["autophagosomes", "ANATOMY", 51, 65], ["infection", "DISEASE", 78, 87], ["Cells", "CELL", 0, 5], ["LC3", "GENE_OR_GENE_PRODUCT", 38, 41], ["autophagosomes", "CELLULAR_COMPONENT", 51, 65], ["LC3", "PROTEIN", 38, 41], ["BKPyV", "PROTEIN", 99, 104], ["Cells", "TEST", 0, 5], ["LC3", "TEST", 38, 41], ["positive autophagosomes", "PROBLEM", 42, 65], ["infection of labeled BKPyV", "PROBLEM", 78, 104], ["Zen imaging software", "TEST", 151, 171], ["positive autophagosomes", "OBSERVATION", 42, 65]]], ["Images analyzed using ImageJ image analysis software.", [["Images", "TEST", 0, 6], ["ImageJ image analysis software", "TEST", 22, 52]]], ["Four representative cells show that BKPyV-Af633 resides within the LC3-GFP\u00fe autophagosome and with smaller LC3-GFP\u00fe punctae (magnification 630X).", [["cells", "ANATOMY", 20, 25], ["autophagosome", "ANATOMY", 76, 89], ["punctae", "ANATOMY", 116, 123], ["cells", "CELL", 20, 25], ["BKPyV-Af633", "GENE_OR_GENE_PRODUCT", 36, 47], ["LC3", "GENE_OR_GENE_PRODUCT", 67, 70], ["GFP", "GENE_OR_GENE_PRODUCT", 71, 74], ["autophagosome", "CELLULAR_COMPONENT", 76, 89], ["LC3-GFP", "GENE_OR_GENE_PRODUCT", 107, 114], ["BKPyV", "PROTEIN", 36, 41], ["Af633", "PROTEIN", 42, 47], ["LC3", "PROTEIN", 67, 70], ["GFP", "PROTEIN", 71, 74], ["LC3", "PROTEIN", 107, 110], ["GFP", "PROTEIN", 111, 114], ["magnification 630X", "PROTEIN", 125, 143], ["Four representative cells", "TEST", 0, 25], ["BKPyV", "TEST", 36, 41], ["Af", "PROBLEM", 42, 44], ["the LC3", "TEST", 63, 70], ["autophagosome", "TEST", 76, 89], ["BKPyV", "OBSERVATION", 36, 41], ["GFP\u00fe autophagosome", "OBSERVATION", 71, 89], ["smaller", "OBSERVATION_MODIFIER", 99, 106], ["LC3", "OBSERVATION_MODIFIER", 107, 110]]], ["(A and B) (ii) An orthogonal Z slice of (iii) (along yellow x-axis). (iii) A magnified image of BKPyV and LC3-GFP\u00fe as shown in (i). (iv) An orthogonal Z slice of (iii) (along yellow y-axis).", [["BKPyV", "GENE_OR_GENE_PRODUCT", 96, 101], ["LC3", "GENE_OR_GENE_PRODUCT", 106, 109], ["GFP", "GENE_OR_GENE_PRODUCT", 110, 113], ["BKPyV", "PROTEIN", 96, 101], ["LC3", "PROTEIN", 106, 109], ["GFP\u00fe", "PROTEIN", 110, 114], ["BKPyV", "TEST", 96, 101], ["BKPyV", "OBSERVATION", 96, 101]]], ["(E) LC3-GFP transfected cells were scored for the pattern of LC3-GFP distribution (n\u00bc 60, left).", [["cells", "ANATOMY", 24, 29], ["left", "ANATOMY", 90, 94], ["LC3", "GENE_OR_GENE_PRODUCT", 4, 7], ["GFP", "GENE_OR_GENE_PRODUCT", 8, 11], ["cells", "CELL", 24, 29], ["LC3", "GENE_OR_GENE_PRODUCT", 61, 64], ["GFP", "GENE_OR_GENE_PRODUCT", 65, 68], ["LC3", "PROTEIN", 4, 7], ["GFP transfected cells", "CELL_LINE", 8, 29], ["LC3", "PROTEIN", 61, 64], ["LC3-GFP transfected cells", "TEST", 4, 29], ["GFP distribution", "TEST", 65, 81], ["transfected cells", "OBSERVATION", 12, 29], ["LC3", "OBSERVATION", 61, 64], ["GFP distribution", "OBSERVATION", 65, 81], ["left", "ANATOMY_MODIFIER", 90, 94]]], ["BKPyV-633 infected/LC3-GFP transfected cells were scored for LC3-GFP distribution (n\u00bc60, middle).", [["cells", "ANATOMY", 39, 44], ["BKPyV-633", "CHEMICAL", 0, 9], ["BKPyV-633", "GENE_OR_GENE_PRODUCT", 0, 9], ["LC3", "GENE_OR_GENE_PRODUCT", 19, 22], ["GFP", "GENE_OR_GENE_PRODUCT", 23, 26], ["cells", "CELL", 39, 44], ["LC3", "GENE_OR_GENE_PRODUCT", 61, 64], ["GFP", "GENE_OR_GENE_PRODUCT", 65, 68], ["BKPyV-633 infected/LC3-GFP transfected cells", "CELL_LINE", 0, 44], ["LC3", "PROTEIN", 61, 64], ["BKPyV", "TEST", 0, 5], ["infected/LC3", "TEST", 10, 22], ["GFP transfected cells", "TEST", 23, 44], ["LC3", "TEST", 61, 64], ["GFP distribution", "TEST", 65, 81], ["transfected cells", "OBSERVATION", 27, 44], ["GFP distribution", "OBSERVATION", 65, 81], ["middle", "ANATOMY_MODIFIER", 89, 95]]], ["BKPyV-633 infected that showed colocalization with LC3-GFO were scored for pattern of LC3-GFP distribution (n\u00bc 60, right). autophagy inhibitors, high amino acid concentrations, and knockdown of autophagy genes reduced BKPyV infection, while rapamycin treatment led to an increase in BKPyV infection.", [["BKPyV-633", "CHEMICAL", 0, 9], ["amino acid", "CHEMICAL", 150, 160], ["infection", "DISEASE", 224, 233], ["rapamycin", "CHEMICAL", 241, 250], ["infection", "DISEASE", 289, 298], ["amino acid", "CHEMICAL", 150, 160], ["rapamycin", "CHEMICAL", 241, 250], ["BKPyV-633", "GENE_OR_GENE_PRODUCT", 0, 9], ["LC3", "GENE_OR_GENE_PRODUCT", 51, 54], ["GFO", "GENE_OR_GENE_PRODUCT", 55, 58], ["LC3", "GENE_OR_GENE_PRODUCT", 86, 89], ["GFP", "GENE_OR_GENE_PRODUCT", 90, 93], ["amino acid", "AMINO_ACID", 150, 160], ["BKPyV", "GENE_OR_GENE_PRODUCT", 218, 223], ["rapamycin", "SIMPLE_CHEMICAL", 241, 250], ["BKPyV", "GENE_OR_GENE_PRODUCT", 283, 288], ["BKPyV", "PROTEIN", 0, 5], ["LC3", "PROTEIN", 51, 54], ["GFO", "PROTEIN", 55, 58], ["LC3", "PROTEIN", 86, 89], ["autophagy genes", "DNA", 194, 209], ["BKPyV", "SPECIES", 218, 223], ["BKPyV", "SPECIES", 283, 288], ["BKPyV", "TEST", 0, 5], ["LC3", "TEST", 51, 54], ["GFO", "TEST", 55, 58], ["LC3", "TEST", 86, 89], ["GFP distribution", "TEST", 90, 106], ["autophagy inhibitors", "TREATMENT", 123, 143], ["high amino acid concentrations", "PROBLEM", 145, 175], ["autophagy genes", "PROBLEM", 194, 209], ["reduced BKPyV infection", "PROBLEM", 210, 233], ["rapamycin treatment", "TREATMENT", 241, 260], ["BKPyV infection", "PROBLEM", 283, 298], ["LC3", "OBSERVATION", 86, 89], ["GFP distribution", "OBSERVATION", 90, 106], ["right", "ANATOMY_MODIFIER", 115, 120], ["autophagy genes", "OBSERVATION", 194, 209], ["reduced", "OBSERVATION_MODIFIER", 210, 217], ["BKPyV", "OBSERVATION_MODIFIER", 218, 223], ["infection", "OBSERVATION", 224, 233], ["increase", "OBSERVATION_MODIFIER", 271, 279], ["BKPyV infection", "OBSERVATION", 283, 298]]], ["BKPyV is sensitive to autophagy inhibitors during the first 8 h of infection, a time period consistent with viral entry and intracellular trafficking (Eash and Atwood, 2005; Eash et al., 2004; Jiang et al., 2009 ).", [["intracellular", "ANATOMY", 124, 137], ["BKPyV", "CHEMICAL", 0, 5], ["infection", "DISEASE", 67, 76], ["BKPyV", "GENE_OR_GENE_PRODUCT", 0, 5], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 124, 137], ["BKPyV", "PROTEIN", 0, 5], ["BKPyV", "PROBLEM", 0, 5], ["autophagy inhibitors", "TREATMENT", 22, 42], ["infection", "PROBLEM", 67, 76], ["viral entry", "PROBLEM", 108, 119], ["infection", "OBSERVATION", 67, 76], ["consistent with", "UNCERTAINTY", 92, 107], ["viral entry", "OBSERVATION", 108, 119], ["intracellular trafficking", "OBSERVATION", 124, 149]]], ["Interestingly we did note that addition of autophagy inhibitors from 24 to 48 h post infection increases BKPyV infection of Vero cells (Fig. 3) .", [["Vero cells", "ANATOMY", 124, 134], ["infection", "DISEASE", 85, 94], ["infection", "DISEASE", 111, 120], ["BKPyV", "GENE_OR_GENE_PRODUCT", 105, 110], ["Vero cells", "CELL", 124, 134], ["Vero cells", "CELL_LINE", 124, 134], ["BKPyV", "SPECIES", 105, 110], ["autophagy inhibitors", "TREATMENT", 43, 63], ["infection", "PROBLEM", 85, 94], ["BKPyV infection of Vero cells", "PROBLEM", 105, 134], ["BKPyV", "OBSERVATION_MODIFIER", 105, 110], ["infection", "OBSERVATION", 111, 120], ["Vero cells", "OBSERVATION", 124, 134]]], ["We also observed a similar increase in infection levels when autophagy inhibitors were added 16-24 h following infection (data not shown).", [["infection", "DISEASE", 39, 48], ["infection", "DISEASE", 111, 120], ["a similar increase in infection levels", "PROBLEM", 17, 55], ["autophagy inhibitors", "TREATMENT", 61, 81], ["infection", "PROBLEM", 111, 120], ["similar", "OBSERVATION_MODIFIER", 19, 26], ["increase", "OBSERVATION_MODIFIER", 27, 35], ["infection", "OBSERVATION", 39, 48]]], ["From 16 to 48 h post infection, T-Ag transcription and protein production, viral replication, and V-Ag protein production occur in this sequential order (Jiang et al., 2009) .", [["infection", "DISEASE", 21, 30], ["Ag", "CHEMICAL", 100, 102], ["T-Ag", "GENE_OR_GENE_PRODUCT", 32, 36], ["V-Ag", "GENE_OR_GENE_PRODUCT", 98, 102], ["Ag", "PROTEIN", 34, 36], ["Ag protein", "PROTEIN", 100, 110], ["infection", "PROBLEM", 21, 30], ["T-Ag transcription", "TREATMENT", 32, 50], ["protein production", "TEST", 55, 73], ["viral replication", "PROBLEM", 75, 92], ["infection", "OBSERVATION", 21, 30], ["viral replication", "OBSERVATION", 75, 92]]], ["Therefore it is possible that at this time frame, autophagy acts has an antiviral mechanism by degrading newly translated viral proteins.", [["viral proteins", "PROTEIN", 122, 136], ["an antiviral mechanism", "PROBLEM", 69, 91]]], ["Addition of autophagy inhibitors midway through the viral lifecycle may allow more viral protein synthesis and virion assembly to occur.", [["virion", "CELLULAR_COMPONENT", 111, 117], ["autophagy inhibitors", "TREATMENT", 12, 32], ["the viral lifecycle", "TREATMENT", 48, 67], ["viral protein synthesis", "TREATMENT", 83, 106]]], ["Eukaryotic cells respond to stressful stimuli using autophagy and the unfolded protein response.", [["cells", "ANATOMY", 11, 16], ["cells", "CELL", 11, 16], ["Eukaryotic cells", "CELL_TYPE", 0, 16], ["Eukaryotic cells", "PROBLEM", 0, 16], ["stressful stimuli", "TEST", 28, 45], ["autophagy", "TREATMENT", 52, 61], ["the unfolded protein response", "PROBLEM", 66, 95], ["protein response", "OBSERVATION", 79, 95]]], ["Recent evidence suggests that Rab1 protein may have important roles in both pathways (Chua and Tang, 2013) .", [["Rab1", "GENE_OR_GENE_PRODUCT", 30, 34], ["Rab1 protein", "PROTEIN", 30, 42], ["Rab1 protein", "PROBLEM", 30, 42], ["Rab1 protein", "OBSERVATION", 30, 42]]], ["Therefore pharmacologically blocking autophagy between 16 h and 48 h post viral challenge may elevate BKPyV infection by reducing the unfolded protein response allowing translation to proceed despite ER-stress.DiscussionUsing confocal immunofluorescence, our data also shows that BKPyV was found within LC3-positive structures 3 h following infection ( Fig. 5A and B) .", [["LC3-positive structures", "ANATOMY", 303, 326], ["BKPyV", "CHEMICAL", 102, 107], ["infection", "DISEASE", 108, 117], ["infection", "DISEASE", 341, 350], ["BKPyV", "GENE_OR_GENE_PRODUCT", 102, 107], ["ER", "GENE_OR_GENE_PRODUCT", 200, 202], ["BKPyV", "GENE_OR_GENE_PRODUCT", 280, 285], ["LC3", "GENE_OR_GENE_PRODUCT", 303, 306], ["ER", "PROTEIN", 200, 202], ["BKPyV", "PROTEIN", 280, 285], ["LC3", "PROTEIN", 303, 306], ["BKPyV", "SPECIES", 102, 107], ["pharmacologically blocking autophagy", "PROBLEM", 10, 46], ["viral challenge", "TREATMENT", 74, 89], ["BKPyV infection", "PROBLEM", 102, 117], ["the unfolded protein response", "PROBLEM", 130, 159], ["confocal immunofluorescence", "TEST", 226, 253], ["our data", "TEST", 255, 263], ["BKPyV", "PROBLEM", 280, 285], ["LC3", "TEST", 303, 306], ["infection", "PROBLEM", 341, 350], ["BKPyV infection", "OBSERVATION", 102, 117], ["BKPyV", "OBSERVATION", 280, 285], ["positive structures", "OBSERVATION_MODIFIER", 307, 326], ["infection", "OBSERVATION", 341, 350]]], ["Strikingly, BKPyV infected cells correlated with a change in the localization of LC3-GFP from a diffuse pattern to a small and large punctate distribution pattern suggesting that BKPyV has a mechanism to stimulate host autophagy (Fig. 5E) .DiscussionSome of the early steps in the BKPyV life cycle have been elucidated in recent years.", [["cells", "ANATOMY", 27, 32], ["BKPyV", "CHEMICAL", 179, 184], ["cells", "CELL", 27, 32], ["LC3", "GENE_OR_GENE_PRODUCT", 81, 84], ["GFP", "GENE_OR_GENE_PRODUCT", 85, 88], ["BKPyV", "GENE_OR_GENE_PRODUCT", 179, 184], ["BKPyV infected cells", "CELL_LINE", 12, 32], ["LC3", "PROTEIN", 81, 84], ["GFP", "PROTEIN", 85, 88], ["BKPyV", "PROTEIN", 179, 184], ["BKPyV infected cells", "PROBLEM", 12, 32], ["a diffuse pattern", "PROBLEM", 94, 111], ["a small and large punctate distribution pattern", "PROBLEM", 115, 162], ["BKPyV", "PROBLEM", 179, 184], ["BKPyV", "OBSERVATION_MODIFIER", 12, 17], ["infected cells", "OBSERVATION", 18, 32], ["change", "OBSERVATION_MODIFIER", 51, 57], ["diffuse", "OBSERVATION_MODIFIER", 96, 103], ["small", "OBSERVATION_MODIFIER", 117, 122], ["large", "OBSERVATION_MODIFIER", 127, 132], ["punctate", "OBSERVATION_MODIFIER", 133, 141], ["distribution pattern", "OBSERVATION", 142, 162], ["BKPyV", "OBSERVATION", 179, 184]]], ["BKPyV attaches to its host cell by binding to a disialic acid-containing b-series ganglioside receptor (GD3, GD2,GD1b, GT1b) (Neu et al., 2013; Low et al., 2006) .", [["cell", "ANATOMY", 27, 31], ["BKPyV", "CHEMICAL", 0, 5], ["ganglioside", "CHEMICAL", 82, 93], ["BKPyV", "GENE_OR_GENE_PRODUCT", 0, 5], ["host cell", "CELL", 22, 31], ["ganglioside receptor", "GENE_OR_GENE_PRODUCT", 82, 102], ["GD3", "GENE_OR_GENE_PRODUCT", 104, 107], ["GD2", "GENE_OR_GENE_PRODUCT", 109, 112], ["GD1b", "GENE_OR_GENE_PRODUCT", 113, 117], ["GT1b", "GENE_OR_GENE_PRODUCT", 119, 123], ["BKPyV", "PROTEIN", 0, 5], ["disialic acid-containing b-series ganglioside receptor", "PROTEIN", 48, 102], ["GD3", "PROTEIN", 104, 107], ["GD2", "PROTEIN", 109, 112], ["GD1b", "PROTEIN", 113, 117], ["GT1b", "PROTEIN", 119, 123], ["BKPyV attaches", "PROBLEM", 0, 14], ["a disialic acid-containing b-series ganglioside receptor", "TEST", 46, 102], ["GD3", "TEST", 104, 107], ["GD2", "TEST", 109, 112], ["GD1b", "TEST", 113, 117], ["host cell", "OBSERVATION", 22, 31]]], ["Upon caveolae-mediated endocytosis, BKPyV enters the cell and requires some acidification event in the first few hours following infection (Eash et al., 2004; Jiang et al., 2009) .", [["caveolae", "ANATOMY", 5, 13], ["cell", "ANATOMY", 53, 57], ["infection", "DISEASE", 129, 138], ["caveolae", "CELLULAR_COMPONENT", 5, 13], ["BKPyV", "GENE_OR_GENE_PRODUCT", 36, 41], ["cell", "CELL", 53, 57], ["BKPyV", "PROTEIN", 36, 41], ["mediated endocytosis", "PROBLEM", 14, 34], ["BKPyV enters the cell", "PROBLEM", 36, 57], ["some acidification event", "PROBLEM", 71, 95], ["infection", "PROBLEM", 129, 138], ["endocytosis", "OBSERVATION", 23, 34], ["BKPyV", "OBSERVATION", 36, 41], ["some", "OBSERVATION_MODIFIER", 71, 75], ["acidification", "OBSERVATION", 76, 89], ["infection", "OBSERVATION", 129, 138]]], ["Dynamic microtubules are thought to help shuttle viral particles to the ER where virus localizes at 8-12 h following adsorption (Jiang et al., 2009) .", [["microtubules", "ANATOMY", 8, 20], ["ER", "ANATOMY", 72, 74], ["microtubules", "CELLULAR_COMPONENT", 8, 20], ["ER", "GENE_OR_GENE_PRODUCT", 72, 74], ["ER", "PROTEIN", 72, 74], ["virus", "PROBLEM", 81, 86]]], ["Within the ER, capsid disassembly occurs.", [["ER", "ANATOMY", 11, 13], ["ER", "GENE_OR_GENE_PRODUCT", 11, 13], ["capsid", "CELLULAR_COMPONENT", 15, 21], ["ER", "PROTEIN", 11, 13], ["capsid disassembly", "OBSERVATION", 15, 33]]], ["BKPyV also utilizes the proteasome and ER-associated degradation pathway (ERAD) to help BKPyV exit from the ER and for viral DNA accumulate in the cytoplasm (Jiang et al., 2009; Bennett et al., 2013) .", [["ER", "ANATOMY", 108, 110], ["cytoplasm", "ANATOMY", 147, 156], ["BKPyV", "CHEMICAL", 0, 5], ["BKPyV", "GENE_OR_GENE_PRODUCT", 0, 5], ["ER-associated degradation pathway", "GENE_OR_GENE_PRODUCT", 39, 72], ["ERAD", "GENE_OR_GENE_PRODUCT", 74, 78], ["BKPyV", "GENE_OR_GENE_PRODUCT", 88, 93], ["ER", "GENE_OR_GENE_PRODUCT", 108, 110], ["DNA", "CELLULAR_COMPONENT", 125, 128], ["cytoplasm", "ORGANISM_SUBSTANCE", 147, 156], ["BKPyV", "PROTEIN", 0, 5], ["proteasome", "PROTEIN", 24, 34], ["ER", "PROTEIN", 39, 41], ["ERAD", "PROTEIN", 74, 78], ["BKPyV", "PROTEIN", 88, 93], ["ER", "PROTEIN", 108, 110], ["viral DNA", "DNA", 119, 128], ["BKPyV", "PROBLEM", 0, 5], ["the proteasome", "TREATMENT", 20, 34], ["viral DNA", "PROBLEM", 119, 128]]], ["Nuclear transport of viral DNA then occurs.", [["Nuclear", "ANATOMY", 0, 7], ["Nuclear", "CELLULAR_COMPONENT", 0, 7], ["DNA", "CELLULAR_COMPONENT", 27, 30], ["viral DNA", "DNA", 21, 30], ["viral DNA", "PROBLEM", 21, 30], ["viral DNA", "OBSERVATION", 21, 30]]], ["This is the first report indicating that autophagy plays a role in BKPyV infection of host cells.", [["cells", "ANATOMY", 91, 96], ["infection", "DISEASE", 73, 82], ["BKPyV", "GENE_OR_GENE_PRODUCT", 67, 72], ["host cells", "CELL", 86, 96], ["host cells", "CELL_TYPE", 86, 96], ["BKPyV", "SPECIES", 67, 72], ["BKPyV infection of host cells", "PROBLEM", 67, 96], ["host cells", "OBSERVATION", 86, 96]]], ["Our study indicates that BKPyV localizes to the autophagosome 3 h post infection and that autophagy aids in productive BKPyV invasion of host cells.", [["autophagosome", "ANATOMY", 48, 61], ["BKPyV", "ANATOMY", 119, 124], ["cells", "ANATOMY", 142, 147], ["infection", "DISEASE", 71, 80], ["BKPyV", "GENE_OR_GENE_PRODUCT", 25, 30], ["autophagosome", "CELLULAR_COMPONENT", 48, 61], ["BKPyV", "GENE_OR_GENE_PRODUCT", 119, 124], ["host cells", "CELL", 137, 147], ["BKPyV", "PROTEIN", 25, 30], ["host cells", "CELL_TYPE", 137, 147], ["BKPyV", "SPECIES", 119, 124], ["Our study", "TEST", 0, 9], ["BKPyV", "PROBLEM", 25, 30], ["infection", "PROBLEM", 71, 80], ["autophagy aids", "PROBLEM", 90, 104], ["productive BKPyV invasion of host cells", "PROBLEM", 108, 147], ["BKPyV", "OBSERVATION", 25, 30], ["infection", "OBSERVATION", 71, 80], ["productive", "OBSERVATION_MODIFIER", 108, 118], ["BKPyV", "OBSERVATION_MODIFIER", 119, 124], ["invasion", "OBSERVATION_MODIFIER", 125, 133], ["host cells", "OBSERVATION", 137, 147]]], ["While the exact reason for this BKPyV-autophagosome interaction has yet to be elucidated, there are many possible explanations.", [["autophagosome", "ANATOMY", 38, 51], ["BKPyV", "GENE_OR_GENE_PRODUCT", 32, 37], ["autophagosome", "CELLULAR_COMPONENT", 38, 51], ["BKPyV", "PROTEIN", 32, 37], ["this BKPyV", "PROBLEM", 27, 37], ["autophagosome interaction", "PROBLEM", 38, 63]]], ["First, an autophagosome may facilitate trafficking the virus towards the ER for viral disassembly.", [["autophagosome", "ANATOMY", 10, 23], ["ER", "ANATOMY", 73, 75], ["autophagosome", "CELLULAR_COMPONENT", 10, 23], ["ER", "GENE_OR_GENE_PRODUCT", 73, 75], ["ER", "PROTEIN", 73, 75], ["trafficking the virus", "PROBLEM", 39, 60], ["viral disassembly", "PROBLEM", 80, 97]]], ["Autophagosomes use microtubules to shuttle themselves towards the lysosome to and group together with other autophagosomes in perinuclear regions (Jahreiss et al., 2008; Mackeh et al., 2013; Bouzas-Rodriguez et al., 2012) .", [["microtubules", "ANATOMY", 19, 31], ["lysosome", "ANATOMY", 66, 74], ["autophagosomes", "ANATOMY", 108, 122], ["perinuclear regions", "ANATOMY", 126, 145], ["Autophagosomes", "SIMPLE_CHEMICAL", 0, 14], ["microtubules", "CELLULAR_COMPONENT", 19, 31], ["lysosome", "CELLULAR_COMPONENT", 66, 74], ["autophagosomes", "CELLULAR_COMPONENT", 108, 122], ["perinuclear regions", "CELLULAR_COMPONENT", 126, 145], ["perinuclear", "ANATOMY_MODIFIER", 126, 137]]], ["Drug studies show that microtubule assemble and disassembly is necessary for BKPyV infection (Eash and Atwood, 2005; Jiang et al., 2009) .", [["microtubule", "ANATOMY", 23, 34], ["infection", "DISEASE", 83, 92], ["microtubule", "CELLULAR_COMPONENT", 23, 34], ["BKPyV", "GENE_OR_GENE_PRODUCT", 77, 82], ["microtubule", "PROTEIN", 23, 34], ["Drug studies", "TEST", 0, 12], ["BKPyV infection", "PROBLEM", 77, 92], ["infection", "OBSERVATION", 83, 92]]], ["Therefore BKPyV may utilize the coordinated interaction between the autophagosome and microtubules to be shuttle closer to the ER.", [["autophagosome", "ANATOMY", 68, 81], ["microtubules", "ANATOMY", 86, 98], ["ER", "ANATOMY", 127, 129], ["BKPyV", "CHEMICAL", 10, 15], ["BKPyV", "GENE_OR_GENE_PRODUCT", 10, 15], ["autophagosome", "CELLULAR_COMPONENT", 68, 81], ["microtubules", "CELLULAR_COMPONENT", 86, 98], ["ER", "GENE_OR_GENE_PRODUCT", 127, 129], ["BKPyV", "PROTEIN", 10, 15], ["microtubules", "PROTEIN", 86, 98], ["ER", "PROTEIN", 127, 129], ["BKPyV", "PROBLEM", 10, 15], ["BKPyV", "OBSERVATION", 10, 15]]], ["BKPyV does not seem to use the canonical early to late endosomal pathway to reach the ER, so this alternative trafficking strategy is a possibility ( (Eash and Atwood, 2005; Eash et al., 2004; Jiang et al., 2009 ) personal communication with Mengxi Jiang and Michael J. Imperiale).DiscussionAnother second possibility is that BKPyV interacts with the autophagosome to utilize the low pH and hydrolase-rich environment during the autophagosome-lysosome fusion process.", [["endosomal", "ANATOMY", 55, 64], ["ER", "ANATOMY", 86, 88], ["autophagosome", "ANATOMY", 351, 364], ["autophagosome", "ANATOMY", 429, 442], ["lysosome", "ANATOMY", 443, 451], ["BKPyV", "GENE_OR_GENE_PRODUCT", 0, 5], ["endosomal", "CELLULAR_COMPONENT", 55, 64], ["ER", "GENE_OR_GENE_PRODUCT", 86, 88], ["BKPyV", "GENE_OR_GENE_PRODUCT", 326, 331], ["autophagosome", "CELLULAR_COMPONENT", 351, 364], ["autophagosome", "CELLULAR_COMPONENT", 429, 442], ["lysosome", "CELLULAR_COMPONENT", 443, 451], ["BKPyV", "PROTEIN", 0, 5], ["ER", "PROTEIN", 86, 88], ["BKPyV", "PROTEIN", 326, 331], ["hydrolase", "PROTEIN", 391, 400], ["BKPyV interacts", "PROBLEM", 326, 341], ["the low pH and hydrolase", "TREATMENT", 376, 400], ["the autophagosome-lysosome fusion process", "TREATMENT", 425, 466], ["BKPyV", "OBSERVATION", 326, 331], ["lysosome fusion", "OBSERVATION", 443, 458]]], ["Other studies have shown that acidification is necessary for viral infection (Mateo et al., 2013; Mackeh et al., 2013) Moreover, BKPyV infection requires an acidification event to occur within 2 h following infection (Eash et al., 2004; Jiang et al., 2009) .", [["viral infection", "DISEASE", 61, 76], ["infection", "DISEASE", 135, 144], ["infection", "DISEASE", 207, 216], ["BKPyV", "GENE_OR_GENE_PRODUCT", 129, 134], ["Other studies", "TEST", 0, 13], ["acidification", "PROBLEM", 30, 43], ["viral infection", "PROBLEM", 61, 76], ["BKPyV infection", "PROBLEM", 129, 144], ["an acidification event", "PROBLEM", 154, 176], ["infection", "PROBLEM", 207, 216], ["BKPyV", "OBSERVATION_MODIFIER", 129, 134], ["infection", "OBSERVATION", 135, 144], ["infection", "OBSERVATION", 207, 216]]], ["BKPyV may utilize this low pH environment or specific enzymes that become activated in low pH to modify its capsid or partially degraded structural proteins.", [["BKPyV", "CHEMICAL", 0, 5], ["BKPyV", "GENE_OR_GENE_PRODUCT", 0, 5], ["BKPyV", "PROTEIN", 0, 5], ["structural proteins", "PROTEIN", 137, 156], ["BKPyV", "PROBLEM", 0, 5], ["this low pH environment", "PROBLEM", 18, 41], ["specific enzymes", "TEST", 45, 61], ["low pH", "PROBLEM", 87, 93], ["its capsid", "PROBLEM", 104, 114], ["partially degraded structural proteins", "PROBLEM", 118, 156], ["structural proteins", "OBSERVATION", 137, 156]]], ["A third possibility is that stimulating autophagy may promote a pro-survival cell response that primes the cell to deal with the stress of a viral infection.", [["cell", "ANATOMY", 77, 81], ["cell", "ANATOMY", 107, 111], ["viral infection", "DISEASE", 141, 156], ["cell", "CELL", 77, 81], ["cell", "CELL", 107, 111], ["stimulating autophagy", "PROBLEM", 28, 49], ["a viral infection", "PROBLEM", 139, 156], ["pro-survival cell", "OBSERVATION", 64, 81], ["viral", "OBSERVATION_MODIFIER", 141, 146], ["infection", "OBSERVATION", 147, 156]]], ["In some cells types, autophagy is reported to inhibit cell death, and this block is cell death has been associated with greater viral yield (Kumar and Rangarajan, 2009; Joubert et al., 2012) .", [["cells", "ANATOMY", 8, 13], ["cell", "ANATOMY", 54, 58], ["cell", "ANATOMY", 84, 88], ["death", "DISEASE", 59, 64], ["death", "DISEASE", 89, 94], ["cells", "CELL", 8, 13], ["cell", "CELL", 54, 58], ["cell", "CELL", 84, 88], ["cell death", "PROBLEM", 54, 64], ["cell death", "PROBLEM", 84, 94], ["cells types", "OBSERVATION", 8, 19]]], ["Conversely for some viruses, activation of autophagy leads to apoptosis, which increases the number of viral particles for same virus species (Xi et al., 2013; Shai et al., 2013) .DiscussionAutophagy is a complex process that affects viruses differently depending on cell type, viral species, and viral life cycle stage.", [["cell", "ANATOMY", 267, 271], ["cell type", "CELL", 267, 276], ["some viruses", "PROBLEM", 15, 27], ["autophagy", "PROBLEM", 43, 52], ["apoptosis", "PROBLEM", 62, 71], ["viral particles", "PROBLEM", 103, 118], ["same virus species", "PROBLEM", 123, 141], ["a complex process", "PROBLEM", 203, 220], ["viruses", "PROBLEM", 234, 241], ["viral species", "PROBLEM", 278, 291], ["viral life cycle stage", "PROBLEM", 297, 319], ["viruses", "OBSERVATION", 20, 27], ["viral species", "OBSERVATION", 278, 291]]], ["Our observations suggest that autophagy plays a positive role in BKPyV infection process.", [["BKPyV", "ANATOMY", 65, 70], ["infection", "DISEASE", 71, 80], ["BKPyV", "CANCER", 65, 70], ["BKPyV", "SPECIES", 65, 70], ["BKPyV infection process", "PROBLEM", 65, 88], ["BKPyV", "OBSERVATION_MODIFIER", 65, 70], ["infection", "OBSERVATION", 71, 80]]], ["How exactly autophagy aids BKPyV and whether these observations extend to other polyomavirus members, including the wide array of recent discovered polyomaviruses, warrant further investigation.Cell and virusVero and HeLa cells (American Type Culture Collection; ATCC) were maintained in a humidified 37 1C CO 2 chamber in Eagle's minimal essential medium (EMEM) (Mediatech) supplemented with 1% penicillin/streptomycin (HyClone) and 5% and 10% heat inactivated fetal bovine serum (Mediatech), respectively.", [["Cell", "ANATOMY", 194, 198], ["Vero", "ANATOMY", 208, 212], ["HeLa cells", "ANATOMY", 217, 227], ["fetal bovine serum", "ANATOMY", 462, 480], ["penicillin", "CHEMICAL", 396, 406], ["streptomycin", "CHEMICAL", 407, 419], ["CO 2", "CHEMICAL", 307, 311], ["penicillin", "CHEMICAL", 396, 406], ["streptomycin", "CHEMICAL", 407, 419], ["BKPyV", "GENE_OR_GENE_PRODUCT", 27, 32], ["polyomavirus", "ORGANISM", 80, 92], ["polyomaviruses", "ORGANISM", 148, 162], ["Cell", "CELL", 194, 198], ["virusVero", "CELL", 203, 212], ["HeLa cells", "CELL", 217, 227], ["American Type Culture Collection; ATCC", "CELL", 229, 267], ["penicillin", "SIMPLE_CHEMICAL", 396, 406], ["streptomycin", "SIMPLE_CHEMICAL", 407, 419], ["bovine", "ORGANISM", 468, 474], ["serum", "ORGANISM_SUBSTANCE", 475, 480], ["Mediatech", "ORGANISM_SUBSTANCE", 482, 491], ["BKPyV", "PROTEIN", 27, 32], ["HeLa cells", "CELL_LINE", 217, 227], ["bovine", "SPECIES", 468, 474], ["American Type Culture Collection; ATCC", "SPECIES", 229, 267], ["bovine", "SPECIES", 468, 474], ["BKPyV", "PROBLEM", 27, 32], ["recent discovered polyomaviruses", "PROBLEM", 130, 162], ["further investigation", "TEST", 172, 193], ["Cell and virusVero and HeLa cells", "PROBLEM", 194, 227], ["ATCC", "TEST", 263, 267], ["a humidified", "TREATMENT", 288, 300], ["1% penicillin", "TREATMENT", 393, 406], ["streptomycin (HyClone)", "TREATMENT", 407, 429], ["10% heat inactivated fetal bovine serum (Mediatech)", "TREATMENT", 441, 492], ["polyomaviruses", "OBSERVATION", 148, 162], ["virusVero", "OBSERVATION", 203, 212], ["HeLa cells", "OBSERVATION", 217, 227]]], ["The Dunlop strain of BKPyV Gardner (ATCC) were propagated in Vero cells and purified using CsCl as described previously (Raptis, 2001; Eash et al., 2004) .", [["Vero cells", "ANATOMY", 61, 71], ["CsCl", "CHEMICAL", 91, 95], ["CsCl", "CHEMICAL", 91, 95], ["BKPyV Gardner", "ORGANISM", 21, 34], ["ATCC", "CELL", 36, 40], ["Vero cells", "CELL", 61, 71], ["CsCl", "SIMPLE_CHEMICAL", 91, 95], ["Vero cells", "CELL_LINE", 61, 71], ["BKPyV Gardner (ATCC)", "TREATMENT", 21, 41], ["CsCl", "TREATMENT", 91, 95], ["BKPyV Gardner", "OBSERVATION", 21, 34], ["Vero cells", "OBSERVATION", 61, 71]]], ["To label BKPyV, fluorochrome conjugation with 10 \u03bcg/mL of AlexaFluor 633 carboxylic acid-succinimidyl ester was added to BKPyV according to the manufacturer's labeling procedure (MP00143; Molecular Probes).", [["AlexaFluor 633 carboxylic acid-succinimidyl ester", "CHEMICAL", 58, 107], ["AlexaFluor 633 carboxylic acid-succinimidyl ester", "CHEMICAL", 58, 107], ["BKPyV", "SIMPLE_CHEMICAL", 9, 14], ["fluorochrome", "SIMPLE_CHEMICAL", 16, 28], ["AlexaFluor 633 carboxylic acid-succinimidyl ester", "SIMPLE_CHEMICAL", 58, 107], ["BKPyV", "SIMPLE_CHEMICAL", 121, 126], ["fluorochrome conjugation", "TREATMENT", 16, 40], ["AlexaFluor", "TREATMENT", 58, 68], ["carboxylic acid-succinimidyl ester", "TREATMENT", 73, 107], ["the manufacturer's labeling procedure", "TREATMENT", 140, 177], ["BKPyV", "OBSERVATION", 9, 14]]], ["The infectivity of CsCl purified BKV before and after labeling (BKPyV-633) was nearly identical.Cell and virusInfection of host cells 5 \u00c2 10 3 cell were plated in 96-well culture plates.", [["Cell", "ANATOMY", 96, 100], ["cells", "ANATOMY", 128, 133], ["cell", "ANATOMY", 143, 147], ["CsCl", "CHEMICAL", 19, 23], ["BKPyV-633", "CHEMICAL", 64, 73], ["BKPyV-633", "CHEMICAL", 64, 73], ["BKV", "ORGANISM", 33, 36], ["Cell", "CELL", 96, 100], ["host cells", "CELL", 123, 133], ["cell", "CELL", 143, 147], ["host cells", "CELL_TYPE", 123, 133], ["BKV", "SPECIES", 33, 36], ["BKPyV", "TEST", 64, 69], ["host cells", "TEST", 123, 133], ["culture plates", "TEST", 171, 185], ["infectivity", "OBSERVATION_MODIFIER", 4, 15], ["CsCl purified", "OBSERVATION_MODIFIER", 19, 32], ["BKV", "OBSERVATION", 33, 36], ["host cells", "OBSERVATION", 123, 133]]], ["The following day, cells were treated with multiple drugs that influence autophagy levels, rapamycin, 3-methyladenine, bafilomycin-A, DMSO, and spautin-1 (Sigma) before and after being infected with BKPyV (MOI:5) for 1 h at 37 1C.", [["cells", "ANATOMY", 19, 24], ["rapamycin", "CHEMICAL", 91, 100], ["3-methyladenine", "CHEMICAL", 102, 117], ["bafilomycin-A", "CHEMICAL", 119, 132], ["DMSO", "CHEMICAL", 134, 138], ["BKPyV", "CHEMICAL", 199, 204], ["rapamycin", "CHEMICAL", 91, 100], ["3-methyladenine", "CHEMICAL", 102, 117], ["bafilomycin-A", "CHEMICAL", 119, 132], ["DMSO", "CHEMICAL", 134, 138], ["spautin-1", "CHEMICAL", 144, 153], ["cells", "CELL", 19, 24], ["rapamycin", "SIMPLE_CHEMICAL", 91, 100], ["3-methyladenine", "SIMPLE_CHEMICAL", 102, 117], ["bafilomycin-A", "SIMPLE_CHEMICAL", 119, 132], ["DMSO", "SIMPLE_CHEMICAL", 134, 138], ["spautin-1", "GENE_OR_GENE_PRODUCT", 144, 153], ["Sigma", "ORGANISM", 155, 160], ["BKPyV", "SPECIES", 199, 204], ["multiple drugs", "TREATMENT", 43, 57], ["autophagy levels", "TEST", 73, 89], ["rapamycin", "TREATMENT", 91, 100], ["methyladenine", "TREATMENT", 104, 117], ["bafilomycin", "TREATMENT", 119, 130], ["DMSO", "TREATMENT", 134, 138], ["infected", "OBSERVATION", 185, 193]]], ["72 h post infection, cells were fixed using 2% paraformaldehyde (EMB) and permeabilized using 0.5% Triton X-100 (Shelton Scientific).", [["cells", "ANATOMY", 21, 26], ["infection", "DISEASE", 10, 19], ["EMB", "CHEMICAL", 65, 68], ["Triton X-100", "CHEMICAL", 99, 111], ["paraformaldehyde", "CHEMICAL", 47, 63], ["EMB", "CHEMICAL", 65, 68], ["Triton X-100", "CHEMICAL", 99, 111], ["cells", "CELL", 21, 26], ["paraformaldehyde", "SIMPLE_CHEMICAL", 47, 63], ["EMB", "SIMPLE_CHEMICAL", 65, 68], ["Triton X-100", "SIMPLE_CHEMICAL", 99, 111], ["infection", "PROBLEM", 10, 19], ["2% paraformaldehyde (EMB", "TREATMENT", 44, 68], ["0.5% Triton", "TREATMENT", 94, 105], ["infection", "OBSERVATION", 10, 19]]], ["To detect the number of infected cells expressing viral protein, cells were incubated with the anti-V antigen (V-Ag) monoclonal antibody PAB597, secondary Alexa-Fluor-488-labeled goat anti-mouse antibody (Molecular Probes), and then counterstained with DAPI-mounting media (Vector Labs).", [["cells", "ANATOMY", 33, 38], ["cells", "ANATOMY", 65, 70], ["Ag", "CHEMICAL", 113, 115], ["Alexa-Fluor-488", "CHEMICAL", 155, 170], ["DAPI", "CHEMICAL", 253, 257], ["cells", "CELL", 33, 38], ["cells", "CELL", 65, 70], ["anti-V antigen", "GENE_OR_GENE_PRODUCT", 95, 109], ["V-Ag", "GENE_OR_GENE_PRODUCT", 111, 115], ["Alexa-Fluor-488", "SIMPLE_CHEMICAL", 155, 170], ["goat", "ORGANISM", 179, 183], ["DAPI", "SIMPLE_CHEMICAL", 253, 257], ["infected cells", "CELL_TYPE", 24, 38], ["viral protein", "PROTEIN", 50, 63], ["anti-V antigen (V-Ag) monoclonal antibody PAB597", "PROTEIN", 95, 143], ["secondary Alexa-Fluor-488-labeled goat anti-mouse antibody", "PROTEIN", 145, 203], ["Molecular Probes", "PROTEIN", 205, 221], ["goat", "SPECIES", 179, 183], ["anti-mouse", "SPECIES", 184, 194], ["goat", "SPECIES", 179, 183], ["infected cells", "PROBLEM", 24, 38], ["viral protein", "TEST", 50, 63], ["the anti-V antigen", "TEST", 91, 109], ["monoclonal antibody", "TEST", 117, 136], ["secondary Alexa-Fluor", "TEST", 145, 166], ["labeled goat anti-mouse antibody", "TEST", 171, 203], ["Molecular Probes", "TEST", 205, 221], ["infected cells", "OBSERVATION", 24, 38]]], ["The PAB597 hybridoma produced a monoclonal antibody against the SV40 major capsid protein VP1 that cross-reacts with BKPyV VP1.", [["PAB597", "CHEMICAL", 4, 10], ["PAB597 hybridoma", "CELL", 4, 20], ["SV40", "ORGANISM", 64, 68], ["VP1", "GENE_OR_GENE_PRODUCT", 90, 93], ["BKPyV VP1", "GENE_OR_GENE_PRODUCT", 117, 126], ["PAB597 hybridoma", "CELL_LINE", 4, 20], ["monoclonal antibody", "PROTEIN", 32, 51], ["SV40 major capsid protein VP1", "PROTEIN", 64, 93], ["BKPyV VP1", "PROTEIN", 117, 126], ["The PAB597 hybridoma", "TEST", 0, 20], ["a monoclonal antibody", "TREATMENT", 30, 51], ["the SV40 major capsid protein VP1", "TREATMENT", 60, 93], ["BKPyV VP1", "TEST", 117, 126]]], ["Infected cells were scored using a Nikon epifluorescence microscope (Eclipse E800; Nikon, Inc.).", [["cells", "ANATOMY", 9, 14], ["cells", "CELL", 9, 14], ["Infected cells", "PROBLEM", 0, 14], ["a Nikon epifluorescence microscope", "TREATMENT", 33, 67]]], ["Approximately 20,000 cells, the entire surface of the 96 well, were screened for V-Ag expression.Amino acid supplementationEMEM media was supplemented with additional the MEM essential amino acids found in MEM media (50 \u00c2 MEM Amino Acid Solution from Life Technologies).", [["cells", "ANATOMY", 21, 26], ["surface", "ANATOMY", 39, 46], ["Amino acid", "CHEMICAL", 97, 107], ["amino acids", "CHEMICAL", 185, 196], ["Ag", "CHEMICAL", 83, 85], ["Amino acid", "CHEMICAL", 97, 107], ["amino acids", "CHEMICAL", 185, 196], ["Amino Acid", "CHEMICAL", 226, 236], ["cells", "CELL", 21, 26], ["surface", "CELLULAR_COMPONENT", 39, 46], ["V-Ag", "GENE_OR_GENE_PRODUCT", 81, 85], ["Amino acid", "SIMPLE_CHEMICAL", 97, 107], ["amino acids", "AMINO_ACID", 185, 196], ["Ag", "PROTEIN", 83, 85], ["Amino acid supplementationEMEM media", "TREATMENT", 97, 133], ["the MEM essential amino acids", "TREATMENT", 167, 196], ["MEM media", "TREATMENT", 206, 215], ["MEM Amino Acid Solution from Life Technologies", "TREATMENT", 222, 268]]], ["The concentration of amino acids found in 1 \u00c2 supplementation experiments is as follows: 1.2 mM L-arginine hydrochloride, 200 nM L-cysteine, 400 nM L-histidine hrdrochloride-H20, 800 nM L-isoleucine, 3.6 mM L-leucine, 790 nM L-lysine hydrochloride, 200 nM L-methionine, 400 nM L-phenylalanine, 800 nM L-threonine, 100 nM L-tryptophan, 400 nM L-tyrosine, and 800 nM L-valine.", [["amino acids", "CHEMICAL", 21, 32], ["L-arginine", "CHEMICAL", 96, 106], ["L-cysteine", "CHEMICAL", 129, 139], ["L-histidine hrdrochloride-H20", "CHEMICAL", 148, 177], ["L-isoleucine", "CHEMICAL", 186, 198], ["L-leucine", "CHEMICAL", 207, 216], ["L-lysine hydrochloride", "CHEMICAL", 225, 247], ["L-methionine", "CHEMICAL", 256, 268], ["L-phenylalanine", "CHEMICAL", 277, 292], ["L-threonine", "CHEMICAL", 301, 312], ["L-tryptophan", "CHEMICAL", 321, 333], ["L-tyrosine", "CHEMICAL", 342, 352], ["L-valine", "CHEMICAL", 365, 373], ["amino acids", "CHEMICAL", 21, 32], ["L-arginine hydrochloride", "CHEMICAL", 96, 120], ["L-cysteine", "CHEMICAL", 129, 139], ["L-histidine hrdrochloride-H20", "CHEMICAL", 148, 177], ["L-isoleucine", "CHEMICAL", 186, 198], ["L-leucine", "CHEMICAL", 207, 216], ["L-lysine hydrochloride", "CHEMICAL", 225, 247], ["L-methionine", "CHEMICAL", 256, 268], ["L-phenylalanine", "CHEMICAL", 277, 292], ["L-threonine", "CHEMICAL", 301, 312], ["L-tryptophan", "CHEMICAL", 321, 333], ["L-tyrosine", "CHEMICAL", 342, 352], ["L-valine", "CHEMICAL", 365, 373], ["amino acids", "AMINO_ACID", 21, 32], ["L-arginine hydrochloride", "SIMPLE_CHEMICAL", 96, 120], ["L-cysteine", "SIMPLE_CHEMICAL", 129, 139], ["L-histidine hrdrochloride-H20", "SIMPLE_CHEMICAL", 148, 177], ["L-isoleucine", "SIMPLE_CHEMICAL", 186, 198], ["L-leucine", "SIMPLE_CHEMICAL", 207, 216], ["L-lysine hydrochloride", "SIMPLE_CHEMICAL", 225, 247], ["L-methionine", "SIMPLE_CHEMICAL", 256, 268], ["L-phenylalanine", "SIMPLE_CHEMICAL", 277, 292], ["L-threonine", "SIMPLE_CHEMICAL", 301, 312], ["L-tryptophan", "SIMPLE_CHEMICAL", 321, 333], ["L-tyrosine", "SIMPLE_CHEMICAL", 342, 352], ["The concentration of amino acids", "TREATMENT", 0, 32], ["mM L-arginine hydrochloride", "TREATMENT", 93, 120], ["nM L-cysteine", "TREATMENT", 126, 139], ["L-histidine hrdrochloride", "TEST", 148, 173], ["H20", "TREATMENT", 174, 177], ["L-isoleucine", "TEST", 186, 198], ["nM L-lysine hydrochloride", "TREATMENT", 222, 247], ["nM L-methionine", "TREATMENT", 253, 268], ["400 nM L-phenylalanine", "TREATMENT", 270, 292], ["800 nM L-threonine", "TREATMENT", 294, 312], ["800 nM L-valine", "TREATMENT", 358, 373]]], ["A 1X supplementation corresponded to the manufacturer's suggested supplementation, while 2 \u00c2 was twice this amount.", [["A 1X supplementation", "TREATMENT", 0, 20], ["the manufacturer's", "TREATMENT", 37, 55]]], ["NaOH was added to restore supplemented media to pH 7.2.", [["NaOH", "CHEMICAL", 0, 4], ["NaOH", "CHEMICAL", 0, 4], ["NaOH", "SIMPLE_CHEMICAL", 0, 4], ["NaOH", "TREATMENT", 0, 4], ["pH", "TEST", 48, 50]]], ["Cells were treated with these media starting 24 h prior to infection and remained present for the 72 h following infection.", [["Cells", "ANATOMY", 0, 5], ["infection", "DISEASE", 59, 68], ["infection", "DISEASE", 113, 122], ["Cells", "CELL", 0, 5], ["these media", "TREATMENT", 24, 35], ["infection", "PROBLEM", 59, 68], ["infection", "PROBLEM", 113, 122], ["infection", "OBSERVATION", 59, 68], ["infection", "OBSERVATION", 113, 122]]], ["During infection, BKPyV in EMEM with 2% FBS and no amino acid supplementation was added to cells.Cell death assaysVero cells were plated at 1 \u00c2 10 4 in 96 well plates.", [["FBS", "ANATOMY", 40, 43], ["cells", "ANATOMY", 91, 96], ["Cell", "ANATOMY", 97, 101], ["Vero cells", "ANATOMY", 114, 124], ["infection", "DISEASE", 7, 16], ["amino acid", "CHEMICAL", 51, 61], ["death", "DISEASE", 102, 107], ["amino acid", "CHEMICAL", 51, 61], ["FBS", "ORGANISM_SUBSTANCE", 40, 43], ["amino acid", "AMINO_ACID", 51, 61], ["cells", "CELL", 91, 96], ["Cell", "CELL", 97, 101], ["Vero cells", "CELL", 114, 124], ["Vero cells", "CELL_LINE", 114, 124], ["BKPyV", "SPECIES", 18, 23], ["infection", "PROBLEM", 7, 16], ["BKPyV in EMEM", "PROBLEM", 18, 31], ["2% FBS", "TREATMENT", 37, 43], ["amino acid supplementation", "TREATMENT", 51, 77], ["Cell death assays", "PROBLEM", 97, 114], ["Vero cells", "PROBLEM", 114, 124], ["infection", "OBSERVATION", 7, 16], ["BKPyV", "OBSERVATION", 18, 23]]], ["Media containing excessive amino acids or drugs were added to cells and incubated for 24 h.", [["cells", "ANATOMY", 62, 67], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "CHEMICAL", 27, 38], ["amino acids", "AMINO_ACID", 27, 38], ["cells", "CELL", 62, 67], ["Media", "TREATMENT", 0, 5], ["excessive amino acids", "TREATMENT", 17, 38], ["drugs", "TREATMENT", 42, 47], ["excessive", "OBSERVATION_MODIFIER", 17, 26], ["amino acids", "OBSERVATION", 27, 38]]], ["To evaluate cell death using trypan blue exclusion, cells were lifted from plate using trypsin for 5 min.", [["cell", "ANATOMY", 12, 16], ["cells", "ANATOMY", 52, 57], ["death", "DISEASE", 17, 22], ["trypan blue", "CHEMICAL", 29, 40], ["trypan blue", "CHEMICAL", 29, 40], ["cell", "CELL", 12, 16], ["trypan blue", "SIMPLE_CHEMICAL", 29, 40], ["cells", "CELL", 52, 57], ["trypsin", "GENE_OR_GENE_PRODUCT", 87, 94], ["trypsin", "PROTEIN", 87, 94], ["cell death", "PROBLEM", 12, 22], ["trypan blue exclusion", "TREATMENT", 29, 50]]], ["Media was added to inactivate trypsin.", [["trypsin", "GENE_OR_GENE_PRODUCT", 30, 37], ["trypsin", "PROTEIN", 30, 37], ["Media", "TREATMENT", 0, 5]]], ["A 1:1 mixture of the cell suspension was mixed with trypan blue.", [["cell", "ANATOMY", 21, 25], ["trypan blue", "CHEMICAL", 52, 63], ["trypan blue", "CHEMICAL", 52, 63], ["cell", "CELL", 21, 25], ["trypan blue", "SIMPLE_CHEMICAL", 52, 63], ["the cell suspension", "TREATMENT", 17, 36], ["trypan blue", "TREATMENT", 52, 63], ["cell suspension", "OBSERVATION", 21, 36], ["trypan blue", "OBSERVATION", 52, 63]]], ["The total cell number versus cells that appeared blue was scored using a hemacytometer.Cell death assaysTo evaluate cell proliferation, 20 \u03bcl of a tertazolium compound from CellTiter 96 Aqueous One Solution Cell Proliferation Assay (MTS) (Promega) was added to media and cells after incubation with amino acids or drugs for 24 h.", [["cell", "ANATOMY", 10, 14], ["cells", "ANATOMY", 29, 34], ["Cell", "ANATOMY", 87, 91], ["cell", "ANATOMY", 116, 120], ["Cell", "ANATOMY", 207, 211], ["cells", "ANATOMY", 271, 276], ["death", "DISEASE", 92, 97], ["tertazolium compound", "CHEMICAL", 147, 167], ["CellTiter 96 Aqueous", "CHEMICAL", 173, 193], ["amino acids", "CHEMICAL", 299, 310], ["tertazolium", "CHEMICAL", 147, 158], ["amino acids", "CHEMICAL", 299, 310], ["cell", "CELL", 10, 14], ["cells", "CELL", 29, 34], ["Cell", "CELL", 87, 91], ["cell", "CELL", 116, 120], ["tertazolium compound", "SIMPLE_CHEMICAL", 147, 167], ["Cell", "CELL", 207, 211], ["Promega", "ORGANISM", 239, 246], ["cells", "CELL", 271, 276], ["amino acids", "AMINO_ACID", 299, 310], ["blue", "PROBLEM", 49, 53], ["a hemacytometer", "TREATMENT", 71, 86], ["Cell death assays", "PROBLEM", 87, 104], ["cell proliferation", "PROBLEM", 116, 134], ["a tertazolium compound", "TREATMENT", 145, 167], ["CellTiter", "TREATMENT", 173, 182], ["Aqueous One Solution Cell Proliferation Assay (MTS) (Promega)", "TREATMENT", 186, 247], ["amino acids", "TREATMENT", 299, 310], ["drugs", "TREATMENT", 314, 319], ["total cell", "OBSERVATION_MODIFIER", 4, 14], ["blue", "OBSERVATION_MODIFIER", 49, 53], ["cell proliferation", "OBSERVATION", 116, 134]]], ["The plate was incubated for 2 h at 37 1C and then absorbance read at 450 nm using plate reader (BioRad).LC3 cellular distributionVero cells were plated at 1 \u00c2 10 5 in a 6 well plate with a glass coverslip and transfected with 1 \u03bcg of human LC3-EGFP (Addgene) using 5 \u03bcl Fugene-HD (Jackson et al., 2005) .", [["cellular", "ANATOMY", 108, 116], ["Vero cells", "ANATOMY", 129, 139], ["LC3", "GENE_OR_GENE_PRODUCT", 104, 107], ["cellular", "CELL", 108, 116], ["Vero cells", "CELL", 129, 139], ["human", "ORGANISM", 234, 239], ["LC3", "GENE_OR_GENE_PRODUCT", 240, 243], ["EGFP", "GENE_OR_GENE_PRODUCT", 244, 248], ["Addgene", "GENE_OR_GENE_PRODUCT", 250, 257], ["LC3", "PROTEIN", 104, 107], ["Vero cells", "CELL_LINE", 129, 139], ["human LC3-EGFP", "DNA", 234, 248], ["Addgene", "PROTEIN", 250, 257], ["human", "SPECIES", 234, 239], ["human", "SPECIES", 234, 239], ["plate reader (BioRad)", "TREATMENT", 82, 103], ["LC3 cellular distributionVero cells", "PROBLEM", 104, 139], ["a glass coverslip", "TREATMENT", 187, 204], ["human LC3", "TREATMENT", 234, 243], ["plate", "OBSERVATION_MODIFIER", 4, 9], ["cellular", "OBSERVATION_MODIFIER", 108, 116], ["distribution", "OBSERVATION_MODIFIER", 117, 129], ["Vero cells", "OBSERVATION", 129, 139]]], ["The next day, transfected cells were treated with complete media, serum starved for 3 h with or without 5 mM 3-MA and the number of LC3 \u00fe punctae in 80 cells was scored using immunofluorescence and oil immersion.", [["cells", "ANATOMY", 26, 31], ["serum", "ANATOMY", 66, 71], ["LC3 \u00fe punctae", "ANATOMY", 132, 145], ["cells", "ANATOMY", 152, 157], ["oil", "ANATOMY", 198, 201], ["3-MA", "CHEMICAL", 109, 113], ["3-MA", "CHEMICAL", 109, 113], ["cells", "CELL", 26, 31], ["serum", "ORGANISM_SUBSTANCE", 66, 71], ["3-MA", "SIMPLE_CHEMICAL", 109, 113], ["LC3", "GENE_OR_GENE_PRODUCT", 132, 135], ["punctae", "CELLULAR_COMPONENT", 138, 145], ["cells", "CELL", 152, 157], ["oil", "ORGANISM_SUBSTANCE", 198, 201], ["transfected cells", "CELL_LINE", 14, 31], ["LC3", "PROTEIN", 132, 135], ["transfected cells", "PROBLEM", 14, 31], ["immunofluorescence", "TEST", 175, 193]]], ["The number of punctae per cell was also determined for LC3-GFP \u00fe transfected Vero cells treated with DMSO, and 100 nM of rapamycin with or without 5 \u03bcM spautin-1 for 24 h. siRNA knockdown 1 \u00c2 10 5 HeLa cells were plated onto a 12 well dish.", [["punctae", "ANATOMY", 14, 21], ["cell", "ANATOMY", 26, 30], ["Vero cells", "ANATOMY", 77, 87], ["HeLa cells", "ANATOMY", 197, 207], ["DMSO", "CHEMICAL", 101, 105], ["rapamycin", "CHEMICAL", 121, 130], ["DMSO", "CHEMICAL", 101, 105], ["rapamycin", "CHEMICAL", 121, 130], ["spautin-1", "CHEMICAL", 152, 161], ["punctae", "CELLULAR_COMPONENT", 14, 21], ["cell", "CELL", 26, 30], ["LC3", "GENE_OR_GENE_PRODUCT", 55, 58], ["GFP", "GENE_OR_GENE_PRODUCT", 59, 62], ["Vero cells", "CELL", 77, 87], ["DMSO", "SIMPLE_CHEMICAL", 101, 105], ["rapamycin", "SIMPLE_CHEMICAL", 121, 130], ["spautin-1", "GENE_OR_GENE_PRODUCT", 152, 161], ["HeLa cells", "CELL", 197, 207], ["LC3", "PROTEIN", 55, 58], ["GFP", "PROTEIN", 59, 62], ["Vero cells", "CELL_LINE", 77, 87], ["HeLa cells", "CELL_LINE", 197, 207], ["LC3", "TEST", 55, 58], ["transfected Vero cells", "PROBLEM", 65, 87], ["DMSO", "TREATMENT", 101, 105], ["rapamycin", "TREATMENT", 121, 130], ["siRNA knockdown", "TEST", 172, 187], ["HeLa cells", "TEST", 197, 207], ["Vero cells", "OBSERVATION", 77, 87]]], ["The next day, cells were transfected with 70 nM siRNA using 4 \u03bcl Lipofectamine 2000 and antibiotic free media (Invitrogen).", [["cells", "ANATOMY", 14, 19], ["cells", "CELL", 14, 19], ["70 nM siRNA", "TREATMENT", 42, 53], ["4 \u03bcl Lipofectamine", "TREATMENT", 60, 78], ["antibiotic free media (Invitrogen)", "TREATMENT", 88, 122]]], ["The following siRNA molecules used in this study consist of a mixture of three to five different sequences that specifically target different regions of the same gene: ATG7 (Hs_APG7L, SI02655373, Qiagen) negative control sequence (1027310, Qiagen), Beclin-1 (sc29797, Santa Cruz), LC3B (sc43390, Santa Cruz) and negative control siRNA-A (sc37007, Santa Cruz).", [["ATG7", "GENE_OR_GENE_PRODUCT", 168, 172], ["Beclin-1", "GENE_OR_GENE_PRODUCT", 249, 257], ["LC3B", "GENE_OR_GENE_PRODUCT", 281, 285], ["ATG7 (Hs_APG7L, SI02655373, Qiagen) negative control sequence", "DNA", 168, 229], ["Beclin", "PROTEIN", 249, 255], ["Santa Cruz", "PROTEIN", 268, 278], ["LC3B", "PROTEIN", 281, 285], ["sc43390", "PROTEIN", 287, 294], ["Santa Cruz", "PROTEIN", 296, 306], ["Santa Cruz", "PROTEIN", 347, 357], ["The following siRNA molecules", "TREATMENT", 0, 29], ["this study", "TEST", 38, 48], ["Hs_APG7L", "TEST", 174, 182], ["Beclin", "TEST", 249, 255]]], ["48 h following transfection with the siRNA molecular, cells were either infected with BKPyV at an MOI:10 and scored for VP1 expression using indirect immunofluorescence or protein lysates was collected.Immunoblot analysisCells were plated at 1 \u00c2 10 5 in 12 well dishes and transfected with siRNA.", [["cells", "ANATOMY", 54, 59], ["lysates", "ANATOMY", 180, 187], ["cells", "CELL", 54, 59], ["VP1", "GENE_OR_GENE_PRODUCT", 120, 123], ["VP1", "PROTEIN", 120, 123], ["transfection", "TREATMENT", 15, 27], ["the siRNA molecular, cells", "PROBLEM", 33, 59], ["BKPyV", "PROBLEM", 86, 91], ["VP1 expression", "TEST", 120, 134], ["indirect immunofluorescence", "TEST", 141, 168], ["protein lysates", "PROBLEM", 172, 187], ["Immunoblot analysisCells", "TEST", 202, 226]]], ["Two days later, protein lysates were collected from adherent cells by removing media and 150 \u03bcl of 2 \u00c2 Laemmli buffer with 5% \u03b2-mercaptoethanol was added.", [["lysates", "ANATOMY", 24, 31], ["cells", "ANATOMY", 61, 66], ["\u03b2-mercaptoethanol", "CHEMICAL", 126, 143], ["\u03b2-mercaptoethanol", "CHEMICAL", 126, 143], ["lysates", "ORGANISM_SUBSTANCE", 24, 31], ["cells", "CELL", 61, 66], ["\u03b2-mercaptoethanol", "SIMPLE_CHEMICAL", 126, 143], ["adherent cells", "CELL_TYPE", 52, 66], ["protein lysates", "TEST", 16, 31], ["media", "TREATMENT", 79, 84], ["Laemmli buffer", "TREATMENT", 103, 117], ["5% \u03b2-mercaptoethanol", "TREATMENT", 123, 143], ["adherent cells", "OBSERVATION", 52, 66]]], ["After 5 min, cell were scraped from the well surface, collected in an eppendorf tube and, boiled for 10 min.", [["cell", "ANATOMY", 13, 17], ["surface", "ANATOMY", 45, 52], ["cell", "CELL", 13, 17], ["eppendorf tube", "TISSUE", 70, 84], ["cell", "TREATMENT", 13, 17], ["an eppendorf tube", "TREATMENT", 67, 84], ["eppendorf tube", "OBSERVATION", 70, 84]]], ["Half of this sample was applied to a 4-15% SDS-PAGE acrylamide gel (Biorad) and gel electrophoresis conducted at 100 V. The protein on the gel was then transferred to an equilibrated PVDF membrane (Biorad) using a semi-dry transfer apparatus (Biorad) at 15 V for 15 min.", [["sample", "ANATOMY", 13, 19], ["membrane", "ANATOMY", 188, 196], ["SDS-PAGE acrylamide", "CHEMICAL", 43, 62], ["acrylamide", "CHEMICAL", 52, 62], ["PVDF", "CHEMICAL", 183, 187], ["SDS-PAGE acrylamide", "SIMPLE_CHEMICAL", 43, 62], ["membrane", "CELLULAR_COMPONENT", 188, 196], ["a 4-15% SDS", "TREATMENT", 35, 46], ["PAGE acrylamide gel", "TREATMENT", 47, 66], ["gel electrophoresis", "TEST", 80, 99], ["an equilibrated PVDF membrane", "TREATMENT", 167, 196], ["a semi-dry transfer apparatus", "TREATMENT", 212, 241]]], ["The membrane was blocked using 5% milk in Tris buffer saline with 1% Tween (TBST) for 1 h.", [["membrane", "ANATOMY", 4, 12], ["Tween", "CHEMICAL", 69, 74], ["membrane", "CELLULAR_COMPONENT", 4, 12], ["milk", "ORGANISM_SUBSTANCE", 34, 38], ["Tris buffer saline", "SIMPLE_CHEMICAL", 42, 60], ["5% milk in Tris buffer saline", "TREATMENT", 31, 60], ["1% Tween (TBST)", "TREATMENT", 66, 81]]], ["Antibodies in 1% milk in TBST were added to the blots and incubated overnight at 4 1C.", [["milk", "ANATOMY", 17, 21], ["milk", "ORGANISM_SUBSTANCE", 17, 21], ["Antibodies", "TEST", 0, 10]]], ["Antibodies used in this study were: rabbit anti-ATG7 (2631, Cell Signaling), rabbit anti-Beclin-1 (sc-11427, Santa Cruz), rabbit anti-GAPDH (14C10, Cell Signaling), mouse anti-tubulin (sc-5286, Santa Cruz), goat anti-mouse Alexa-Fluor 790 (A-11375, Technologies), and goat anti-rabbit AlexaFluor 680 (A-21076, Life Technologies).", [["Cell", "ANATOMY", 60, 64], ["Cell", "ANATOMY", 148, 152], ["sc-5286", "CHEMICAL", 185, 192], ["A-11375", "CHEMICAL", 240, 247], ["A-21076", "CHEMICAL", 301, 308], ["AlexaFluor 680", "CHEMICAL", 285, 299], ["rabbit", "ORGANISM", 36, 42], ["anti-ATG7", "GENE_OR_GENE_PRODUCT", 43, 52], ["Cell", "CELL", 60, 64], ["rabbit", "ORGANISM", 77, 83], ["anti-Beclin-1", "GENE_OR_GENE_PRODUCT", 84, 97], ["sc-11427", "SIMPLE_CHEMICAL", 99, 107], ["Santa Cruz", "ORGANISM", 109, 119], ["rabbit", "ORGANISM", 122, 128], ["anti-GAPDH", "GENE_OR_GENE_PRODUCT", 129, 139], ["14C10", "GENE_OR_GENE_PRODUCT", 141, 146], ["Cell", "CELL", 148, 152], ["mouse", "ORGANISM", 165, 170], ["anti-tubulin", "GENE_OR_GENE_PRODUCT", 171, 183], ["sc-5286", "SIMPLE_CHEMICAL", 185, 192], ["Santa Cruz", "ORGANISM", 194, 204], ["goat", "ORGANISM", 207, 211], ["Alexa-Fluor 790", "SIMPLE_CHEMICAL", 223, 238], ["A-11375", "SIMPLE_CHEMICAL", 240, 247], ["goat", "ORGANISM", 268, 272], ["anti-rabbit AlexaFluor 680", "SIMPLE_CHEMICAL", 273, 299], ["A-21076", "SIMPLE_CHEMICAL", 301, 308], ["Santa Cruz", "PROTEIN", 109, 119], ["rabbit anti-GAPDH", "PROTEIN", 122, 139], ["14C10", "PROTEIN", 141, 146], ["mouse anti-tubulin", "PROTEIN", 165, 183], ["Santa Cruz", "PROTEIN", 194, 204], ["rabbit", "SPECIES", 36, 42], ["rabbit", "SPECIES", 77, 83], ["rabbit", "SPECIES", 122, 128], ["mouse", "SPECIES", 165, 170], ["goat", "SPECIES", 207, 211], ["anti-mouse", "SPECIES", 212, 222], ["goat", "SPECIES", 268, 272], ["anti-rabbit", "SPECIES", 273, 284], ["rabbit", "SPECIES", 36, 42], ["rabbit anti-Beclin-1 (sc-11427", "SPECIES", 77, 107], ["rabbit", "SPECIES", 122, 128], ["mouse", "SPECIES", 165, 170], ["goat anti-mouse Alexa-Fluor 790 (A-11375", "SPECIES", 207, 247], ["goat", "SPECIES", 268, 272], ["Antibodies", "TEST", 0, 10], ["this study", "TEST", 19, 29], ["rabbit anti-ATG7", "TEST", 36, 52], ["rabbit anti-Beclin", "TEST", 77, 95], ["rabbit anti-GAPDH", "TREATMENT", 122, 139], ["goat anti-rabbit AlexaFluor", "TREATMENT", 268, 295]]], ["The TBST washed blots were incubated with the secondary antibody in 1% milk in TBSTS for 1 h at room temperature and developed using Li-Cor blot scanner and densitometry measured using ImageJ.Confocal microscopy1 \u00c2 10 5 Vero cells were plated onto a 6-well dish containing a glass coverslip and transfected with 1 \u03bcg of LC3-GFP using 5 \u03bcl of Fugene-HD.", [["milk", "ANATOMY", 71, 75], ["Vero cells", "ANATOMY", 220, 230], ["TBSTS", "CHEMICAL", 79, 84], ["milk", "ORGANISM_SUBSTANCE", 71, 75], ["TBSTS", "SIMPLE_CHEMICAL", 79, 84], ["Vero cells", "CELL", 220, 230], ["LC3", "GENE_OR_GENE_PRODUCT", 320, 323], ["GFP", "GENE_OR_GENE_PRODUCT", 324, 327], ["Fugene-HD", "ORGANISM", 342, 351], ["microscopy1 \u00c2 10 5 Vero cells", "CELL_LINE", 201, 230], ["LC3", "PROTEIN", 320, 323], ["GFP", "PROTEIN", 324, 327], ["The TBST washed blots", "TREATMENT", 0, 21], ["the secondary antibody", "TREATMENT", 42, 64], ["Li-Cor blot scanner", "TEST", 133, 152], ["densitometry", "TEST", 157, 169], ["ImageJ", "TEST", 185, 191], ["Confocal microscopy1", "TEST", 192, 212], ["Vero cells", "TREATMENT", 220, 230], ["a glass coverslip", "TREATMENT", 273, 290], ["Fugene", "TREATMENT", 342, 348], ["HD", "TREATMENT", 349, 351]]], ["24 h after transfection, cells were challenged with BKPyV-633 (MOI 20) in 2% FBS EMEM media for 3 h.", [["cells", "ANATOMY", 25, 30], ["BKPyV-633", "CHEMICAL", 52, 61], ["BKPyV-633", "CHEMICAL", 52, 61], ["cells", "CELL", 25, 30], ["BKPyV-633", "SIMPLE_CHEMICAL", 52, 61], ["FBS", "ORGANISM_SUBSTANCE", 77, 80], ["BKPyV", "TEST", 52, 57], ["2% FBS EMEM media", "TREATMENT", 74, 91]]], ["Cells were then washed 2 \u00c2 with EMEM and fixed using 2% paraformaldehyde for 15 min.", [["Cells", "ANATOMY", 0, 5], ["paraformaldehyde", "CHEMICAL", 56, 72], ["Cells", "CELL", 0, 5], ["paraformaldehyde", "SIMPLE_CHEMICAL", 56, 72], ["2% paraformaldehyde", "TREATMENT", 53, 72]]], ["Cells were counterstained with DAPI-mounting media (Vector Labs) and applied to a microscope slide and visualized using Zeiss LSM 510 Meta laser-scanning confocal microscope.", [["Cells", "ANATOMY", 0, 5], ["DAPI", "CHEMICAL", 31, 35], ["Cells", "CELL", 0, 5], ["DAPI", "SIMPLE_CHEMICAL", 31, 35], ["DAPI-mounting media", "TREATMENT", 31, 50], ["a microscope slide", "TEST", 80, 98]]], ["Images were analyzed using ImageJ image analysis software.", [["Images", "TEST", 0, 6], ["ImageJ image analysis software", "TEST", 27, 57]]], ["Colocalization of BKPyV-633 and LC3-GFP \u00fe vesicles was investigated in 60 cells.", [["LC3-GFP \u00fe vesicles", "ANATOMY", 32, 50], ["cells", "ANATOMY", 74, 79], ["BKPyV-633", "GENE_OR_GENE_PRODUCT", 18, 27], ["LC3-GFP", "GENE_OR_GENE_PRODUCT", 32, 39], ["cells", "CELL", 74, 79], ["BKPyV", "PROTEIN", 18, 23], ["LC3", "PROTEIN", 32, 35], ["GFP", "PROTEIN", 36, 39], ["60 cells", "CELL_LINE", 71, 79], ["BKPyV", "TEST", 18, 23], ["LC3", "TEST", 32, 35], ["GFP \u00fe vesicles", "TEST", 36, 50], ["BKPyV", "OBSERVATION", 18, 23], ["60 cells", "OBSERVATION", 71, 79]]], ["Cells were also scored for their predominate type of LC3 distribution in (1) all cells, (2) only cells where BKPyV had entered, and (3) only cells where colocalization of BKPyV-633 and LC3-GFP was observed.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 81, 86], ["cells", "ANATOMY", 97, 102], ["BKPyV", "ANATOMY", 109, 114], ["cells", "ANATOMY", 141, 146], ["Cells", "CELL", 0, 5], ["LC3", "GENE_OR_GENE_PRODUCT", 53, 56], ["cells", "CELL", 81, 86], ["cells", "CELL", 97, 102], ["BKPyV", "CELL", 109, 114], ["cells", "CELL", 141, 146], ["BKPyV-633", "GENE_OR_GENE_PRODUCT", 171, 180], ["LC3", "GENE_OR_GENE_PRODUCT", 185, 188], ["GFP", "GENE_OR_GENE_PRODUCT", 189, 192], ["LC3", "PROTEIN", 53, 56], ["BKPyV", "PROTEIN", 109, 114], ["BKPyV", "PROTEIN", 171, 176], ["LC3", "PROTEIN", 185, 188], ["GFP", "PROTEIN", 189, 192], ["all cells", "TEST", 77, 86], ["cells", "TEST", 97, 102], ["BKPyV", "TEST", 109, 114], ["BKPyV", "TEST", 171, 176], ["LC3", "TEST", 185, 188], ["GFP", "TEST", 189, 192], ["LC3 distribution", "OBSERVATION", 53, 69]]]], "PMC7177124": [["IntroductionTelemedicine uses audiovisual technological aids to help care for patients [38] and has historically been used to provide care for patients in rural and low-resource settings.", [["patients", "ORGANISM", 78, 86], ["patients", "ORGANISM", 143, 151], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 143, 151]]], ["[50, 67] Telemedicine involves a range of technologies, including \u201csmartphones,\u201d computer tablets, mobile applications, and video conferencing, to allow healthcare providers to evaluate, diagnose, monitor, treat, and educate patients \u201cvirtually.\u201d [24, 67] Telemedicine is currently the fastest growing sector of healthcare.", [["patients", "ORGANISM", 225, 233], ["patients", "SPECIES", 225, 233]]], ["[36] Additionally, patients report better provider communication and access, better medication adherence, [28] and overall high satisfaction scores with telemedicine clinical outcomes.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27]]], ["[45]IntroductionAlthough only half of U.S. hospitals use telemedicine, primarily for radiology physician-to-physician communication [38], and only 4% of Medicare patients use telemedicine, [6] many believe the expansion of telemedicine is inevitable.", [["patients", "ORGANISM", 162, 170], ["patients", "SPECIES", 162, 170]]], ["[11] Reimbursement of remote clinical services is one barrier to implementation.", [["remote clinical services", "TREATMENT", 22, 46]]], ["[38] The current coronavirus disease 2019 (COVID-19) pandemic, which spreads via droplets and has a 1%\u20132% estimated mortality rate, [20] presents an urgent need for expansion of telemedicine to minimize the risk of disease transmission by practicing social distancing.", [["coronavirus disease", "DISEASE", 17, 36], ["COVID-19", "CHEMICAL", 43, 51], ["coronavirus", "ORGANISM", 17, 28], ["The current coronavirus disease", "PROBLEM", 5, 36], ["COVID", "TEST", 43, 48], ["pandemic", "PROBLEM", 53, 61], ["mortality rate", "TEST", 116, 130], ["expansion of telemedicine", "TREATMENT", 165, 190], ["disease transmission", "PROBLEM", 215, 235], ["coronavirus disease", "OBSERVATION", 17, 36], ["disease", "OBSERVATION", 215, 222]]], ["The necessity of in-person visits deserves careful consideration and provides reason and opportunity to render care via telemedicine when appropriate.Problem StatementTo slow the spread of COVID-19, the U.S. Centers for Disease Control and Prevention (CDC), in conjunction with state and local governments, has implemented social distancing and quarantine rules.", [["COVID", "TEST", 189, 194], ["Disease Control", "TREATMENT", 220, 235]]], ["Specifically, they advise to \u201creduce unnecessary healthcare visits\u201d and \u201cexplore alternatives to face-to-face triage and visits.\u201d [15] A major challenge during this crisis is to keep patients and the healthcare team safely distant while providing patients with effective and efficient care.", [["patients", "ORGANISM", 183, 191], ["patients", "ORGANISM", 247, 255], ["patients", "SPECIES", 183, 191], ["patients", "SPECIES", 247, 255]]], ["Telemedicine is a logical solution to help address this challenge.Problem StatementOrthopaedic surgeons who primarily perform total joint arthroplasty (TJA) of the hip and knee treat a predominantly outpatient population that is at high risk for complications and death from COVID-19.", [["joint", "ANATOMY", 132, 137], ["hip", "ANATOMY", 164, 167], ["knee", "ANATOMY", 172, 176], ["death", "DISEASE", 264, 269], ["joint", "MULTI-TISSUE_STRUCTURE", 132, 137], ["hip", "ORGANISM_SUBDIVISION", 164, 167], ["knee", "ORGANISM_SUBDIVISION", 172, 176], ["a logical solution", "TREATMENT", 16, 34], ["this challenge", "TREATMENT", 51, 65], ["total joint arthroplasty", "TREATMENT", 126, 150], ["TJA) of the hip and knee", "TREATMENT", 152, 176], ["complications", "PROBLEM", 246, 259], ["death", "PROBLEM", 264, 269], ["COVID", "TEST", 275, 280], ["joint", "ANATOMY", 132, 137], ["arthroplasty", "OBSERVATION", 138, 150], ["hip", "ANATOMY", 164, 167], ["knee", "ANATOMY", 172, 176]]], ["[8, 44, 54] Most patients of adult reconstruction clinics are older than 60 years, and many have comorbidities that put them at high risk of contracting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) if exposed.", [["acute respiratory syndrome coronavirus", "DISEASE", 160, 198], ["patients", "ORGANISM", 17, 25], ["patients", "SPECIES", 17, 25], ["severe acute respiratory syndrome coronavirus", "SPECIES", 153, 198], ["SARS-CoV-2", "SPECIES", 202, 212], ["contracting severe acute respiratory syndrome coronavirus", "PROBLEM", 141, 198], ["severe", "OBSERVATION_MODIFIER", 153, 159], ["acute", "OBSERVATION_MODIFIER", 160, 165], ["respiratory syndrome", "OBSERVATION", 166, 186]]], ["[65] Therefore, an effective and efficient TJA telemedicine practice may enable providers to continue delivering care while preventing unnecessary exposure of at-risk patients to the outpatient clinic during this pandemic.Problem StatementTelemedicine presents challenges for providers and patients, necessitating a comprehensive analysis of a practice and its patients to determine the best way to implement a telemedicine workflow.", [["patients", "ORGANISM", 167, 175], ["patients", "ORGANISM", 290, 298], ["patients", "ORGANISM", 361, 369], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 290, 298], ["patients", "SPECIES", 361, 369], ["efficient TJA telemedicine practice", "TREATMENT", 33, 68], ["delivering care", "TREATMENT", 102, 117], ["a comprehensive analysis", "TEST", 314, 338], ["a telemedicine workflow", "TREATMENT", 409, 432]]], ["Providers cite poor information technology (IT) platform design and \u201cinformation overload\u201d with regard to the chosen system as barriers to use.", [["information overload", "PROBLEM", 69, 89]]], ["[51] Low levels of computer literacy and high patient expectations can lead to patient dissatisfaction with telemedicine encounters.", [["patient", "ORGANISM", 46, 53], ["patient", "ORGANISM", 79, 86], ["patient", "SPECIES", 46, 53], ["patient", "SPECIES", 79, 86]]], ["Maintaining independence and autonomy are critical, particularly among elderly patients [35], so choosing an IT system that addresses these needs is essential.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87]]], ["For organizations, effectiveness, efficiency, workflow, and implementation models are most often cited as considerations when implementing new technology.", [["workflow", "TEST", 46, 54]]], ["[51] Ultimately, when choosing a telemedicine platform for a TJA outpatient clinic, it is important to choose one that is simple and intuitive to use and easy to implement.Patient Readiness ::: Proposed SolutionsIt is important to confirm the readiness and willingness of patients to use telemedicine technology because success depends on active patient participation.", [["patients", "ORGANISM", 272, 280], ["patient", "ORGANISM", 346, 353], ["Patient", "SPECIES", 172, 179], ["patients", "SPECIES", 272, 280], ["patient", "SPECIES", 346, 353], ["Proposed Solutions", "TREATMENT", 194, 212], ["telemedicine technology", "TREATMENT", 288, 311]]], ["[33] Providers should review their patients\u2019 demographic characteristics.", [["patients", "ORGANISM", 35, 43], ["patients", "SPECIES", 35, 43]]], ["[23, 33, 45, 51] Elderly patients, in particular, may be apprehensive about computer-based services and concerned about privacy, so addressing these factors is imperative.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33]]], ["[18] However, the desire for telemedicine among TJA patients is high, with approximately 70% of patients reporting that they are willing to use telemedicine for their care needs.", [["patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 96, 104], ["patients", "SPECIES", 52, 60], ["patients", "SPECIES", 96, 104]]], ["[40]Patient Readiness ::: Proposed SolutionsThe COVID-19 pandemic is an extraordinary circumstance requiring immediate action to establish a telemedicine program.", [["Patient", "SPECIES", 4, 11], ["The COVID", "TREATMENT", 44, 53], ["a telemedicine program", "TREATMENT", 139, 161]]], ["In an ideal situation, in which telemedicine can be phased in over a longer period, patient attitudes and technological abilities can be assessed through focus group discussions [31] and/or surveys.", [["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91]]], ["[25, 63] The purpose of such tools is to determine patient desires and motivations for their care, experience with telemedicine and technology, and health literacy levels.", [["patient", "ORGANISM", 51, 58], ["patient", "SPECIES", 51, 58]]], ["Areas of focus include reasons patients come to the clinic, barriers to traveling to the clinic, patient comfort with and access to technology, patient experience and/or comfort with telemedicine, and patient comfort and trust with receiving instructions through digital communications.", [["patients", "ORGANISM", 31, 39], ["patient", "ORGANISM", 97, 104], ["patient", "ORGANISM", 144, 151], ["patient", "ORGANISM", 201, 208], ["patients", "SPECIES", 31, 39], ["patient", "SPECIES", 97, 104], ["patient", "SPECIES", 144, 151], ["patient", "SPECIES", 201, 208], ["telemedicine", "TREATMENT", 183, 195], ["focus", "OBSERVATION", 9, 14]]], ["[13, 17, 23, 25, 41, 47, 66] Patients with greater health literacy and engagement are more likely to embrace telemedicine.", [["[13, 17, 23", "SIMPLE_CHEMICAL", 0, 11], ["Patients", "ORGANISM", 29, 37], ["Patients", "SPECIES", 29, 37]]], ["[42, 51] Quantitative and qualitative data can reveal areas where patient education and support are needed.Patient Readiness ::: Proposed SolutionsAfter readiness is confirmed, a patient\u2019s consent to receive care through telemedicine must be confirmed.", [["patient", "ORGANISM", 66, 73], ["patient", "ORGANISM", 179, 186], ["patient", "SPECIES", 66, 73], ["Patient", "SPECIES", 107, 114], ["patient", "SPECIES", 179, 186], ["qualitative data", "TEST", 26, 42], ["support", "TREATMENT", 88, 95], ["Proposed Solutions", "TREATMENT", 129, 147], ["care through telemedicine", "TREATMENT", 208, 233]]], ["Risks and benefits of and alternatives to receiving care through telemedicine should be addressed, as well as the patient\u2019s permission for the use of video.", [["patient", "ORGANISM", 114, 121], ["patient", "SPECIES", 114, 121], ["care", "TREATMENT", 52, 56], ["telemedicine", "TREATMENT", 65, 77]]], ["Furthermore, consent should include consideration of billing and any other charges patients may incur through participation in telemedicine, including through telephone communication.", [["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91]]], ["Notably, during the COVID-19 pandemic, the Department of Health and Human Services (HHS) allows providers to reduce out-of-pocket payments for federal healthcare programs.Patient Readiness ::: Proposed SolutionsAfter a TJA practice has confirmed willingness among its patients and received informed consent, implementation of a telemedicine program can proceed.", [["Human", "ORGANISM", 68, 73], ["patients", "ORGANISM", 268, 276], ["Human", "SPECIES", 68, 73], ["Patient", "SPECIES", 171, 178], ["patients", "SPECIES", 268, 276], ["federal healthcare programs", "TREATMENT", 143, 170], ["Proposed Solutions", "TREATMENT", 193, 211], ["a TJA practice", "TREATMENT", 217, 231], ["a telemedicine program", "TREATMENT", 326, 348]]], ["In preparation, patient education and engagement should occur through several means.", [["patient", "ORGANISM", 16, 23], ["patient", "SPECIES", 16, 23]]], ["[56] Clinical staff must be trained to facilitate the workflow of a virtual clinic by helping patients prepare for telemedicine appointments.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102]]], ["Additional means of education include patient messaging portals with step-by-step instructions on how to use the telemedicine technology [25] and informational fliers with troubleshooting guidance and answers to frequently asked questions.", [["patient", "ORGANISM", 38, 45], ["patient", "SPECIES", 38, 45]]], ["For patients who are seen in person, verbal and written communication can be used to inform them of the benefits of telemedicine for future encounters.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["person", "SPECIES", 29, 35]]], ["[56]Synchronous vs. Asynchronous Telemedicine ::: Proposed SolutionsCare via telemedicine can be synchronous or asynchronous.", [["Proposed Solutions", "TREATMENT", 50, 68]]], ["Each mode has different IT infrastructure requirements.", [["different IT infrastructure requirements", "PROBLEM", 14, 54], ["different", "OBSERVATION_MODIFIER", 14, 23], ["infrastructure requirements", "OBSERVATION", 27, 54]]], ["Synchronous sessions should be used when discussion is needed, such as during new patient consultations, preoperative counseling, postoperative evaluations, and follow-up visits.Synchronous vs. Asynchronous Telemedicine ::: Proposed SolutionsAsynchronous (i.e., \u201cstore-and-forward\u201d) telemedicine involves the gathering, summarizing, storing, and sharing of data for a patient or, more often, another provider to review at a later time.", [["patient", "ORGANISM", 82, 89], ["patient", "ORGANISM", 368, 375], ["patient", "SPECIES", 82, 89], ["patient", "SPECIES", 368, 375], ["Synchronous sessions", "TREATMENT", 0, 20], ["preoperative counseling", "TREATMENT", 105, 128], ["postoperative evaluations", "TEST", 130, 155]]], ["[4] Medical record annotation, email, and recorded video messages are means of asynchronous telemedicine, [38] which is ideal for educating patients outside of an encounter.", [["patients", "ORGANISM", 140, 148], ["patients", "SPECIES", 140, 148]]], ["The differences between synchronous and asynchronous telemedicine encounters determine not only the necessary IT infrastructure, but also the billing and coding options for the encounter.Internet Connection ::: Technology and Equipment ::: Proposed SolutionsA major consideration when implementing telemedicine is access to a broadband internet connection, which is necessary for patients when using technology other than a telephone.", [["patients", "ORGANISM", 380, 388], ["patients", "SPECIES", 380, 388], ["synchronous", "OBSERVATION_MODIFIER", 24, 35]]], ["[7] Poor connectivity and lack of adequate equipment can be barriers to delivering care.", [["Poor connectivity", "PROBLEM", 4, 21]]], ["[32] An estimated 91% of the U.S. population owns a mobile phone, and 61% of these phones have video capability.", [["video capability", "TEST", 95, 111]]], ["[49] Although barriers to technology access exist, most patients have sufficient resources to support participation in telemedicine.System Type ::: Technology and Equipment ::: Proposed SolutionsThe choice of telemedicine system is crucial to the success of a telemedicine practice.", [["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["Proposed Solutions", "TREATMENT", 177, 195], ["telemedicine system", "TREATMENT", 209, 228], ["a telemedicine practice", "TREATMENT", 258, 281]]], ["Closed systems (e.g., Praxis, Infor-Med Inc., San Francisco, CA) include all necessary hardware and software but do not integrate with components from other manufacturers or with existing technology systems.", [["all necessary hardware", "TREATMENT", 73, 95], ["Med", "ANATOMY", 36, 39], ["hardware", "OBSERVATION", 87, 95]]], ["In contrast, open systems (e.g., Zoom, Zoom Video Communications, San Jose, CA; and Polycom, Plantronics, Inc., Santa Cruz, CA) can be integrated piecemeal into existing electronic medical record and telemedicine systems.", [["Polycom", "TREATMENT", 84, 91]]], ["[7]Technical Support ::: Proposed SolutionsSelecting and implementing a product with an IT platform that provides accessible and capable technical support staff can help ensure adequate training and active support as long as the telemedicine platform is in use.", [["an IT platform", "TREATMENT", 85, 99], ["adequate training", "TREATMENT", 177, 194], ["active support", "TREATMENT", 199, 213]]], ["Physician \u201cchampions\u201d who are facile with technology are good targets for initial rollout and can provide \u201cat-the-elbow\u201d support to facilitate and encourage adoption of telemedicine among their peers.", [["elbow", "ANATOMY", 114, 119]]], ["[7]Training ::: Proposed SolutionsAll individuals who will interact with patients through the telemedicine portal must be trained.", [["patients", "ORGANISM", 73, 81], ["portal", "MULTI-TISSUE_STRUCTURE", 107, 113], ["patients", "SPECIES", 73, 81], ["Proposed Solutions", "TREATMENT", 16, 34], ["portal", "ANATOMY", 107, 113]]], ["Insufficient training and unfamiliarity with the technology are major barriers to adoption and application of telemedicine.", [["Insufficient training", "TREATMENT", 0, 21], ["telemedicine", "TREATMENT", 110, 122]]], ["[22, 26] In response to the growing utility and complexity of telemedicine, medical education curricula have begun integrating telemedicine training concepts early during medical training, which may increase trainees\u2019 familiarity with telemedicine systems in the future.", [["medical education curricula", "TREATMENT", 76, 103], ["telemedicine training", "TREATMENT", 127, 148], ["medical training", "TREATMENT", 171, 187]]], ["[19]Training ::: Proposed SolutionsOne approach to streamlining the training process is to focus first on training \u201ccommunities of practice,\u201d meaning groups of employees who work in the same care setting, managing the same patients.", [["patients", "ORGANISM", 223, 231], ["patients", "SPECIES", 223, 231], ["Proposed Solutions", "TREATMENT", 17, 35]]], ["This approach is effective in workplace training because it increases the group\u2019s comfort with and knowledge of the technology.", [["workplace training", "TREATMENT", 30, 48], ["effective", "OBSERVATION_MODIFIER", 17, 26]]], ["[19]Training ::: Proposed SolutionsGiven the limited use of telemedicine among TJA providers, it is typically necessary to train them not only on the technology but also on the business and interpersonal aspects of managing a telemedicine practice and caring for patients remotely.", [["patients", "ORGANISM", 263, 271], ["patients", "SPECIES", 263, 271], ["Proposed Solutions", "TREATMENT", 17, 35], ["TJA providers", "TREATMENT", 79, 92], ["a telemedicine practice", "TREATMENT", 224, 247]]], ["Because these factors are integral to managing a traditional TJA practice (without telemedicine), TJA providers may be well prepared for the transition to delivering safe, effective, and compliant care via telemedicine.", [["a traditional TJA practice", "TREATMENT", 47, 73], ["TJA providers", "TREATMENT", 98, 111]]], ["[21, 61] Furthermore, most TJA providers are familiar with other technological practice tools, such as computer-assisted surgery and robotics.Insurance Reimbursement and Compliance ::: Proposed SolutionsDespite the fact that telemedicine decreases wait times, reduces or eliminates travel, and lowers costs for TJA patients, it has not been universally adopted.", [["TJA", "DISEASE", 311, 314], ["patients", "ORGANISM", 315, 323], ["patients", "SPECIES", 315, 323], ["computer-assisted surgery", "TREATMENT", 103, 128], ["robotics", "TREATMENT", 133, 141], ["Proposed Solutions", "TREATMENT", 185, 203], ["TJA patients", "TREATMENT", 311, 323]]], ["[27, 48, 64] Obstacles to widespread use include the costs of implementation and the lack of reimbursement for telemedicine.", [["telemedicine", "TREATMENT", 111, 123]]], ["[51]Insurance Reimbursement and Compliance ::: Proposed SolutionsBefore the modifications of Medicare and Medicaid rules during the current pandemic, government-funded insurance plans had various approaches to reimbursing physicians for telemedicine.", [["Proposed Solutions", "TREATMENT", 47, 65], ["Medicare", "TREATMENT", 93, 101]]], ["Under Medicare Part B, physician reimbursement for telemedicine services was strictly regulated.", [["telemedicine services", "TREATMENT", 51, 72]]], ["Requirements for reimbursement included that the patient be located in a designated \u201crural health professional shortage area,\u201d a county not part of metropolitan area, or a facility participating in a Federal Telemedicine Demonstration Project.", [["patient", "ORGANISM", 49, 56], ["patient", "SPECIES", 49, 56], ["reimbursement", "TREATMENT", 17, 30]]], ["[60] Low-resource or underfunded institutions outside such areas did not qualify for telemedicine reimbursement.", [["telemedicine reimbursement", "TREATMENT", 85, 111]]], ["[29] These limitations prevented the use of telemedicine for most patients.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["telemedicine", "TREATMENT", 44, 56]]], ["In contrast, the Veterans Health Administration operates the nation\u2019s largest telemedicine program and offers free telemedicine to all patients enrolled in their insurance program.", [["patients", "ORGANISM", 135, 143], ["patients", "SPECIES", 135, 143]]], ["[30, 39] Private insurers have various reimbursement plans, based on local coverage determinations for a given payer.", [["local coverage determinations", "TREATMENT", 69, 98]]], ["State mandates for private insurance reimbursement for telemedicine services, in some cases irrespective of rural or non-rural setting, have resulted in expansion of telemedicine coverage.", [["telemedicine services", "TREATMENT", 55, 76], ["telemedicine coverage", "TREATMENT", 166, 187]]], ["[39]Insurance Reimbursement and Compliance ::: Proposed SolutionsIn response to the COVID-19 pandemic and in accordance with CDC guidance, many practices have implemented telemedicine to avoid in-person contact between providers and patients.", [["patients", "ORGANISM", 233, 241], ["patients", "SPECIES", 233, 241], ["the COVID", "TEST", 80, 89]]], ["Federal and state reimbursement laws have evolved rapidly to accommodate this change, with the most liberating adjustments coming through the Coronavirus Preparedness and Response Supplemental Appropriations Act, which was passed on March 6, 2020.", [["the Coronavirus Preparedness", "TREATMENT", 138, 166]]], ["This act has provided emergency funding, estimated at $500 million, resulting in expanded reimbursement for all telemedicine services provided to Medicare patients, regardless of originating site, during the pandemic.", [["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 155, 163], ["all telemedicine services", "TREATMENT", 108, 133]]], ["The act gives states the option to suspend interstate licensure requirements that had hampered the delivery of telemedicine across state lines.", [["lines", "CELL", 137, 142]]], ["[1, 55] Additionally, the expansion allows TJA providers to evaluate and treat patients on the basis of history and discussion when it is impractical to perform a physical examination.", [["patients", "ORGANISM", 79, 87], ["patients", "SPECIES", 79, 87], ["TJA providers", "TREATMENT", 43, 56], ["a physical examination", "TEST", 161, 183]]], ["[59]Insurance Reimbursement and Compliance ::: Proposed SolutionsAlso in response to the COVID-19 pandemic, Health Insurance Portability and Accountability Act (HIPAA) regulations have been relaxed.", [["Proposed Solutions", "TREATMENT", 47, 65]]], ["[59] The primary goal of the HHS during this emergency is to enable the provision of quality care to patients regardless of location.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109]]], ["HHS acknowledges that compliance with HIPAA regulations may not always be possible during telemedicine delivery.", [["HIPAA regulations", "TREATMENT", 38, 55], ["telemedicine delivery", "TREATMENT", 90, 111]]], ["Thus, the HHS and the Office of Civil Rights have exercised their discretionary authority to decline prosecution for HIPAA compliance violations that occur during \u201cgood-faith\u201d efforts to provide patient care during the pandemic.Licensing and Legal Requirements ::: Future Direction And Long-Term FocusAfter the COVID-19 pandemic has ended, continued expansion of telemedicine will depend on licensing restrictions and legal changes.", [["patient", "ORGANISM", 195, 202], ["patient", "SPECIES", 195, 202], ["HIPAA compliance violations", "PROBLEM", 117, 144], ["Long-Term FocusAfter the COVID", "TREATMENT", 286, 316]]], ["These requirements vary by state; therefore, practice leaders should consult legal and compliance advisors before creating or continuing their telemedicine practices to confirm ongoing compliance.", [["their telemedicine practices", "TREATMENT", 137, 165]]], ["[2, 10, 14] During the pandemic, regulatory changes have evolved rapidly, and practice managers and providers should update their understanding of these changes on a daily basis.Feasibility of Telemedicine in a TJA Practice ::: Future Direction And Long-Term FocusTJA patients in several stages of evaluation are appropriate for telemedicine encounters.", [["patients", "ORGANISM", 268, 276], ["patients", "SPECIES", 268, 276], ["evaluation", "TEST", 298, 308], ["rapidly", "OBSERVATION_MODIFIER", 65, 72], ["Long-Term", "OBSERVATION_MODIFIER", 249, 258]]], ["For patient counseling and education, as well as imaging review, remote synchronous video encounters appear to be equivalent to in-person visits.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["imaging review", "TEST", 49, 63]]], ["However, because of the need for hands-on patient care and in-office procedures, traditional clinic visits cannot be replaced entirely in TJA practices.Feasibility of Telemedicine in a TJA Practice ::: Future Direction And Long-Term FocusGiven the current pandemic, our department rapidly implemented a telemedicine TJA clinic to treat all patients except those deemed to require in-person evaluation.", [["patient", "ORGANISM", 42, 49], ["patients", "ORGANISM", 340, 348], ["patient", "SPECIES", 42, 49], ["patients", "SPECIES", 340, 348], ["patient care", "TREATMENT", 42, 54], ["evaluation", "TEST", 390, 400]]], ["In-person visits were limited to first postoperative visits and urgent care needs that could not be managed remotely; otherwise, all patients capable of doing so were evaluated via telemedicine.", [["patients", "ORGANISM", 133, 141], ["person", "SPECIES", 3, 9], ["patients", "SPECIES", 133, 141], ["urgent care needs", "TREATMENT", 64, 81]]], ["Telemedicine was used for new patients, as well as established patients.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 63, 71], ["Telemedicine", "TREATMENT", 0, 12]]], ["The range of topics addressed at these visits included nonoperative treatment options, preoperative counseling, imaging review, acute concerns not requiring in-person evaluation, routine postoperative follow-up, and long-term surveillance.", [["nonoperative treatment options", "TREATMENT", 55, 85], ["preoperative counseling", "TREATMENT", 87, 110], ["imaging review", "TEST", 112, 126], ["evaluation", "TEST", 167, 177], ["long-term surveillance", "TEST", 216, 238], ["acute", "OBSERVATION_MODIFIER", 128, 133]]], ["The patient education typically provided before TJA can also be accomplished through interactive telemedicine.", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11], ["TJA", "TREATMENT", 48, 51]]], ["[57] Thomas et al [57] reported practical tips to improve the telemedicine patient-provider experience (Table 1).", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["practical tips", "TREATMENT", 32, 46]]], ["A TJA practice should choose which patients are appropriate for telemedicine based on practice philosophy, the needs of the patient, and, during the current pandemic, the greater good of society.", [["patients", "ORGANISM", 35, 43], ["patient", "ORGANISM", 124, 131], ["patients", "SPECIES", 35, 43], ["patient", "SPECIES", 124, 131], ["A TJA practice", "TREATMENT", 0, 14], ["telemedicine", "TREATMENT", 64, 76], ["practice philosophy", "TREATMENT", 86, 105], ["TJA", "OBSERVATION", 2, 5], ["greater", "OBSERVATION_MODIFIER", 171, 178], ["good", "OBSERVATION_MODIFIER", 179, 183]]], ["Neither the American Association of Hip and Knee Surgeons nor the American Association of Orthopaedic Surgeons has yet made recommendations regarding which patients would benefit from telemedicine versus in-person visits.", [["patients", "ORGANISM", 156, 164], ["patients", "SPECIES", 156, 164], ["Hip", "ANATOMY", 36, 39], ["Knee", "ANATOMY", 44, 48]]], ["[5] Such decisions may be based on data from other fields and determined experientially.Feasibility of Telemedicine in a TJA Practice ::: Future Direction And Long-Term FocusEvidence supports the effectiveness of telemedicine for TJA patients.", [["TJA", "DISEASE", 230, 233], ["patients", "ORGANISM", 234, 242], ["patients", "SPECIES", 234, 242], ["TJA patients", "TREATMENT", 230, 242]]], ["One study found that orthopaedic surgeons reported that telemedicine, including telemedicine for TJA patients, was not inferior to standard clinic visits across the spectrum of visit types, from new consultations through long-term follow-up.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["One study", "TEST", 0, 9]]], ["[12] The authors reported no significant difference in duration of evaluation in telemedicine visits compared with in-person encounters but emphasized the importance of having radiographs taken before the evaluation and available for remote review.", [["evaluation", "TEST", 67, 77], ["radiographs", "TEST", 176, 187], ["the evaluation", "TEST", 201, 215], ["no", "UNCERTAINTY", 26, 28], ["significant", "OBSERVATION_MODIFIER", 29, 40]]], ["Importantly, their exclusion criteria for telemedicine visits included the inability to provide informed consent, which can prevent the use of telemedicine for patients with advanced cognitive dysfunction, incarcerated patients, patients who need an interpreter, and patients with complex problems requiring extensive physical examination.", [["cognitive dysfunction", "DISEASE", 183, 204], ["patients", "ORGANISM", 160, 168], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 229, 237], ["patients", "ORGANISM", 267, 275], ["patients", "SPECIES", 160, 168], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 229, 237], ["patients", "SPECIES", 267, 275], ["advanced cognitive dysfunction", "PROBLEM", 174, 204], ["complex problems", "PROBLEM", 281, 297], ["extensive physical examination", "TEST", 308, 338]]], ["Although the need for an interpreter has been cited as a reason not to use telemedicine, current IT platforms and telemedicine workflows allow the use of remote interpreter services, which expands the pool of potentially eligible patients.Feasibility of Telemedicine in a TJA Practice ::: Future Direction And Long-Term FocusConsistent with recommendations made by Buvik et al [12], we have imaging readily available when the physician or advanced practice provider meets the patient.", [["patients", "ORGANISM", 230, 238], ["patient", "ORGANISM", 476, 483], ["patients", "SPECIES", 230, 238], ["patient", "SPECIES", 476, 483], ["telemedicine", "TREATMENT", 75, 87], ["telemedicine workflows", "TREATMENT", 114, 136], ["remote interpreter services", "TREATMENT", 154, 181], ["imaging", "TEST", 391, 398]]], ["This practice is accomplished by having imaging completed prior to the scheduled appointment.", [["imaging", "TEST", 40, 47]]], ["For patients who have had their imaging performed an imaging center that is unaffiliated with our institution, a HIPAA-compliant cloud-based imaging application can allow for remote review of images.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["their imaging", "TEST", 26, 39], ["an imaging", "TEST", 50, 60], ["a HIPAA", "TEST", 111, 118], ["remote review of images", "TEST", 175, 198]]], ["Most telecommunications platforms have a \u201cshare-screen\u201d function, so that imaging and laboratory results can be reviewed with the patient in real time.Feasibility of Telemedicine in a TJA Practice ::: Future Direction And Long-Term FocusAlthough data are scarce regarding telemedicine in TJA practice, evidence suggests that telemedicine compares favorably with traditional clinic visits for TJA patients, including the ability to examine patients via surrogate findings.", [["TJA", "DISEASE", 392, 395], ["patient", "ORGANISM", 130, 137], ["patients", "ORGANISM", 396, 404], ["patients", "ORGANISM", 439, 447], ["patient", "SPECIES", 130, 137], ["patients", "SPECIES", 396, 404], ["patients", "SPECIES", 439, 447], ["imaging", "TEST", 74, 81], ["TJA patients", "TREATMENT", 392, 404]]], ["[37] Additionally, Sharareh and Schwarzkopf [52] found that 33 postoperative TJA patients seen through telemedicine had significantly higher satisfaction rates, fewer unscheduled clinic visits, and fewer telephone calls to the office during the 90-day period after TJA compared with 40 patients who were seen in traditional clinic visits.", [["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 286, 294], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 286, 294], ["TJA", "TREATMENT", 265, 268]]], ["No postoperative adverse events occurred in either the in-person or the telemedicine group during the 3-month study period.", [["person", "SPECIES", 58, 64], ["postoperative adverse events", "PROBLEM", 3, 31], ["postoperative", "OBSERVATION_MODIFIER", 3, 16], ["adverse", "OBSERVATION", 17, 24]]], ["Similar findings have been noted in other surgical and nonsurgical fields.RecommendationsWe recommend the following actions to facilitate the adoption and expansion of telemedicine:1.Federal and state rules regarding physician licensing requirements and originating site should be optimized to support the use of telemedicine to evaluate and treat appropriately selected patients.2.Medicare supplement and Medicaid reimbursement policies for telemedicine services, which currently vary by state, should be harmonized to the extent possible to remove financial disincentives to providing telemedicine care.3.Practices and providers should be educated about the benefits of telemedicine, as well as factors essential to its adoption.", [["patients", "ORGANISM", 371, 379], ["patients", "SPECIES", 371, 379], ["telemedicine", "TREATMENT", 313, 325], ["telemedicine services", "TREATMENT", 442, 463], ["telemedicine care", "TREATMENT", 587, 604], ["telemedicine", "TREATMENT", 672, 684], ["surgical", "OBSERVATION", 42, 50], ["nonsurgical", "OBSERVATION", 55, 66]]], ["These topics include costs and components of telemedicine platforms, information on documentation, reimbursement guidance, tips to improve telemedicine workflow efficiency, and liability and privacy considerations.4.Patients should be educated about the use and benefits of telemedicine, and they should be assessed for their technological competency and willingness to use telemedicine.", [["Patients", "ORGANISM", 216, 224], ["Patients", "SPECIES", 216, 224], ["telemedicine platforms", "TREATMENT", 45, 67], ["tips", "TREATMENT", 123, 127], ["telemedicine", "TREATMENT", 274, 286]]]], "82ed334c851c0f0cd0fc73d05322f50898ae13d9": [["Patients with cancer have a higher risk (0.79-8.3%) of developing SARS-CoV-2 infection than the general population.", [["cancer", "ANATOMY", 14, 20], ["cancer", "DISEASE", 14, 20], ["SARS-CoV-2 infection", "DISEASE", 66, 86], ["Patients", "ORGANISM", 0, 8], ["cancer", "CANCER", 14, 20], ["SARS-CoV-2", "ORGANISM", 66, 76], ["Patients", "SPECIES", 0, 8], ["cancer", "PROBLEM", 14, 20], ["developing SARS", "PROBLEM", 55, 70], ["CoV-2 infection", "PROBLEM", 71, 86], ["cancer", "OBSERVATION", 14, 20], ["SARS", "OBSERVATION", 66, 70], ["infection", "OBSERVATION", 77, 86]]]], "a3ad96383b993c205e6f34967deaa19ff5fd8d4c": [["IntroductionIncreased production of calcitonin by medullary thyroid carcinoma (MTC) is well known, and serum calcitonin is used as a marker of this cancer.", [["medullary thyroid carcinoma", "ANATOMY", 50, 77], ["MTC", "ANATOMY", 79, 82], ["serum", "ANATOMY", 103, 108], ["cancer", "ANATOMY", 148, 154], ["calcitonin", "CHEMICAL", 36, 46], ["medullary thyroid carcinoma", "DISEASE", 50, 77], ["MTC", "DISEASE", 79, 82], ["calcitonin", "CHEMICAL", 109, 119], ["cancer", "DISEASE", 148, 154], ["calcitonin", "GENE_OR_GENE_PRODUCT", 36, 46], ["medullary thyroid carcinoma", "CANCER", 50, 77], ["MTC", "CANCER", 79, 82], ["serum", "ORGANISM_SUBSTANCE", 103, 108], ["calcitonin", "GENE_OR_GENE_PRODUCT", 109, 119], ["cancer", "CANCER", 148, 154], ["calcitonin", "TREATMENT", 36, 46], ["medullary thyroid carcinoma", "PROBLEM", 50, 77], ["serum calcitonin", "TREATMENT", 103, 119], ["this cancer", "PROBLEM", 143, 154], ["thyroid", "ANATOMY", 60, 67], ["carcinoma", "OBSERVATION", 68, 77], ["cancer", "OBSERVATION", 148, 154]]], ["High serum concentrations of calcitonin-like immunoreactivity have also been reported in various extrathyroid disorders, including many cancers, acute and chronic inflammatory disease of the lung, acute pancreatitis, renal failure, benign liver disease, and fulminating infantile meningococcaemia.", [["serum", "ANATOMY", 5, 10], ["extrathyroid", "ANATOMY", 97, 109], ["cancers", "ANATOMY", 136, 143], ["lung", "ANATOMY", 191, 195], ["renal", "ANATOMY", 217, 222], ["benign liver", "ANATOMY", 232, 244], ["calcitonin", "CHEMICAL", 29, 39], ["extrathyroid disorders", "DISEASE", 97, 119], ["cancers", "DISEASE", 136, 143], ["inflammatory disease of the lung", "DISEASE", 163, 195], ["pancreatitis", "DISEASE", 203, 215], ["renal failure", "DISEASE", 217, 230], ["liver disease", "DISEASE", 239, 252], ["infantile meningococcaemia", "DISEASE", 270, 296], ["serum", "ORGANISM_SUBSTANCE", 5, 10], ["calcitonin", "GENE_OR_GENE_PRODUCT", 29, 39], ["cancers", "CANCER", 136, 143], ["lung", "ORGAN", 191, 195], ["renal", "ORGAN", 217, 222], ["liver", "ORGAN", 239, 244], ["High serum concentrations of calcitonin-like immunoreactivity", "PROBLEM", 0, 61], ["various extrathyroid disorders", "PROBLEM", 89, 119], ["many cancers", "PROBLEM", 131, 143], ["acute and chronic inflammatory disease of the lung", "PROBLEM", 145, 195], ["acute pancreatitis", "PROBLEM", 197, 215], ["renal failure", "PROBLEM", 217, 230], ["benign liver disease", "PROBLEM", 232, 252], ["fulminating infantile meningococcaemia", "PROBLEM", 258, 296], ["serum concentrations", "OBSERVATION_MODIFIER", 5, 25], ["many", "OBSERVATION_MODIFIER", 131, 135], ["cancers", "OBSERVATION", 136, 143], ["acute", "OBSERVATION_MODIFIER", 145, 150], ["chronic", "OBSERVATION_MODIFIER", 155, 162], ["inflammatory", "OBSERVATION", 163, 175], ["lung", "ANATOMY", 191, 195], ["acute", "OBSERVATION_MODIFIER", 197, 202], ["pancreatitis", "OBSERVATION", 203, 215], ["renal", "ANATOMY", 217, 222], ["failure", "OBSERVATION", 223, 230], ["benign", "OBSERVATION_MODIFIER", 232, 238], ["liver", "ANATOMY", 239, 244], ["disease", "OBSERVATION", 245, 252], ["fulminating", "OBSERVATION_MODIFIER", 258, 269], ["infantile", "OBSERVATION_MODIFIER", 270, 279], ["meningococcaemia", "OBSERVATION", 280, 296]]], ["[1] [2] [3] [4] [5] [6] [7] [8] [9] The presence of several circulating immunoreactive forms of calcitonin and its precursors in MTC patients has been shown by several groups '11,10-13 but the nature of circulating immunoreactive calcitonin species in other disorders remains unknown.", [["calcitonin", "CHEMICAL", 96, 106], ["MTC", "DISEASE", 129, 132], ["calcitonin", "CHEMICAL", 230, 240], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 0, 35], ["calcitonin", "GENE_OR_GENE_PRODUCT", 96, 106], ["MTC", "CANCER", 129, 132], ["patients", "ORGANISM", 133, 141], ["calcitonin", "GENE_OR_GENE_PRODUCT", 230, 240], ["patients", "SPECIES", 133, 141], ["2] [3] [4] [5] [6] [7] [8", "TEST", 5, 30], ["calcitonin", "TREATMENT", 96, 106], ["circulating immunoreactive calcitonin species in other disorders", "PROBLEM", 203, 267], ["immunoreactive calcitonin species", "OBSERVATION", 215, 248]]], ["However, Ghillani and colleagues8 lately showed that, unlike MTC, which produces both precursors and mature hormones, most of the extrathyroid diseases produce calcitonin precursors in the absence of mature hormone.IntroductionWe have investigated calcitonin species in patients with severe bacterial infections and sepsis.Patients and methodsTwo groups of patients were studied.", [["extrathyroid", "ANATOMY", 130, 142], ["MTC", "DISEASE", 61, 64], ["extrathyroid diseases", "DISEASE", 130, 151], ["calcitonin", "CHEMICAL", 160, 170], ["calcitonin", "CHEMICAL", 248, 258], ["bacterial infections", "DISEASE", 291, 311], ["sepsis", "DISEASE", 316, 322], ["MTC", "CANCER", 61, 64], ["calcitonin", "GENE_OR_GENE_PRODUCT", 160, 170], ["calcitonin", "GENE_OR_GENE_PRODUCT", 248, 258], ["patients", "ORGANISM", 270, 278], ["Patients", "ORGANISM", 323, 331], ["patients", "ORGANISM", 357, 365], ["patients", "SPECIES", 270, 278], ["Patients", "SPECIES", 323, 331], ["patients", "SPECIES", 357, 365], ["both precursors and mature hormones", "PROBLEM", 81, 116], ["the extrathyroid diseases", "PROBLEM", 126, 151], ["calcitonin precursors", "PROBLEM", 160, 181], ["IntroductionWe", "TREATMENT", 215, 229], ["calcitonin species", "PROBLEM", 248, 266], ["severe bacterial infections", "PROBLEM", 284, 311], ["sepsis", "PROBLEM", 316, 322], ["MTC", "OBSERVATION", 61, 64], ["mature hormones", "OBSERVATION", 101, 116], ["calcitonin precursors", "OBSERVATION", 160, 181], ["calcitonin species", "OBSERVATION", 248, 266], ["severe", "OBSERVATION_MODIFIER", 284, 290], ["bacterial", "OBSERVATION_MODIFIER", 291, 300], ["infections", "OBSERVATION", 301, 311], ["sepsis", "OBSERVATION", 316, 322]]], ["The first comprised 79 newborn and older infants and children admitted to a paediatric unit with suspected infections (table) and the second included 9 severely burned patients admitted to an intensive care unit (burn injuries 16-80% of body surface area).", [["body surface area", "ANATOMY", 237, 254], ["infections", "DISEASE", 107, 117], ["injuries", "DISEASE", 218, 226], ["infants", "ORGANISM", 41, 48], ["children", "ORGANISM", 53, 61], ["patients", "ORGANISM", 168, 176], ["body", "ORGANISM_SUBDIVISION", 237, 241], ["infants", "SPECIES", 41, 48], ["children", "SPECIES", 53, 61], ["patients", "SPECIES", 168, 176], ["suspected infections", "PROBLEM", 97, 117], ["burn injuries", "TEST", 213, 226], ["infections", "OBSERVATION", 107, 117]]], ["Blood samples were centrifuged for 15 min at 1500 g and serum was stored at -20\u00b0C until analysis.", [["Blood samples", "ANATOMY", 0, 13], ["serum", "ANATOMY", 56, 61], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["Blood samples", "TEST", 0, 13], ["serum", "TEST", 56, 61], ["analysis", "TEST", 88, 96]]], ["Procalcitonin was measured with a monoclonal immunoradiometric assay (m-IRMA).8 This assay uses two monoclonal antibodies, one directed against residues 96-106 of procalcitonin, as the capture antibody, and one recognising residues 70-76, as the tracer antibody ( fig 1) .", [["Procalcitonin", "GENE_OR_GENE_PRODUCT", 0, 13], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 163, 176], ["monoclonal antibodies", "PROTEIN", 100, 121], ["procalcitonin", "PROTEIN", 163, 176], ["capture antibody", "PROTEIN", 185, 201], ["tracer antibody", "PROTEIN", 246, 261], ["Procalcitonin", "TEST", 0, 13], ["a monoclonal immunoradiometric assay", "TEST", 32, 68], ["This assay", "TEST", 80, 90], ["two monoclonal antibodies", "TREATMENT", 96, 121], ["procalcitonin", "TEST", 163, 176], ["the capture antibody", "TEST", 181, 201], ["the tracer antibody", "TEST", 242, 261]]], ["This assay has a detection limit of 100 pg/mL.", [["This assay", "TEST", 0, 10]]], ["Serum calcitonin was measured with a commercial m-IRMA (CIS Bio-International, Gif sur Yvette, France) which is specific for mature calcitonin and has a sensitivity limit of 10 pg/mL.", [["Serum", "ANATOMY", 0, 5], ["calcitonin", "CHEMICAL", 6, 16], ["calcitonin", "CHEMICAL", 132, 142], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["calcitonin", "GENE_OR_GENE_PRODUCT", 6, 16], ["calcitonin", "GENE_OR_GENE_PRODUCT", 132, 142], ["Serum calcitonin", "TEST", 0, 16], ["mature calcitonin", "PROBLEM", 125, 142]]], ["Circulating immunoreactive forms of calcitonin were analysed by reverse-phase high-performance liquid chromatography (HPLC).", [["calcitonin", "CHEMICAL", 36, 46], ["calcitonin", "GENE_OR_GENE_PRODUCT", 36, 46], ["calcitonin", "TREATMENT", 36, 46]]], ["After partial purification on a Sep-Pak cartridge, serum was injected into a C 18-Nucleosil (Macherey-Nagel, Diiren, Germany) column equilibrated with 0-1% (by volume) trifluoroacetic acid.", [["serum", "ANATOMY", 51, 56], ["trifluoroacetic acid", "CHEMICAL", 168, 188], ["trifluoroacetic acid", "CHEMICAL", 168, 188], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["trifluoroacetic acid", "SIMPLE_CHEMICAL", 168, 188], ["a Sep-Pak cartridge", "TREATMENT", 30, 49], ["serum", "TEST", 51, 56], ["a C", "TEST", 75, 78], ["Nucleosil (Macherey-Nagel", "TREATMENT", 82, 107], ["trifluoroacetic acid", "TREATMENT", 168, 188]]], ["The column was eluted at room temperature and at a flow rate of 1 mL per min with a 60 min gradient of 20-70% acetonitrile in 0-1% trifluoracetic acid.CLINICAL DATA FOR STUDY CHILDRENImmunoreactivity of the fractions was tested by four assays: the two described above; a radioimmunoassay based on a polyclonal goat antiserum directed against residues 1-57 of procalcitonin, which recognises both procalcitonin and the putative cleavage peptide N-proCTI-57; and an IRMA that uses the polyclonal antiserum against procalcitonin 1-57 and the monoclonal antibody directed against residues 96-106, which can detect only entire procalcitonin ( fig 1) .ResultsFig 2 shows the distribution of procalcitonin concentrations in the five subgroups of children with and without infection.", [["acetonitrile", "CHEMICAL", 110, 122], ["trifluoracetic acid", "CHEMICAL", 131, 150], ["infection", "DISEASE", 765, 774], ["acetonitrile", "CHEMICAL", 110, 122], ["trifluoracetic acid", "CHEMICAL", 131, 150], ["acetonitrile", "SIMPLE_CHEMICAL", 110, 122], ["trifluoracetic acid", "SIMPLE_CHEMICAL", 131, 150], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 359, 372], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 396, 409], ["procalcitonin 1-57", "GENE_OR_GENE_PRODUCT", 512, 530], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 622, 635], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 685, 698], ["children", "ORGANISM", 739, 747], ["procalcitonin", "PROTEIN", 359, 372], ["procalcitonin", "PROTEIN", 396, 409], ["procalcitonin 1-57", "PROTEIN", 512, 530], ["monoclonal antibody", "PROTEIN", 539, 558], ["procalcitonin", "PROTEIN", 622, 635], ["procalcitonin", "PROTEIN", 685, 698], ["goat", "SPECIES", 310, 314], ["children", "SPECIES", 739, 747], ["goat", "SPECIES", 310, 314], ["a flow rate", "TEST", 49, 60], ["acetonitrile", "TREATMENT", 110, 122], ["a radioimmunoassay", "TEST", 269, 287], ["a polyclonal goat antiserum", "TREATMENT", 297, 324], ["procalcitonin", "TEST", 359, 372], ["procalcitonin", "TEST", 396, 409], ["N-proCTI", "TEST", 444, 452], ["an IRMA", "TEST", 461, 468], ["the polyclonal antiserum", "TEST", 479, 503], ["procalcitonin", "TEST", 512, 525], ["the monoclonal antibody", "TEST", 535, 558], ["entire procalcitonin", "TEST", 615, 635], ["ResultsFig", "TEST", 646, 656], ["procalcitonin concentrations", "PROBLEM", 685, 713], ["infection", "PROBLEM", 765, 774], ["column", "OBSERVATION_MODIFIER", 4, 10], ["distribution", "OBSERVATION_MODIFIER", 669, 681], ["procalcitonin concentrations", "OBSERVATION", 685, 713], ["five subgroups", "OBSERVATION_MODIFIER", 721, 735], ["without", "UNCERTAINTY", 757, 764], ["infection", "OBSERVATION", 765, 774]]], ["Procalcitonin was undetectable (<0-1 1 ng/mL) in 21 children without infection.", [["infection", "DISEASE", 69, 78], ["Procalcitonin", "GENE_OR_GENE_PRODUCT", 0, 13], ["children", "ORGANISM", 52, 60], ["children", "SPECIES", 52, 60], ["Procalcitonin", "TEST", 0, 13], ["infection", "PROBLEM", 69, 78], ["without", "UNCERTAINTY", 61, 68], ["infection", "OBSERVATION", 69, 78]]], ["At the time of diagnosis, 10 newborn infants and 9 older infants or children with severe bacterial infection (100%) had high serum concentrations of procalcitonin (6-53 ng/mL).", [["serum", "ANATOMY", 125, 130], ["bacterial infection", "DISEASE", 89, 108], ["infants", "ORGANISM", 37, 44], ["infants", "ORGANISM", 57, 64], ["children", "ORGANISM", 68, 76], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 149, 162], ["procalcitonin", "PROTEIN", 149, 162], ["infants", "SPECIES", 37, 44], ["infants", "SPECIES", 57, 64], ["children", "SPECIES", 68, 76], ["severe bacterial infection", "PROBLEM", 82, 108], ["high serum concentrations", "PROBLEM", 120, 145], ["procalcitonin", "TEST", 149, 162], ["severe", "OBSERVATION_MODIFIER", 82, 88], ["bacterial", "OBSERVATION_MODIFIER", 89, 98], ["infection", "OBSERVATION", 99, 108]]], ["Antibiotic treatment rapidly decreased procalcitonin concentrations (days 2-6 of treatment).", [["procalcitonin", "GENE_OR_GENE_PRODUCT", 39, 52], ["procalcitonin", "PROTEIN", 39, 52], ["Antibiotic treatment", "TREATMENT", 0, 20], ["procalcitonin concentrations", "TREATMENT", 39, 67], ["treatment", "TREATMENT", 81, 90]]], ["Among the 5 infants and children with locoregional infection and the 6 newborn infants with skin bacterial colonisation and no sepsis, procalcitonin concentrations did not exceed 1-5 ng/mL (0-3-1-5 ng/mL).ResultsOf the 21 patients with viral infections, 18 (86%) had values within or slightly above the normal range (maximum 1-4 ng/mL); 2 children with gastroenteritis (1 coronavirus, 1 rotavirus) had values of 3-5 ng/mL and 8-0 ng/mL, and a child with acute hepatitis A had concentrations of 17 ng/mL on admission and 2 ng/mL on day 8.", [["skin", "ANATOMY", 92, 96], ["locoregional infection", "DISEASE", 38, 60], ["skin bacterial colonisation", "DISEASE", 92, 119], ["sepsis", "DISEASE", 127, 133], ["viral infections", "DISEASE", 236, 252], ["gastroenteritis", "DISEASE", 353, 368], ["acute hepatitis A", "DISEASE", 454, 471], ["infants", "ORGANISM", 12, 19], ["children", "ORGANISM", 24, 32], ["infants", "ORGANISM", 79, 86], ["skin", "ORGAN", 92, 96], ["patients", "ORGANISM", 222, 230], ["children", "ORGANISM", 339, 347], ["rotavirus", "ORGANISM", 387, 396], ["infants", "SPECIES", 12, 19], ["children", "SPECIES", 24, 32], ["infants", "SPECIES", 79, 86], ["patients", "SPECIES", 222, 230], ["children", "SPECIES", 339, 347], ["child", "SPECIES", 443, 448], ["locoregional infection", "PROBLEM", 38, 60], ["skin bacterial colonisation", "PROBLEM", 92, 119], ["sepsis", "PROBLEM", 127, 133], ["procalcitonin concentrations", "TREATMENT", 135, 163], ["viral infections", "PROBLEM", 236, 252], ["values", "TEST", 267, 273], ["gastroenteritis", "PROBLEM", 353, 368], ["1 coronavirus", "PROBLEM", 370, 383], ["values", "TEST", 402, 408], ["acute hepatitis A", "PROBLEM", 454, 471], ["infection", "OBSERVATION", 51, 60], ["skin", "ANATOMY", 92, 96], ["bacterial colonisation", "OBSERVATION", 97, 119], ["no", "UNCERTAINTY", 124, 126], ["sepsis", "OBSERVATION", 127, 133], ["viral", "OBSERVATION_MODIFIER", 236, 241], ["infections", "OBSERVATION", 242, 252], ["normal range", "OBSERVATION_MODIFIER", 303, 315], ["gastroenteritis", "OBSERVATION", 353, 368], ["acute", "OBSERVATION_MODIFIER", 454, 459], ["hepatitis", "OBSERVATION", 460, 469]]], ["Serum procalcitonin concentrations varied widely among the 9 burns patients from 0-to 120 ng/mL.", [["Serum", "ANATOMY", 0, 5], ["burns", "DISEASE", 61, 66], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 6, 19], ["patients", "ORGANISM", 67, 75], ["patients", "SPECIES", 67, 75], ["Serum procalcitonin concentrations", "TEST", 0, 34]]], ["Three procalcitonin concentrations of 2 ng/mL and 3 ng/mL within 3 days of the burn; concentrations then fell progressively to normal (subgroup I).", [["procalcitonin", "GENE_OR_GENE_PRODUCT", 6, 19], ["Three procalcitonin concentrations", "TREATMENT", 0, 34], ["the burn", "PROBLEM", 75, 83], ["burn", "OBSERVATION", 79, 83], ["normal", "OBSERVATION", 127, 133]]], ["These patients did not have any infectious complications during the hospital stay.", [["patients", "ORGANISM", 6, 14], ["patients", "SPECIES", 6, 14], ["any infectious complications", "PROBLEM", 28, 56], ["infectious", "OBSERVATION_MODIFIER", 32, 42]]], ["3 patients (subgroup II) had higher values, up to 19 ng/mL.", [["patients", "ORGANISM", 2, 10], ["patients", "SPECIES", 2, 10], ["higher values", "PROBLEM", 29, 42]]], ["The peak concentrations were found at the onset of sepsis, confirmed by clinical and microbiological signs.", [["sepsis", "DISEASE", 51, 57], ["The peak concentrations", "TEST", 0, 23], ["sepsis", "PROBLEM", 51, 57], ["microbiological signs", "TEST", 85, 106], ["peak concentrations", "OBSERVATION", 4, 23], ["sepsis", "OBSERVATION", 51, 57]]], ["In subgroup III, serum concentrations of 3 patients were high 1 day after the burn (14 ng/mL, 21 ng/mL, and 78 ng/mL) and continued to rise during the next few days, during acute septic episodes.", [["serum", "ANATOMY", 17, 22], ["burn", "DISEASE", 78, 82], ["serum", "ORGANISM_SUBSTANCE", 17, 22], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["serum concentrations", "TEST", 17, 37], ["acute septic episodes", "PROBLEM", 173, 194], ["subgroup III", "OBSERVATION_MODIFIER", 3, 15], ["acute", "OBSERVATION_MODIFIER", 173, 178], ["septic episodes", "OBSERVATION", 179, 194]]], ["1 of these patients, who had severe infectious complications (E coli positive blood culture on day 4, septic shock on day 6, Pseudomonas aerwinosa positive culture on day 20), had high concentrations of procalcitonin in all serum samples; the highest value (120 ng/mL) was measured during septic shock.", [["blood", "ANATOMY", 78, 83], ["serum samples", "ANATOMY", 224, 237], ["septic shock", "DISEASE", 102, 114], ["septic shock", "DISEASE", 289, 301], ["patients", "ORGANISM", 11, 19], ["blood", "ORGANISM_SUBSTANCE", 78, 83], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 203, 216], ["serum samples", "ORGANISM_SUBSTANCE", 224, 237], ["procalcitonin", "PROTEIN", 203, 216], ["patients", "SPECIES", 11, 19], ["E coli", "SPECIES", 62, 68], ["Pseudomonas aerwinosa", "SPECIES", 125, 146], ["E coli", "SPECIES", 62, 68], ["Pseudomonas aerwinosa", "SPECIES", 125, 146], ["severe infectious complications", "PROBLEM", 29, 60], ["E coli", "PROBLEM", 62, 68], ["blood culture", "TEST", 78, 91], ["septic shock", "PROBLEM", 102, 114], ["Pseudomonas aerwinosa positive culture", "PROBLEM", 125, 163], ["high concentrations of procalcitonin", "PROBLEM", 180, 216], ["all serum samples", "TEST", 220, 237], ["the highest value", "TEST", 239, 256], ["septic shock", "PROBLEM", 289, 301], ["severe", "OBSERVATION_MODIFIER", 29, 35], ["infectious", "OBSERVATION", 36, 46], ["septic shock", "OBSERVATION", 289, 301]]], ["The 4th patient in subgroup III had toxic shock syndrome 18 days after the bum, and procalcitonin reached a maximum of 70 ng/mL at that time.ResultsOnly 1 burns patient (subgroup II) died (pulmonary embolism 57 days after injury).", [["pulmonary", "ANATOMY", 189, 198], ["toxic shock syndrome", "DISEASE", 36, 56], ["burns", "DISEASE", 155, 160], ["pulmonary embolism", "DISEASE", 189, 207], ["patient", "ORGANISM", 8, 15], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 84, 97], ["patient", "ORGANISM", 161, 168], ["pulmonary", "ORGAN", 189, 198], ["patient", "SPECIES", 8, 15], ["patient", "SPECIES", 161, 168], ["toxic shock syndrome", "PROBLEM", 36, 56], ["procalcitonin", "TREATMENT", 84, 97], ["pulmonary embolism", "PROBLEM", 189, 207], ["injury", "PROBLEM", 222, 228], ["toxic", "OBSERVATION_MODIFIER", 36, 41], ["shock syndrome", "OBSERVATION", 42, 56], ["pulmonary", "ANATOMY", 189, 198], ["embolism", "OBSERVATION", 199, 207]]], ["Concentrations of mature calcitonin were normal at all times in both burns patients and children.", [["calcitonin", "CHEMICAL", 25, 35], ["burns", "DISEASE", 69, 74], ["calcitonin", "GENE_OR_GENE_PRODUCT", 25, 35], ["patients", "ORGANISM", 75, 83], ["children", "ORGANISM", 88, 96], ["patients", "SPECIES", 75, 83], ["children", "SPECIES", 88, 96], ["mature calcitonin", "PROBLEM", 18, 35], ["mature", "OBSERVATION_MODIFIER", 18, 24], ["calcitonin", "OBSERVATION", 25, 35]]], ["Analysis of serum extracts by reverse-phase HPLC showed a major peak eluting at 37-39 min, as detected by several immunoassays (fig 4) .", [["serum extracts", "ANATOMY", 12, 26], ["serum", "ORGANISM_SUBSTANCE", 12, 17], ["extracts", "ORGANISM_SUBSTANCE", 18, 26], ["Analysis of serum extracts", "TEST", 0, 26], ["reverse-phase HPLC", "TEST", 30, 48], ["several immunoassays", "TEST", 106, 126]]], ["It is likely that this immunoreactive peak corresponded to the whole molecule of procalcitonin.", [["procalcitonin", "GENE_OR_GENE_PRODUCT", 81, 94], ["procalcitonin", "PROTEIN", 81, 94], ["this immunoreactive peak", "PROBLEM", 18, 42], ["procalcitonin", "TEST", 81, 94], ["is likely", "UNCERTAINTY", 3, 12]]], ["Two other small peaks detected in some samples could not be identified.", [["samples", "ANATOMY", 39, 46], ["samples", "CANCER", 39, 46], ["Two other small peaks", "PROBLEM", 0, 21], ["small", "OBSERVATION_MODIFIER", 10, 15], ["peaks", "OBSERVATION", 16, 21], ["could not be", "UNCERTAINTY", 47, 59]]], ["Calcitonin was consistently undetectable by a specific m-IRMA.DiscussionSerum calcitonin-like immunoreactivity has been reported in various extrathyroid diseases.1-9 Our study shows that serum concentrations of a substance immunologically identical to procalcitonin increase at the onset of infections.", [["extrathyroid", "ANATOMY", 140, 152], ["serum", "ANATOMY", 187, 192], ["Calcitonin", "CHEMICAL", 0, 10], ["calcitonin", "CHEMICAL", 78, 88], ["extrathyroid diseases", "DISEASE", 140, 161], ["infections", "DISEASE", 291, 301], ["Calcitonin", "GENE_OR_GENE_PRODUCT", 0, 10], ["calcitonin", "GENE_OR_GENE_PRODUCT", 78, 88], ["extrathyroid", "CANCER", 140, 152], ["serum", "ORGANISM_SUBSTANCE", 187, 192], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 252, 265], ["procalcitonin", "PROTEIN", 252, 265], ["Calcitonin", "TREATMENT", 0, 10], ["calcitonin", "TEST", 78, 88], ["various extrathyroid diseases", "PROBLEM", 132, 161], ["Our study", "TEST", 166, 175], ["serum concentrations", "PROBLEM", 187, 207], ["procalcitonin", "TEST", 252, 265], ["infections", "PROBLEM", 291, 301], ["extrathyroid diseases", "OBSERVATION", 140, 161], ["infections", "OBSERVATION", 291, 301]]], ["In addition, serum concentrations of this substance seemed to be correlated with the severity of the infection.", [["serum", "ANATOMY", 13, 18], ["infection", "DISEASE", 101, 110], ["serum", "ORGANISM_SUBSTANCE", 13, 18], ["serum concentrations", "TEST", 13, 33], ["the infection", "PROBLEM", 97, 110], ["infection", "OBSERVATION", 101, 110]]], ["In all but 2 children with procalcitonin concentrations above 5 ng/mL, the diagnosis of severe bacterial sepsis was confirmed microbiologically.", [["bacterial sepsis", "DISEASE", 95, 111], ["children", "ORGANISM", 13, 21], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 27, 40], ["procalcitonin", "PROTEIN", 27, 40], ["children", "SPECIES", 13, 21], ["procalcitonin concentrations", "TREATMENT", 27, 55], ["severe bacterial sepsis", "PROBLEM", 88, 111], ["severe", "OBSERVATION_MODIFIER", 88, 94], ["bacterial", "OBSERVATION_MODIFIER", 95, 104], ["sepsis", "OBSERVATION", 105, 111]]], ["The study of bums patients suggests that bum injuries may lead to moderate systemic release of procalcitonin.", [["injuries", "DISEASE", 45, 53], ["bums", "ORGANISM", 13, 17], ["patients", "ORGANISM", 18, 26], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 95, 108], ["procalcitonin", "PROTEIN", 95, 108], ["patients", "SPECIES", 18, 26], ["The study", "TEST", 0, 9], ["bum injuries", "PROBLEM", 41, 53], ["moderate systemic release of procalcitonin", "PROBLEM", 66, 108]]], ["However, among these patients, very high peak concentrations of procalcitonin were associated with septic complications, although no direct correlation was found between the post-bum course of the procalcitonin concentrations and the size of the bum or pulmonary injury.", [["bum", "ANATOMY", 246, 249], ["pulmonary", "ANATOMY", 253, 262], ["septic complications", "DISEASE", 99, 119], ["pulmonary injury", "DISEASE", 253, 269], ["patients", "ORGANISM", 21, 29], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 64, 77], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 197, 210], ["pulmonary", "ORGAN", 253, 262], ["procalcitonin", "PROTEIN", 64, 77], ["procalcitonin", "PROTEIN", 197, 210], ["patients", "SPECIES", 21, 29], ["very high peak concentrations of procalcitonin", "PROBLEM", 31, 77], ["septic complications", "PROBLEM", 99, 119], ["the procalcitonin concentrations", "TREATMENT", 193, 225], ["pulmonary injury", "PROBLEM", 253, 269], ["septic complications", "OBSERVATION", 99, 119], ["size", "OBSERVATION_MODIFIER", 234, 238], ["bum", "ANATOMY", 246, 249], ["pulmonary", "ANATOMY", 253, 262], ["injury", "OBSERVATION", 263, 269]]], ["The correlation of procalcitonin with the severity of infection was confirmed by findings of serum concentrations up to 200 ng/mL (2000 times the normal value) in patients with septic shock (data not shown).", [["serum", "ANATOMY", 93, 98], ["infection", "DISEASE", 54, 63], ["septic shock", "DISEASE", 177, 189], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 19, 32], ["serum", "ORGANISM_SUBSTANCE", 93, 98], ["patients", "ORGANISM", 163, 171], ["procalcitonin", "PROTEIN", 19, 32], ["patients", "SPECIES", 163, 171], ["procalcitonin", "TREATMENT", 19, 32], ["infection", "PROBLEM", 54, 63], ["serum concentrations", "TEST", 93, 113], ["septic shock", "PROBLEM", 177, 189], ["infection", "OBSERVATION", 54, 63], ["septic shock", "OBSERVATION", 177, 189]]], ["Antibiotic treatment lowered procalcitonin rapidly.", [["procalcitonin", "GENE_OR_GENE_PRODUCT", 29, 42], ["procalcitonin", "PROTEIN", 29, 42], ["Antibiotic treatment", "TREATMENT", 0, 20], ["procalcitonin", "TREATMENT", 29, 42]]], ["By contrast, high circulating procalcitonin concentrations persisted in 1 burns patient who had overwhelming microbial invasion and a long septic episode.", [["burns", "DISEASE", 74, 79], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 30, 43], ["patient", "ORGANISM", 80, 87], ["procalcitonin", "PROTEIN", 30, 43], ["patient", "SPECIES", 80, 87], ["high circulating procalcitonin concentrations", "PROBLEM", 13, 58], ["overwhelming microbial invasion", "PROBLEM", 96, 127], ["a long septic episode", "PROBLEM", 132, 153], ["microbial invasion", "OBSERVATION", 109, 127], ["long", "OBSERVATION_MODIFIER", 134, 138], ["septic", "OBSERVATION_MODIFIER", 139, 145]]], ["Do the procalcitonin molecules originate from the thyroid gland or from other tissues in these patients?", [["thyroid gland", "ANATOMY", 50, 63], ["tissues", "ANATOMY", 78, 85], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 7, 20], ["thyroid gland", "ORGAN", 50, 63], ["tissues", "TISSUE", 78, 85], ["patients", "ORGANISM", 95, 103], ["procalcitonin molecules", "PROTEIN", 7, 30], ["patients", "SPECIES", 95, 103], ["the procalcitonin molecules", "TEST", 3, 30], ["thyroid gland", "ANATOMY", 50, 63]]], ["Thyroid C-cells do not seem to be the production site of procalcitonin; indeed, 1 burns patient who had undergone thyroidectomy 2 years earlier had high procalcitonin values but no secretion of mature calcitonin.", [["Thyroid C-cells", "ANATOMY", 0, 15], ["burns", "DISEASE", 82, 87], ["calcitonin", "CHEMICAL", 201, 211], ["Thyroid C-cells", "CELL", 0, 15], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 57, 70], ["patient", "ORGANISM", 88, 95], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 153, 166], ["calcitonin", "GENE_OR_GENE_PRODUCT", 201, 211], ["Thyroid C-cells", "CELL_TYPE", 0, 15], ["procalcitonin", "PROTEIN", 57, 70], ["procalcitonin", "PROTEIN", 153, 166], ["patient", "SPECIES", 88, 95], ["Thyroid C-cells", "PROBLEM", 0, 15], ["procalcitonin", "TREATMENT", 57, 70], ["thyroidectomy", "TREATMENT", 114, 127], ["high procalcitonin values", "PROBLEM", 148, 173], ["secretion of mature calcitonin", "PROBLEM", 181, 211], ["thyroidectomy", "OBSERVATION", 114, 127]]], ["The finding that procalcitonin was detectable in the absence of mature calcitonin shows that the procalcitonin-producing cells are unable to process this precursor form to the mature hormone.", [["cells", "ANATOMY", 121, 126], ["calcitonin", "CHEMICAL", 71, 81], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 17, 30], ["calcitonin", "GENE_OR_GENE_PRODUCT", 71, 81], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 97, 110], ["cells", "CELL", 121, 126], ["procalcitonin", "PROTEIN", 17, 30], ["procalcitonin-producing cells", "CELL_TYPE", 97, 126], ["procalcitonin", "TEST", 17, 30], ["mature calcitonin", "PROBLEM", 64, 81], ["the procalcitonin", "TEST", 93, 110]]], ["MTC are capable of producing and secreting all the biosynthetic pathway products.12-14 Pulmonary neuroendocrine cells in the bronchial epithelium have been reported to be a major source of calcitonin immunoreactivity.'S However, most of our patients with sepsis did not have pulmonary injury.", [["Pulmonary neuroendocrine cells", "ANATOMY", 87, 117], ["bronchial epithelium", "ANATOMY", 125, 145], ["pulmonary", "ANATOMY", 275, 284], ["MTC", "DISEASE", 0, 3], ["calcitonin", "CHEMICAL", 189, 199], ["sepsis", "DISEASE", 255, 261], ["pulmonary injury", "DISEASE", 275, 291], ["MTC", "SIMPLE_CHEMICAL", 0, 3], ["Pulmonary neuroendocrine cells", "CELL", 87, 117], ["bronchial epithelium", "TISSUE", 125, 145], ["calcitonin", "GENE_OR_GENE_PRODUCT", 189, 199], ["patients", "ORGANISM", 241, 249], ["pulmonary", "ORGAN", 275, 284], ["Pulmonary neuroendocrine cells", "CELL_TYPE", 87, 117], ["patients", "SPECIES", 241, 249], ["calcitonin immunoreactivity", "PROBLEM", 189, 216], ["sepsis", "PROBLEM", 255, 261], ["pulmonary injury", "PROBLEM", 275, 291], ["Pulmonary", "ANATOMY", 87, 96], ["neuroendocrine cells", "OBSERVATION", 97, 117], ["bronchial", "ANATOMY", 125, 134], ["epithelium", "ANATOMY_MODIFIER", 135, 145], ["calcitonin immunoreactivity", "OBSERVATION", 189, 216], ["sepsis", "OBSERVATION", 255, 261], ["pulmonary", "ANATOMY", 275, 284], ["injury", "OBSERVATION", 285, 291]]], ["Others have reported the isolated presence of calcitonin precursors in patients with benign liver diseases (such as hepatitis) or with hepatocellular carcinoma, and also the presence of calcitonin-related RNA in this tumour.8 Perhaps the liver is the site of procalcitonin production in patients with sepsis.", [["benign liver", "ANATOMY", 85, 97], ["hepatocellular carcinoma", "ANATOMY", 135, 159], ["tumour", "ANATOMY", 217, 223], ["liver", "ANATOMY", 238, 243], ["calcitonin", "CHEMICAL", 46, 56], ["liver diseases", "DISEASE", 92, 106], ["hepatitis", "DISEASE", 116, 125], ["hepatocellular carcinoma", "DISEASE", 135, 159], ["calcitonin", "CHEMICAL", 186, 196], ["tumour", "DISEASE", 217, 223], ["sepsis", "DISEASE", 301, 307], ["calcitonin", "GENE_OR_GENE_PRODUCT", 46, 56], ["patients", "ORGANISM", 71, 79], ["liver", "ORGAN", 92, 97], ["hepatocellular carcinoma", "CANCER", 135, 159], ["calcitonin", "GENE_OR_GENE_PRODUCT", 186, 196], ["tumour", "CANCER", 217, 223], ["liver", "ORGAN", 238, 243], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 259, 272], ["patients", "ORGANISM", 287, 295], ["calcitonin-related RNA", "RNA", 186, 208], ["patients", "SPECIES", 71, 79], ["patients", "SPECIES", 287, 295], ["calcitonin precursors", "PROBLEM", 46, 67], ["benign liver diseases", "PROBLEM", 85, 106], ["hepatitis", "PROBLEM", 116, 125], ["hepatocellular carcinoma", "PROBLEM", 135, 159], ["calcitonin-related RNA in this tumour", "PROBLEM", 186, 223], ["procalcitonin production", "PROBLEM", 259, 283], ["sepsis", "PROBLEM", 301, 307], ["calcitonin precursors", "OBSERVATION", 46, 67], ["benign", "OBSERVATION_MODIFIER", 85, 91], ["liver", "ANATOMY", 92, 97], ["diseases", "OBSERVATION", 98, 106], ["hepatocellular", "ANATOMY", 135, 149], ["carcinoma", "OBSERVATION", 150, 159], ["calcitonin", "OBSERVATION", 186, 196], ["tumour", "OBSERVATION", 217, 223], ["liver", "ANATOMY", 238, 243], ["procalcitonin production", "OBSERVATION", 259, 283], ["sepsis", "OBSERVATION", 301, 307]]], ["Since serum calcitonin-like immunoreactivity has been described in a wide variety of extrathyroid diseases, it is likely that inflammatory processes other than infection lead to the elaboration of calcitonin-like immunoreactivity by various types of cells.", [["serum", "ANATOMY", 6, 11], ["extrathyroid", "ANATOMY", 85, 97], ["cells", "ANATOMY", 250, 255], ["calcitonin", "CHEMICAL", 12, 22], ["extrathyroid diseases", "DISEASE", 85, 106], ["infection", "DISEASE", 160, 169], ["calcitonin", "CHEMICAL", 197, 207], ["serum", "ORGANISM_SUBSTANCE", 6, 11], ["calcitonin", "GENE_OR_GENE_PRODUCT", 12, 22], ["extrathyroid", "CANCER", 85, 97], ["calcitonin", "GENE_OR_GENE_PRODUCT", 197, 207], ["cells", "CELL", 250, 255], ["serum calcitonin", "TEST", 6, 22], ["extrathyroid diseases", "PROBLEM", 85, 106], ["inflammatory processes", "PROBLEM", 126, 148], ["infection", "PROBLEM", 160, 169], ["calcitonin-like immunoreactivity", "PROBLEM", 197, 229], ["extrathyroid diseases", "OBSERVATION", 85, 106], ["is likely", "UNCERTAINTY", 111, 120], ["inflammatory", "OBSERVATION", 126, 138], ["infection", "OBSERVATION", 160, 169]]], ["Such immunoreactivity and a clinical picture resembling sepsis have been reported in some patients with acute pancreatitis.s The place, if any, of procalcitonin induction in the cytokine cascade that occurs in sepsis and other inflammatory processes remains to be investigated.", [["sepsis", "DISEASE", 56, 62], ["pancreatitis", "DISEASE", 110, 122], ["sepsis", "DISEASE", 210, 216], ["patients", "ORGANISM", 90, 98], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 147, 160], ["procalcitonin", "PROTEIN", 147, 160], ["cytokine", "PROTEIN", 178, 186], ["patients", "SPECIES", 90, 98], ["Such immunoreactivity", "PROBLEM", 0, 21], ["a clinical picture", "PROBLEM", 26, 44], ["sepsis", "PROBLEM", 56, 62], ["acute pancreatitis", "PROBLEM", 104, 122], ["procalcitonin induction", "TREATMENT", 147, 170], ["the cytokine cascade", "PROBLEM", 174, 194], ["sepsis", "PROBLEM", 210, 216], ["other inflammatory processes", "PROBLEM", 221, 249], ["sepsis", "OBSERVATION", 56, 62], ["acute", "OBSERVATION_MODIFIER", 104, 109], ["pancreatitis", "OBSERVATION", 110, 122], ["sepsis", "OBSERVATION", 210, 216], ["inflammatory", "OBSERVATION", 227, 239]]], ["Rapid and substantial release of procalcitonin, at the same time as tumour necrosis factor alpha and before interleukin-6, has been observed in patients with renal cancer after intravenous administration of interleukin-2 (unpublished).", [["renal cancer", "ANATOMY", 158, 170], ["intravenous", "ANATOMY", 177, 188], ["necrosis", "DISEASE", 75, 83], ["renal cancer", "DISEASE", 158, 170], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 33, 46], ["tumour necrosis factor alpha", "GENE_OR_GENE_PRODUCT", 68, 96], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 108, 121], ["patients", "ORGANISM", 144, 152], ["renal cancer", "CANCER", 158, 170], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 177, 188], ["interleukin-2", "GENE_OR_GENE_PRODUCT", 207, 220], ["procalcitonin", "PROTEIN", 33, 46], ["tumour necrosis factor alpha", "PROTEIN", 68, 96], ["interleukin-6", "PROTEIN", 108, 121], ["interleukin", "PROTEIN", 207, 218], ["patients", "SPECIES", 144, 152], ["procalcitonin", "TREATMENT", 33, 46], ["tumour necrosis factor alpha", "PROBLEM", 68, 96], ["interleukin", "TEST", 108, 119], ["renal cancer", "PROBLEM", 158, 170], ["intravenous administration of interleukin", "TREATMENT", 177, 218], ["substantial", "OBSERVATION_MODIFIER", 10, 21], ["procalcitonin", "OBSERVATION", 33, 46], ["tumour", "OBSERVATION_MODIFIER", 68, 74], ["necrosis", "OBSERVATION", 75, 83], ["renal", "ANATOMY", 158, 163], ["cancer", "OBSERVATION", 164, 170]]], ["This observation could help elucidate the mechanism of rapid procalcitonin production in the septic process.", [["septic", "DISEASE", 93, 99], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 61, 74], ["This observation", "TEST", 0, 16], ["rapid procalcitonin production", "PROBLEM", 55, 85], ["the septic process", "PROBLEM", 89, 107], ["rapid", "OBSERVATION_MODIFIER", 55, 60], ["procalcitonin", "OBSERVATION", 61, 74], ["septic", "OBSERVATION", 93, 99]]], ["Our results, based on several specific immunoassays, strongly suggest that the molecule detected in the serum of patients with sepsis is procalcitonin.", [["serum", "ANATOMY", 104, 109], ["sepsis", "DISEASE", 127, 133], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["patients", "ORGANISM", 113, 121], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 137, 150], ["patients", "SPECIES", 113, 121], ["several specific immunoassays", "TEST", 22, 51], ["the molecule", "PROBLEM", 75, 87], ["sepsis", "PROBLEM", 127, 133], ["procalcitonin", "PROBLEM", 137, 150], ["sepsis", "OBSERVATION", 127, 133]]], ["However, we cannot exclude the possibility that some of the aminoacids not involved in the recognised epitopes may differ.", [["aminoacids", "CHEMICAL", 60, 70], ["epitopes", "PROTEIN", 102, 110], ["the aminoacids", "TREATMENT", 56, 70]]], ["A second calcitonin messenger, encoding a procalcitonin bearing eight different aminoacid residues on the carboxy-terminal region, has been identified in the thyroid.", [["thyroid", "ANATOMY", 158, 165], ["calcitonin", "CHEMICAL", 9, 19], ["aminoacid", "CHEMICAL", 80, 89], ["carboxy", "CHEMICAL", 106, 113], ["calcitonin", "GENE_OR_GENE_PRODUCT", 9, 19], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 42, 55], ["thyroid", "ORGAN", 158, 165], ["procalcitonin", "PROTEIN", 42, 55], ["carboxy-terminal region", "PROTEIN", 106, 129], ["A second calcitonin messenger", "TREATMENT", 0, 29], ["a procalcitonin bearing", "TREATMENT", 40, 63], ["different aminoacid residues", "PROBLEM", 70, 98], ["calcitonin messenger", "OBSERVATION", 9, 29], ["aminoacid residues", "OBSERVATION", 80, 98], ["carboxy", "ANATOMY_MODIFIER", 106, 113], ["terminal", "ANATOMY_MODIFIER", 114, 122], ["region", "ANATOMY_MODIFIER", 123, 129], ["thyroid", "ANATOMY", 158, 165]]], ["16 Concentrations of calcitonin gene-related peptide, the product of the calcitonin gene in nerve cells, are also increased in patients with sepsis.1?DiscussionFurther studies are needed to elucidate the importance of procalcitonin production in association with infection and to assess a potential role in diagnosis and follow-up of patients with bacterial sepsis.DiscussionWe thank Mr Johny Bombled and Mr Lionel Fougeat for excellent assistance; Dr Walter Bom (Research Laboratory for Calcium Metabolism, University of Zurich) for proGr 1-57 peptide and polyclonal antiserum; and Dr Jean-Michel Bidart for reviewing the manuscript.", [["nerve cells", "ANATOMY", 92, 103], ["calcitonin gene-related peptide", "CHEMICAL", 21, 52], ["calcitonin", "CHEMICAL", 73, 83], ["sepsis", "DISEASE", 141, 147], ["infection", "DISEASE", 263, 272], ["bacterial sepsis", "DISEASE", 348, 364], ["Calcium", "CHEMICAL", 488, 495], ["proGr 1-57 peptide", "CHEMICAL", 534, 552], ["Calcium", "CHEMICAL", 488, 495], ["calcitonin gene-related peptide", "GENE_OR_GENE_PRODUCT", 21, 52], ["calcitonin", "GENE_OR_GENE_PRODUCT", 73, 83], ["nerve cells", "CELL", 92, 103], ["patients", "ORGANISM", 127, 135], ["procalcitonin", "GENE_OR_GENE_PRODUCT", 218, 231], ["patients", "ORGANISM", 334, 342], ["antiserum", "ORGANISM_SUBSTANCE", 568, 577], ["calcitonin gene", "DNA", 73, 88], ["nerve cells", "CELL_TYPE", 92, 103], ["procalcitonin", "PROTEIN", 218, 231], ["patients", "SPECIES", 127, 135], ["patients", "SPECIES", 334, 342], ["calcitonin gene", "TREATMENT", 21, 36], ["related peptide", "PROBLEM", 37, 52], ["the calcitonin gene in nerve cells", "PROBLEM", 69, 103], ["sepsis", "PROBLEM", 141, 147], ["DiscussionFurther studies", "TEST", 150, 175], ["procalcitonin production", "PROBLEM", 218, 242], ["infection", "PROBLEM", 263, 272], ["bacterial sepsis", "PROBLEM", 348, 364], ["Calcium Metabolism", "TEST", 488, 506], ["proGr", "TEST", 534, 539], ["polyclonal antiserum", "TREATMENT", 557, 577], ["nerve cells", "OBSERVATION", 92, 103], ["increased", "OBSERVATION_MODIFIER", 114, 123], ["sepsis", "OBSERVATION", 141, 147], ["bacterial", "OBSERVATION_MODIFIER", 348, 357], ["sepsis", "OBSERVATION", 358, 364]]]], "909883c25d334b68bf00d348b2605c8506035a00": [["pneumonia.", [["pneumonia", "DISEASE", 0, 9], ["pneumonia", "PROBLEM", 0, 9]]], ["Pneumonia was documented by computed tomography and infection was established by RT-PCR.", [["Pneumonia", "DISEASE", 0, 9], ["infection", "DISEASE", 52, 61], ["Pneumonia", "PROBLEM", 0, 9], ["computed tomography", "TEST", 28, 47], ["infection", "PROBLEM", 52, 61], ["PCR", "TEST", 84, 87], ["infection", "OBSERVATION", 52, 61]]], ["Blood samples were taken on admission.", [["Blood samples", "ANATOMY", 0, 13], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["Blood samples", "TEST", 0, 13]]], ["Statistical analysis was performed with t test after log-transformation for non-normally distributed variables and with exact Fisher test for frequency comparisons.", [["Statistical analysis", "TEST", 0, 20], ["t test", "TEST", 40, 46], ["exact Fisher test", "TEST", 120, 137], ["frequency comparisons", "TEST", 142, 163]]], ["Table 1 shows features of the patients, prevalence of autoimmune markers, and features of the patients stratified by presence/absence of ANA and lupus anticoagulant.", [["lupus", "DISEASE", 145, 150], ["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 94, 102], ["autoimmune markers", "PROTEIN", 54, 72], ["ANA", "PROTEIN", 137, 140], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 94, 102], ["autoimmune markers", "PROBLEM", 54, 72], ["ANA", "PROBLEM", 137, 140], ["lupus anticoagulant", "TREATMENT", 145, 164], ["autoimmune markers", "OBSERVATION", 54, 72], ["lupus anticoagulant", "OBSERVATION", 145, 164]]], ["Several autoimmune markers were present.", [["Several autoimmune markers", "PROBLEM", 0, 26], ["autoimmune markers", "OBSERVATION", 8, 26]]], ["The prevalence of antinuclear antibodies (ANA) (35.6%) and lupus anticoagulant (11.1%) was very high.", [["lupus anticoagulant", "DISEASE", 59, 78], ["antinuclear antibodies", "GENE_OR_GENE_PRODUCT", 18, 40], ["antinuclear antibodies", "PROTEIN", 18, 40], ["ANA", "PROTEIN", 42, 45], ["antinuclear antibodies", "TEST", 18, 40], ["ANA", "TEST", 42, 45], ["lupus anticoagulant", "TEST", 59, 78], ["antinuclear antibodies", "OBSERVATION", 18, 40], ["lupus", "OBSERVATION", 59, 64]]], ["Moreover, borderline values of lupus anticoagulant were present in a high percentage of subjects (35.5%).", [["lupus", "DISEASE", 31, 36], ["lupus anticoagulant", "GENE_OR_GENE_PRODUCT", 31, 50], ["lupus anticoagulant", "PROBLEM", 31, 50], ["borderline", "OBSERVATION_MODIFIER", 10, 20], ["values", "OBSERVATION_MODIFIER", 21, 27], ["lupus anticoagulant", "OBSERVATION", 31, 50]]], ["No difference was found between subjects with positive and those with borderline lupus anticoagulant, so we grouped the two together in our analysis.", [["borderline lupus anticoagulant", "PROBLEM", 70, 100], ["our analysis", "TEST", 136, 148], ["difference", "OBSERVATION_MODIFIER", 3, 13], ["lupus", "OBSERVATION", 81, 86]]]], "PMC4437985": [["IntroductionDihydropyrimidinase catalyzes the reversible cyclization of dihydrouracil or dihydrothymine to N-carbamoyl-\u03b2-alanine or N-carbamyl-\u03b2-aminoisobutyrate in the second step of the pyrimidine degradation pathway, respectively [1,2].", [["Dihydropyrimidinase", "CHEMICAL", 12, 31], ["dihydrouracil", "CHEMICAL", 72, 85], ["dihydrothymine", "CHEMICAL", 89, 103], ["N-carbamoyl-\u03b2-alanine", "CHEMICAL", 107, 128], ["N-carbamyl-\u03b2-aminoisobutyrate", "CHEMICAL", 132, 161], ["pyrimidine", "CHEMICAL", 188, 198], ["Dihydropyrimidinase", "CHEMICAL", 12, 31], ["dihydrouracil", "CHEMICAL", 72, 85], ["dihydrothymine", "CHEMICAL", 89, 103], ["N-carbamoyl-\u03b2-alanine", "CHEMICAL", 107, 128], ["N-carbamyl-\u03b2-aminoisobutyrate", "CHEMICAL", 132, 161], ["pyrimidine", "CHEMICAL", 188, 198], ["Dihydropyrimidinase", "SIMPLE_CHEMICAL", 12, 31], ["dihydrouracil", "SIMPLE_CHEMICAL", 72, 85], ["dihydrothymine", "SIMPLE_CHEMICAL", 89, 103], ["N-carbamoyl-\u03b2-alanine", "SIMPLE_CHEMICAL", 107, 128], ["N-carbamyl-\u03b2-aminoisobutyrate", "SIMPLE_CHEMICAL", 132, 161], ["pyrimidine", "SIMPLE_CHEMICAL", 188, 198], ["IntroductionDihydropyrimidinase", "TREATMENT", 0, 31], ["the reversible cyclization", "TREATMENT", 42, 68], ["dihydrouracil", "TREATMENT", 72, 85], ["dihydrothymine", "TREATMENT", 89, 103], ["carbamoyl-\u03b2-alanine", "TREATMENT", 109, 128], ["carbamyl", "TREATMENT", 134, 142], ["aminoisobutyrate", "TREATMENT", 145, 161], ["the pyrimidine degradation pathway", "TREATMENT", 184, 218]]], ["Dihydropyrimidinase, a component in the chain of pyrimidine catabolism, is also capable of detoxifying xenobiotics with an imide functional group that ranges from linear imides to heterocyclic imides [3,4,5] and organic cyclic carbonates [6].", [["Dihydropyrimidinase", "CHEMICAL", 0, 19], ["pyrimidine", "CHEMICAL", 49, 59], ["imides", "CHEMICAL", 170, 176], ["heterocyclic imides [3,4,5] and organic cyclic carbonates", "CHEMICAL", 180, 237], ["Dihydropyrimidinase", "CHEMICAL", 0, 19], ["pyrimidine", "CHEMICAL", 49, 59], ["imide", "CHEMICAL", 123, 128], ["imides", "CHEMICAL", 170, 176], ["heterocyclic imides", "CHEMICAL", 180, 199], ["cyclic carbonates", "CHEMICAL", 220, 237], ["Dihydropyrimidinase", "SIMPLE_CHEMICAL", 0, 19], ["pyrimidine", "SIMPLE_CHEMICAL", 49, 59], ["imides", "SIMPLE_CHEMICAL", 170, 176], ["heterocyclic imides [3,4,5]", "SIMPLE_CHEMICAL", 180, 207], ["organic cyclic carbonates [6]", "SIMPLE_CHEMICAL", 212, 241], ["Dihydropyrimidinase", "TREATMENT", 0, 19], ["pyrimidine catabolism", "TREATMENT", 49, 70], ["detoxifying xenobiotics", "TREATMENT", 91, 114], ["an imide functional group", "TREATMENT", 120, 145], ["linear imides to heterocyclic imides", "TREATMENT", 163, 199], ["organic cyclic carbonates", "TREATMENT", 212, 237]]], ["These different imide-hydrolyzing enzymes from microorganisms are normally known as hydantoinase because of their role as biocatalysts in the synthesis of D- and L-amino acids for the industrial production of the precursors of antibiotics [7,8].", [["imide", "CHEMICAL", 16, 21], ["D- and L-amino acids", "CHEMICAL", 155, 175], ["imide", "CHEMICAL", 16, 21], ["hydantoinase", "CHEMICAL", 84, 96], ["D- and L-amino acids", "CHEMICAL", 155, 175], ["hydantoinase", "SIMPLE_CHEMICAL", 84, 96], ["D", "SIMPLE_CHEMICAL", 155, 156], ["L-amino acids", "SIMPLE_CHEMICAL", 162, 175], ["imide-hydrolyzing enzymes", "PROTEIN", 16, 41], ["These different imide", "TEST", 0, 21], ["hydrolyzing enzymes", "TEST", 22, 41], ["microorganisms", "PROBLEM", 47, 61], ["D- and L-amino acids", "TREATMENT", 155, 175], ["the precursors of antibiotics", "TREATMENT", 209, 238]]], ["Although dihydropyrimidinase and hydantoinase generally have a similar active site, their overall sequence identity and substrate specificity differ [9].", [["dihydropyrimidinase", "CHEMICAL", 9, 28], ["hydantoinase", "CHEMICAL", 33, 45], ["dihydropyrimidinase", "CHEMICAL", 9, 28], ["hydantoinase", "CHEMICAL", 33, 45], ["dihydropyrimidinase", "GENE_OR_GENE_PRODUCT", 9, 28], ["hydantoinase", "SIMPLE_CHEMICAL", 33, 45], ["dihydropyrimidinase", "PROTEIN", 9, 28], ["hydantoinase", "PROTEIN", 33, 45], ["dihydropyrimidinase", "TREATMENT", 9, 28], ["hydantoinase", "TREATMENT", 33, 45], ["a similar active site", "PROBLEM", 61, 82]]], ["Thus, some bacterial hydantoinases are still named and identified as dihydropyrimidinase because of the catalytic activity toward the natural substrates dihydrouracil and dihydrothymine.IntroductionBased on their functional and structural similarities, dihydropyrimidinase, hydantoinase, imidase, allantoinase, and dihydroorotase belong to the cyclic amidohydrolase family [10].", [["dihydropyrimidinase", "CHEMICAL", 69, 88], ["dihydrouracil", "CHEMICAL", 153, 166], ["dihydrothymine", "CHEMICAL", 171, 185], ["dihydropyrimidinase", "CHEMICAL", 253, 272], ["allantoinase", "CHEMICAL", 297, 309], ["dihydroorotase", "CHEMICAL", 315, 329], ["dihydropyrimidinase", "CHEMICAL", 69, 88], ["dihydrouracil", "CHEMICAL", 153, 166], ["dihydrothymine", "CHEMICAL", 171, 185], ["dihydropyrimidinase", "CHEMICAL", 253, 272], ["dihydropyrimidinase", "SIMPLE_CHEMICAL", 69, 88], ["dihydrouracil", "SIMPLE_CHEMICAL", 153, 166], ["dihydrothymine", "SIMPLE_CHEMICAL", 171, 185], ["dihydropyrimidinase", "SIMPLE_CHEMICAL", 253, 272], ["hydantoinase", "SIMPLE_CHEMICAL", 274, 286], ["imidase", "SIMPLE_CHEMICAL", 288, 295], ["allantoinase", "SIMPLE_CHEMICAL", 297, 309], ["dihydroorotase", "SIMPLE_CHEMICAL", 315, 329], ["dihydropyrimidinase", "PROTEIN", 253, 272], ["hydantoinase", "PROTEIN", 274, 286], ["imidase", "PROTEIN", 288, 295], ["allantoinase", "PROTEIN", 297, 309], ["dihydroorotase", "PROTEIN", 315, 329], ["cyclic amidohydrolase family", "PROTEIN", 344, 372], ["some bacterial hydantoinases", "PROBLEM", 6, 34], ["dihydropyrimidinase", "TREATMENT", 69, 88], ["the catalytic activity", "PROBLEM", 100, 122], ["the natural substrates dihydrouracil", "TREATMENT", 130, 166], ["dihydrothymine", "TREATMENT", 171, 185], ["dihydropyrimidinase", "TREATMENT", 253, 272], ["hydantoinase", "TREATMENT", 274, 286], ["imidase", "TREATMENT", 288, 295], ["allantoinase", "TREATMENT", 297, 309], ["dihydroorotase", "TREATMENT", 315, 329], ["bacterial hydantoinases", "OBSERVATION", 11, 34]]], ["Even if these enzymes have similar functions, they have relatively low amino acid sequence identity.", [["amino acid", "CHEMICAL", 71, 81], ["amino acid", "CHEMICAL", 71, 81], ["amino acid", "AMINO_ACID", 71, 81], ["enzymes", "PROTEIN", 14, 21], ["these enzymes", "TEST", 8, 21], ["relatively low amino acid sequence identity", "PROBLEM", 56, 99]]], ["These metal-dependent enzymes catalyze the ring-opening hydrolysis of the cyclic amide bond of each substrate in either five- or six-membered rings in the metabolism of purines, pyrimidines, and many xenobiotics (Fig 1A) [9,11,12,13].", [["metal", "CHEMICAL", 6, 11], ["purines", "CHEMICAL", 169, 176], ["pyrimidines", "CHEMICAL", 178, 189], ["cyclic amide", "CHEMICAL", 74, 86], ["purines", "CHEMICAL", 169, 176], ["pyrimidines", "CHEMICAL", 178, 189], ["purines", "SIMPLE_CHEMICAL", 169, 176], ["pyrimidines", "SIMPLE_CHEMICAL", 178, 189], ["9,11,12,13]", "SIMPLE_CHEMICAL", 222, 233], ["metal-dependent enzymes", "PROTEIN", 6, 29], ["six-membered rings", "TREATMENT", 129, 147], ["pyrimidines", "TREATMENT", 178, 189], ["ring", "OBSERVATION_MODIFIER", 43, 47], ["opening hydrolysis", "OBSERVATION", 48, 66]]], ["Almost all the active sites of dihydropyrimidinase, hydantoinase, allantoinase, and dihydroorotase contain four histidines, one aspartate, and one post-carboxylated lysine residue, which are required for metal binding and catalytic activity.", [["dihydropyrimidinase", "CHEMICAL", 31, 50], ["hydantoinase", "CHEMICAL", 52, 64], ["allantoinase", "CHEMICAL", 66, 78], ["dihydroorotase", "CHEMICAL", 84, 98], ["aspartate", "CHEMICAL", 128, 137], ["dihydropyrimidinase", "CHEMICAL", 31, 50], ["hydantoinase", "CHEMICAL", 52, 64], ["dihydroorotase", "CHEMICAL", 84, 98], ["histidines", "CHEMICAL", 112, 122], ["aspartate", "CHEMICAL", 128, 137], ["lysine", "CHEMICAL", 165, 171], ["dihydropyrimidinase", "GENE_OR_GENE_PRODUCT", 31, 50], ["hydantoinase", "SIMPLE_CHEMICAL", 52, 64], ["allantoinase", "SIMPLE_CHEMICAL", 66, 78], ["dihydroorotase", "SIMPLE_CHEMICAL", 84, 98], ["aspartate", "SIMPLE_CHEMICAL", 128, 137], ["dihydropyrimidinase", "PROTEIN", 31, 50], ["hydantoinase", "PROTEIN", 52, 64], ["allantoinase", "PROTEIN", 66, 78], ["dihydroorotase", "PROTEIN", 84, 98], ["dihydropyrimidinase", "TREATMENT", 31, 50], ["hydantoinase", "TREATMENT", 52, 64], ["allantoinase", "TREATMENT", 66, 78], ["dihydroorotase", "TREATMENT", 84, 98], ["four histidines", "TREATMENT", 107, 122], ["one post-carboxylated lysine residue", "TREATMENT", 143, 179], ["metal binding", "PROBLEM", 204, 217], ["active", "OBSERVATION_MODIFIER", 15, 21]]], ["The presence of a post-carboxylated lysine in hydantoinase is also required in binuclear metal center self-assembly [12], and it increases the nucleophilicity of the hydroxide for catalysis [14].", [["lysine", "CHEMICAL", 36, 42], ["hydantoinase", "CHEMICAL", 46, 58], ["lysine", "CHEMICAL", 36, 42], ["hydantoinase", "CHEMICAL", 46, 58], ["hydroxide", "CHEMICAL", 166, 175], ["lysine", "AMINO_ACID", 36, 42], ["hydantoinase", "SIMPLE_CHEMICAL", 46, 58], ["hydroxide", "SIMPLE_CHEMICAL", 166, 175], ["a post-carboxylated lysine in hydantoinase", "TREATMENT", 16, 58], ["the hydroxide", "TREATMENT", 162, 175], ["post-carboxylated lysine", "OBSERVATION", 18, 42]]], ["Previous studies indicated that cyclic amidohydrolases should use a nearly identical mechanism for catalysis.", [["cyclic amidohydrolases", "SIMPLE_CHEMICAL", 32, 54], ["Previous studies", "TEST", 0, 16], ["cyclic amidohydrolases", "TREATMENT", 32, 54]]], ["However, the substrate selectivity and specificity of dihydropyrimidinase, hydantoinase, allantoinase, and dihydroorotase highly differ.", [["dihydropyrimidinase", "CHEMICAL", 54, 73], ["allantoinase", "CHEMICAL", 89, 101], ["dihydroorotase", "CHEMICAL", 107, 121], ["dihydropyrimidinase", "CHEMICAL", 54, 73], ["hydantoinase", "CHEMICAL", 75, 87], ["dihydroorotase", "CHEMICAL", 107, 121], ["dihydropyrimidinase", "SIMPLE_CHEMICAL", 54, 73], ["hydantoinase", "SIMPLE_CHEMICAL", 75, 87], ["allantoinase", "SIMPLE_CHEMICAL", 89, 101], ["dihydroorotase", "SIMPLE_CHEMICAL", 107, 121], ["dihydropyrimidinase", "PROTEIN", 54, 73], ["hydantoinase", "PROTEIN", 75, 87], ["allantoinase", "PROTEIN", 89, 101], ["the substrate selectivity", "TEST", 9, 34], ["dihydropyrimidinase", "PROBLEM", 54, 73], ["allantoinase", "TREATMENT", 89, 101], ["dihydroorotase", "TREATMENT", 107, 121]]], ["For example, dihydroorotase does not hydrolyze dihydropyrimidine, hydantoin, and allantoin [15].", [["dihydroorotase", "CHEMICAL", 13, 27], ["dihydropyrimidine", "CHEMICAL", 47, 64], ["hydantoin", "CHEMICAL", 66, 75], ["allantoin", "CHEMICAL", 81, 90], ["dihydroorotase", "CHEMICAL", 13, 27], ["dihydropyrimidine", "CHEMICAL", 47, 64], ["hydantoin", "CHEMICAL", 66, 75], ["allantoin", "CHEMICAL", 81, 90], ["dihydroorotase", "SIMPLE_CHEMICAL", 13, 27], ["dihydropyrimidine", "SIMPLE_CHEMICAL", 47, 64], ["hydantoin", "SIMPLE_CHEMICAL", 66, 75], ["allantoin [15]", "SIMPLE_CHEMICAL", 81, 95], ["dihydroorotase", "TREATMENT", 13, 27], ["hydrolyze dihydropyrimidine", "TREATMENT", 37, 64], ["hydantoin", "TREATMENT", 66, 75], ["allantoin", "TREATMENT", 81, 90]]], ["Thus, whether the substrate and inhibitor of each enzyme in this family competitively inhibit dihydropyrimidinase remains unclear.IntroductionFew therapies are effective against the six antibiotic-resistant ESKAPE pathogens.", [["dihydropyrimidinase", "CHEMICAL", 94, 113], ["dihydropyrimidinase", "CHEMICAL", 94, 113], ["dihydropyrimidinase", "SIMPLE_CHEMICAL", 94, 113], ["dihydropyrimidinase", "PROTEIN", 94, 113], ["each enzyme", "TEST", 45, 56], ["dihydropyrimidinase", "PROBLEM", 94, 113], ["IntroductionFew therapies", "TREATMENT", 130, 155], ["the six antibiotic", "TREATMENT", 178, 196], ["resistant ESKAPE pathogens", "PROBLEM", 197, 223]]], ["The increased prevalence of beta-lactamases in P. aeruginosa and other bacteria has begun to reduce the clinical efficacy of beta-lactams against the most common opportunistic pathogen [16].", [["beta-lactamases", "CHEMICAL", 28, 43], ["beta-lactams", "CHEMICAL", 125, 137], ["beta-lactamases", "GENE_OR_GENE_PRODUCT", 28, 43], ["P. aeruginosa", "ORGANISM", 47, 60], ["beta-lactams", "SIMPLE_CHEMICAL", 125, 137], ["P. aeruginosa", "SPECIES", 47, 60], ["P. aeruginosa", "SPECIES", 47, 60], ["beta-lactamases", "PROBLEM", 28, 43], ["P. aeruginosa", "PROBLEM", 47, 60], ["other bacteria", "PROBLEM", 65, 79], ["beta-lactams", "TREATMENT", 125, 137], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["beta-lactamases", "OBSERVATION", 28, 43]]], ["To date, over 800 beta-lactamases have been identified, of which at least 120 beta-lactamases have been detected in P. aeruginosa [17].", [["beta-lactamases", "GENE_OR_GENE_PRODUCT", 18, 33], ["beta-lactamases", "GENE_OR_GENE_PRODUCT", 78, 93], ["P. aeruginosa", "ORGANISM", 116, 129], ["beta", "PROTEIN", 18, 22], ["beta", "PROTEIN", 78, 82], ["P. aeruginosa", "SPECIES", 116, 129], ["P. aeruginosa", "SPECIES", 116, 129], ["beta-lactamases", "TEST", 18, 33], ["beta-lactamases", "TEST", 78, 93]]], ["The development of clinically useful small-molecule antibiotics and identification of new targets in microorganisms are seminal events in the field of infectious diseases [18].IntroductionFlavonols belong to flavonoids, the most common group of plant polyphenols that is responsible for most of the flavor and color of fruits and vegetables [19].", [["seminal", "ANATOMY", 120, 127], ["fruits", "ANATOMY", 319, 325], ["vegetables", "ANATOMY", 330, 340], ["infectious diseases", "DISEASE", 151, 170], ["Flavonols", "CHEMICAL", 188, 197], ["flavonoids", "CHEMICAL", 208, 218], ["Flavonols", "CHEMICAL", 188, 197], ["flavonoids", "CHEMICAL", 208, 218], ["polyphenols", "CHEMICAL", 251, 262], ["Flavonols", "SIMPLE_CHEMICAL", 188, 197], ["flavonoids", "SIMPLE_CHEMICAL", 208, 218], ["polyphenols", "SIMPLE_CHEMICAL", 251, 262], ["fruits", "ORGANISM_SUBDIVISION", 319, 325], ["vegetables", "ORGANISM_SUBDIVISION", 330, 340], ["small-molecule antibiotics", "TREATMENT", 37, 63], ["new targets in microorganisms", "PROBLEM", 86, 115], ["seminal events", "PROBLEM", 120, 134], ["IntroductionFlavonols", "TREATMENT", 176, 197], ["flavonoids", "TREATMENT", 208, 218], ["plant polyphenols", "TREATMENT", 245, 262], ["new", "OBSERVATION_MODIFIER", 86, 89], ["targets", "OBSERVATION_MODIFIER", 90, 97], ["infectious", "OBSERVATION", 151, 161], ["plant polyphenols", "OBSERVATION", 245, 262]]], ["Over 5,000 different flavonoids have been identified, many of which display structure-dependent biological and pharmacological activities [20,21,22], including antimicrobial agents [23,24].", [["flavonoids", "CHEMICAL", 21, 31], ["flavonoids", "CHEMICAL", 21, 31], ["flavonoids", "SIMPLE_CHEMICAL", 21, 31], ["20,21,22", "SIMPLE_CHEMICAL", 139, 147], ["antimicrobial agents", "TREATMENT", 160, 180], ["flavonoids", "OBSERVATION", 21, 31], ["dependent", "OBSERVATION_MODIFIER", 86, 95]]], ["These natural products are safe as pharmaceuticals because they have fewer side effects for human use.IntroductionIn this study, we investigated the effects of the substrates and inhibitors of allantoinase and dihydroorotase, including the flavonols myricetin, quercetin, kaempferol, and galangin, on inhibiting the catalytic activity of a putative dihydropyrimidinase from P. aeruginosa PAO1.", [["allantoinase", "CHEMICAL", 193, 205], ["dihydroorotase", "CHEMICAL", 210, 224], ["myricetin", "CHEMICAL", 250, 259], ["quercetin", "CHEMICAL", 261, 270], ["kaempferol", "CHEMICAL", 272, 282], ["galangin", "CHEMICAL", 288, 296], ["dihydropyrimidinase", "CHEMICAL", 349, 368], ["dihydroorotase", "CHEMICAL", 210, 224], ["flavonols", "CHEMICAL", 240, 249], ["myricetin", "CHEMICAL", 250, 259], ["quercetin", "CHEMICAL", 261, 270], ["kaempferol", "CHEMICAL", 272, 282], ["galangin", "CHEMICAL", 288, 296], ["human", "ORGANISM", 92, 97], ["allantoinase", "SIMPLE_CHEMICAL", 193, 205], ["dihydroorotase", "SIMPLE_CHEMICAL", 210, 224], ["flavonols", "SIMPLE_CHEMICAL", 240, 249], ["myricetin", "SIMPLE_CHEMICAL", 250, 259], ["quercetin", "SIMPLE_CHEMICAL", 261, 270], ["kaempferol", "SIMPLE_CHEMICAL", 272, 282], ["galangin", "SIMPLE_CHEMICAL", 288, 296], ["dihydropyrimidinase", "SIMPLE_CHEMICAL", 349, 368], ["P. aeruginosa PAO1", "ORGANISM", 374, 392], ["human", "SPECIES", 92, 97], ["P. aeruginosa", "SPECIES", 374, 387], ["human", "SPECIES", 92, 97], ["P. aeruginosa", "SPECIES", 374, 387], ["this study", "TEST", 117, 127], ["the substrates", "TREATMENT", 160, 174], ["inhibitors", "TREATMENT", 179, 189], ["allantoinase", "TREATMENT", 193, 205], ["dihydroorotase", "TREATMENT", 210, 224], ["the flavonols myricetin", "TREATMENT", 236, 259], ["quercetin", "TREATMENT", 261, 270], ["kaempferol", "TREATMENT", 272, 282], ["galangin", "TREATMENT", 288, 296], ["P. aeruginosa PAO1", "PROBLEM", 374, 392]]], ["The derivatives of myricetin, namely, dihydromyricetin and myricitrin, were further used to test the structure\u2013inhibition relationship of dihydropyrimidinase.Construction of the dihydropyrimidinase expression plasmid ::: Materials and Methods", [["myricetin", "CHEMICAL", 19, 28], ["dihydromyricetin", "CHEMICAL", 38, 54], ["myricitrin", "CHEMICAL", 59, 69], ["dihydropyrimidinase", "CHEMICAL", 138, 157], ["myricetin", "CHEMICAL", 19, 28], ["dihydromyricetin", "CHEMICAL", 38, 54], ["myricitrin", "CHEMICAL", 59, 69], ["dihydropyrimidinase", "CHEMICAL", 138, 157], ["myricetin", "SIMPLE_CHEMICAL", 19, 28], ["dihydromyricetin", "SIMPLE_CHEMICAL", 38, 54], ["myricitrin", "SIMPLE_CHEMICAL", 59, 69], ["dihydropyrimidinase", "SIMPLE_CHEMICAL", 138, 157], ["dihydropyrimidinase", "GENE_OR_GENE_PRODUCT", 178, 197], ["dihydropyrimidinase", "PROTEIN", 138, 157], ["dihydropyrimidinase expression plasmid", "DNA", 178, 216], ["myricetin", "TREATMENT", 19, 28], ["dihydromyricetin", "TREATMENT", 38, 54], ["myricitrin", "TREATMENT", 59, 69], ["dihydropyrimidinase", "PROBLEM", 138, 157], ["Methods", "TREATMENT", 235, 242]]]], "PMC7392848": [["Ethical statementThe study design, the procedure of results communication, the information circular and the questionnaire have been submitted to and approved by our hospital's ethics committee (ethical agreement number: CEHIS/2020-19).", [["The study", "TEST", 17, 26]]], ["An informed consent form has been requested from each participant, guaranteeing anonymity of the data and requesting permission to use them for statistical analysis.", [["statistical analysis", "TEST", 144, 164]]], ["Out of respect for everyone's privacy, the participant was free to not answer to certain questions.Declaration of competing interestAuthors state no conflict of interest.", [["participant", "SPECIES", 43, 54]]]]}